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PREFACE 
The general indications that the pineal gland might be involved 
in homeostasis, and more specifically the evidence suggesting a 
role in amelioration of seizure states warranted further 
inv es tigation . No reports had examined a possible link between 
anticonvulsant drug administration and pineal gland function, and 
few enabled any type of presumption to be made as to possible 
effects. This study was an attempt to evaluate in which ways 
anticonvulsant drugs might alter pineal gland indole metabolism, 
with a view to increasing understanding of the role of the pineal 
in modulation of epil eptic di scharges. 
In order to make the study as meaningful as possible extensive 
preliminary investigations were necessary. 
Pharmacokinetic determinations gave an indication of tissue 
concentrations of the drugs, which could then be related to 
observed effects. As far as possible, where existing information 
was lacking, the catalytic behaviour of the various enzymes was 
characterised in order to explain any observed effects at a 
molecular level. 
An attempt was also made to characterise the regulatory 
mechanisms controlling indole metabolism, again in order to 
define the pharmacological effects exerted by the drugs used. The 
complexity of the system made it impossible to suggest a single 
uniform regulatory hypothesis, although some significant 
observations were [,lade. 
Finally, the studies involving the anticonvulsan~ drugs were 
conducted on intact animals, isolated organs and individual 
enzymes in an attempt to determine whether the observed effects 
were occur ing at a molecular, local or central level. 
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CHAPTER 1 
LITERATURE REVIEW 
The pineal gland is unique in that it enjoys a large measure of 
protection by virtue of its location and yet is directly exposed 
to the vascular system. This provides it \'iith an ideal 
environment in which to monitor homeostasis and, consideri ng the 
many physiological effects attributed to the pineal gland [1], it 
is indeed possible that it is involved in such a function. 
Another observation which underlines the possible importance of 
the pineal gland in the control of physiologic mechanisms is 
that, of all tissues except the kidney, it is the most richly 
perfused by the vascular system [2]. This blood supply originates 
from the pos teri or cerebral artery [3]. 
The pi neal has been claimed to be part of the diffuse 
neuroendocrine system [4] and fulfils the requirements of an APUD 
organ [5] which suggests neuroendocrine modulatory functions. The 
pineal consists primarily of interstitial cells, possibly 
macroglia [6] and pinealocytes which are the recepto-sensory 
components [7]. It is the pinealocyte activity which makes the 
pineal part of the APUD system and enables it to function in the 
diffuse neuroendocrine system . 
The physiologically significant pineal products are considered to 
be mainly the methoxyindoles and peptides, although 
hydroxyindoles have been thought to exert physiological effects 
[8,9,10] . 
There appear to be numerous nervous connections between the 
pineal and various parts of the central nervous system. The best 
documented pathway is that which conveys information from the 
retina to the pineal along the retinohypothalamic tract, through 
the suprachiasmatic nucleus, medial forebrain bundle and superior 
cervical ganglion [11,12]. Photic information also travels to the 
pineal via the habenular posterior commissure complex [12,13,14]. 
This pathway is faster than that via the suprachiasmatic nucleus 
[13]. The suprachiasmatic nucleus is thought to be important for 
the generation of nonnal photic rhythms in the pineal [15,16,17] 
and acetyl choline may be involved in the transmission of such 
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information [18J. Fibres containing oxytocin and vasopressin 
which extend from the suprachiasmatic nucleus to the pi neal vi a 
the habenular commisure, also appear to exist, and may indicate a 
role in fluid and electrolyte balance [19,20J . It has also been 
suggested that a link exists between the pineal and diencephalon 
[21]. Evidence, however, suggests that the bulk of inputs arrive 
through the stalk [22J. 
The sympathetic nervous connections to the pineal have received 
the most attention and, apart from the classic transmitter 
noradrenal i ne, it has been suggested that serotoni n may serve 
some transmitter functions [23,24J although it has been shown not 
to stimulate pineal activity [25J. Noradrenal ine was found to act 
on highly speci fic receptors [26J which have been identified as 
B-adrenergic receptors [27J. These probably belong to the B1-
subgroup [28J. Information which results in stimulation of these 
receptors travels along sympathetic nerves from the superior 
cervical ganglion [29,30J. Activation of these receptors 
stimulates adenyl cyclase production of cyclic AMP whiCh, in 
turn, is responsible for increased synthesis of the enzyme 
serotonin N-acetyltransferase [31,32,33J. This B-stimulated 
induction of enzyme levels has been suggested to occur via two 
routes; increase in transcription, and enhancement of post-
transcriptional events. Transcription, however, is not always 
necessary for enzyme induction [32J. Stimulation of 
transcriptional events results in the synthesis of messenger RNA 
[34J, presumably involving phosphorylation of nuclear proteins 
[35,36J and resulting in increased synthesis of serotonin N-
ace ty 1t ran S fer a s e [32 J. I tis i n t ere s tin g ton 0 t e t hat B-
stimulation regulates activity of cyclic AMP phosphodiesterase 
[37,38J and appears to stimulate serotonin synthesis '[39J. 
Although it has been shown that adenyl cyclase is linked to 
postsynaptic B-receptors [40J effects of B-stimulation may not be 
mediated exclusively by cyclic AMP. Hyperpolarization of 
pinealocyte membranes resulting from activation of B-receptors 
might be involved in such effects, possibly independently of 
cyclic AMP [41J. It is possible that both increase in cyclic A~lP 
and hyperpolarization are necessary for complete expression of 
the B-stimulatory effects in the pineal [41J and it has been 
shown that calciur.l ions are essential for such activity [42 ,43J. 
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Activation of e-receptors also leads to a release of taurine from 
pinealocytes; a process presumed to occur as a result of membrane 
hyperpolarization [44 ] and a cyclic AMP mediated mechanism [45]. 
This released taurine has been implicated as an extracellular 
feedback messenger [44] and has been shown to stimulate e-
receptors [46]. 
To further complicate the matter sensitivity of the e-receptors 
to stimulation varies. These receptors exhibit supersensitivity 
at the onset of the dark phase, presumably as a resul t of 
decreased noradrenaline release during the light phase [4748]. 
Conversely, increased transmitter release during the dark phase 
1 eads to the developement of e-receptor subsensitivity [47]. 
Receptor stimulation causes a decrease in the quantity of 
receptors and in the activity of hormone sensitive adenyl cyclase 
[49], suggesting that receptor sensitivity is dependent, at least 
to a certain extent, on the sensitivity of adenyl cyclase to 
stimulation. Lack of stimulation, on the other hand, leads to an 
increase in sensitivity of adenyl cyclase [49]. Apart from this 
1 i nk between e-receptor and adenyl cyclase sens i tivi ty it appears 
that receptor sensitivity might be affected by changes in 
phosphodiesterase activity [50]. Calcium ions and cyclic GMP have 
also been implicated as mediators in the process of developement 
of e-receptor subsens itivity [51]. The number of e-recep tors has 
been found to be highest at the start and lowest at the end of 
the dark phase [52] which parallels changes in sensitivity and 
may contri bute to the developement of sub- or super-sens itivity. 
Under certain circumstances sex hormones can increase sensitivity 
of e-receptors to stimulation [53]. 
Presynaptic calcium dependent a -adr energic receptors appear to 
exist in the pineal gland, stimulation leading to production of 
cyclic GHP [54,55]. This effect appears to be inhibitory leading 
to decreased noradrenaline release [55]. Generation of cyclic GMP 
has al so been shown to occur as a result of some postsynaptic 
· mechanism and might act as a physiological antagonist of cyclic 
AMP [56]. Stimulation of these postsynaptic a-receptors enhances 
phosphorylation of phosphatidylinositol [57,58]. Bo th pre- and 
post-synaptic "'-receptors present in the pineal fulfil the 
requirements for "i-adrenergic receptors [59]. There has been a 
suggestion that noradrenaline may act on both receptors, with the 
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effect on a-receptors 1 eadi ng to a decrease in B-receptor 
sensitivity [60J. Such dual receptor activation provides a means 
whereby the pi neal may control a number of responses concurrently 
[60J. Apart from the sympathetic connections it appears that 
there are parasympathetic fibres which cause depletion of 
pinealocyte serotonin stores [61], possibly by action on 
muscarinic receptors [62J. These muscarinic cholinergic receptors 
seem to be located mainly on sympathetic terminals [61,62J, 
although some may occur on pinealocytes [62J. Parasympathetic 
fibres apparently pass through the superior cervical ganglion 
[61], cause release of arginine vasotocin [63J and seem to be 
involved to some extent in the mediation of the effects of light 
on the pi neal gland [64J. Muscarinic receptors are regulated by 
guanyl nucleotides [65,66J which suggests that a-receptor 
activation might modify cholinergic transmission in the pineal 
gland. Carbachol has, however, been shown to have no stimulatory 
action on the pineal [25J which tends to favour a modulatory role 
for the para-sympathetic nervous system in pineal function. 
The enzymes involved in synthesis and degradation of gamma-amino 
butyric acid (GABA) are present in the pineal gland [67] which is 
suggestive of a transmitter role. Although such a role is not 
favoured by some reports [25,67] GABA has been shown to inhibit 
noradrenergic stimulation of pineal e-receptors [68J. GABA 
itself, although not affected by catecholamines or photic inputs 
[69J, may in some ~Iay modulate pineal function . 
Noradrenaline in pineal sympathetic nerves appears to be 
regulated by dopamine levels [70J and dopamine has been shown to 
affect phospholipid metabolism [71J. This latter effect is 
apparently mediated via a-receptors and not true 'dopaminergic 
receptors [58] which suggests that, although it may exert some 
modulatory actions, it is unlikely that a dopaminergic 
i nnerva t ion per ~ has any i nfl uence on pi neal activity. 
The presence of a circadian rllYthm in pineal histamine [71J may 
indicate that this biogenic amine has some transmitter function 
in the pineal although evidence in favour of such a proposal is 
1 acki ng and it has been shown to have no effect on pineal 
activity [25J, 
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Apart from the nervous stimuli the pineal is affected by adrenal 
hormones with stress leading to an increase in adrenaline and 
dopamine content of the pineal [72J. 
From the foregoing discussion it is apparent that B-adrenergic 
receptors exert the most stiking effect on pineal indole 
metaboli sm. Modulation of such activity, however, may occur as a 
result of "-adrenergic, muscarinic cholinergic or GABA receptors. 
Although evidence for the participation of other transmitters is 
lacking it cannot be completely rejected until disproved. 
Metabolically the pineal gland is very active with large amounts 
of oxidative enzymes [73J. Of these enzymes glucose-6-phosphate 
dehy drogenase and 1 actate dehydrogenase appear to be present in 
the highest concentrations [73J. The former may be important for 
synthesis of pentose nucleotides or for production of NADPH while 
the presence of relatively large amounts of cytochrome oxidase 
[73J implies that the pineal gland normally requires a large 
amount of oxygen. 
Although a highly specific allosteric serotonin carrier has been 
characterised in pinealocyte membranes [74J, pineal indole 
metaboli sm probably begins with uptake of dietary tryptophan. The 
uptake of tryptophan and its conversion to 5-hydroxytryptophan in 
the pi neal appears to be unaffected by serotonin [75J unlike the 
carrier system which is modulated by serotonin concentrations 
[74J. Certain aspects of indole metabolism are contentious but by 
and large can be summarized (Figure l)[from 76-82J. 
Although it has not been documented 6-hydroxymelatonin may be 
formed in the pineal gland (unpublished results). 
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Figure 1: Indol e metabolism in the pineal 
HIOt~T = hydroxyi ndole-O-methyltransferase and 
N -acetyltransferase , 
gland [from 76-82J. 
SHAT = (serotonin) 
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Since the discovery of melatonin [83J considerable work has 
suggested physiological roles for pineal indol ic products, 
especi a lly the methoxyindoles. Originally melatonin was thought 
to be a unique product of the pineal gland. This view has, 
however, been disputed and melatonin has been found in the retina 
[84J and enterochromaffin cells [85J. The presence of melatonin 
in the plasma of pinealectomized animals [86,87,88J supports an 
extra-pineal source, although comp let e abolition of melatonin 
follovling pinealectomy has also been reported [89J. 
Pineal tryptophan hydroxylase appears to be di fferent from the 
cerebral enzyme [90J and may be involved in regulation of indole 
synthesis although contradictory evidence exists. Tryptophan 
hydroxylase appears -to be localized in pinealocytes and may not 
undergo a circadian rhythm [91] although other reports suggest 
the presence of a rhythm with peak activity duri ng the dark phase 
[92,93J. This nocturnal increase in enzyme activity may be under 
,,"adrenergic control [93J although, again, there is evidence to 
the contrary [94J. The activity of hydroxy tryptophan 
decarboxylase a ls o appears to be under sympathetic nervous 
control with peak activity during the light phase [95J. 
Monoamine oxidase is found in the outer mitochondrial membrane 
[96,97] in asso ciation with lipid [97] and activ ity has been 
shown t o increase with oxygen concentration [98J. Two types of 
monoamine oxidase have been isolated [99J and only one of these 
(type A) can utilize serotonin and 5-methoxytryptamine as 
substrates [lOOJ. This implies that it is the type A monoamine 
oxidase which is involved in pineal indole metabol i sm. Monoamine 
oxi da s e activi ty may be regul a ted to a certa in extent by 
phospholipids [1 01] which could in dicate an involVement of the 
sy mpathetic nervou s system. It is of interest that administration 
of monoamine oxidase inhibitors leads to increased production of 
N-acetylserotonin in the pinea l , an effect probably resulting 
from increased serotonin l evels [102,103J. The presence of 
endogenous monoamine oxidase inhibitors [104,105J may indicate a 
function in control of pineal indole metabolism. 
Al dehyde dehydrogenase occurs as several isozymes [106J l ocated 
in mitochondria [107]. The catalytic mechanism is ordered with 
NAD being the o)l l igatory first subst ra te t o bind; s uch binding 
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allowing aldehyde entry into the catalytic site, and acid 
formation preceeding NADH removal from the enzyme [108,109] . 
Hormonal modi fication of a l dehyde dehydrogenase activity 
[110,111] may participate in regulation of indole output from the 
pineal. 
The catalytic mechanism for alcohol dehydrogenase (aldehyde 
reductase) may be ordered Bi-Bi [112,113] or ordered Theorell-
Chance [114] but in both cases NAD is the first substrate to bind 
to the enzyme followed by the alcohol. In the pineal gland this 
reaction proceeds in the opposite direction to produce 5-
hydroxytryptophol from 5-hydroxyindole-3-acetaldehyde and by 
inference catalysis can be assumed to begin with binding of NADH 
to the enzyme. Di fferent forms of thi s enzyme exi st, some of 
which are dependent on NAD/NADH [112], the others on NADP/NADPH 
[115J. The NADPH dependent aldehyde reductase can be inhibited by 
both 5-hydroxyindole-3-acetic acid and 5-hydroxytryptop hol [1l5J 
a nd may be the type present in the pi neal. If thi sis indeed the 
case then aldehyde reductase activity could be modulated by 
glucose-6-phosphate dehydrogenase activity and by hydroxyindole 
concentratio n . Activi ty of al dehyde reductase may al so be 
modulated by pyridoxal compounds [116,117J and hormones [118J. 
Serotoni n N -acetyltransferase (SNATl, the enzyme responsible for 
formation of N-acetylserotonin in the melatonin biosynthetic 
pathway, undergoes a circadian rhythm in the pineal with peak 
activity during the dark phase [26J. The rhythm in SNAT activity 
is apparently under the control of a complex two - oscillator 
pacemaking system [119J. A similar rhythm has been found for the 
enzyme present in the eyes [.120], suggesting that the plasma 
melatonin rythm may not be due solely to pineal gland activi ty. 
N -acetyltransferase activi ty has been found in fi fteen brain 
areas [121], raiSing the possibi 1 i ty that mel atoni n may be 
synthesized in the brain. 
The nocturnal induction of SNAT in the pineal is controlled by a 
B-adrenergic cyclic At1P dependent mechanism causing increased 
synthesis of enzyme molecules [33,68,122]. This process may be 
under dual regulatory mechanisms - firstly induction is dependent 
on increased cyclic AMP l evels and secondly intracellular 
mechanisms must be capable of responding to this increase [123J. 
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The effects of light on SNAT activity [124,125] are probably 
mediated by this mechanism. Cyclic AMP may be necessary for 
maintaining SNAT in a stable form and any decrease in cyclic AMP 
levels would result in reduction of SNAT activity [126,127]. 
Likewise both acetyl coenzyme A and sulphhydryl protecting 
compounds have been shO\~n to exert a stabil izi ng effect on the 
thermolabile enzyme [128,129,130]. This has led to the suggestion 
that a disulphide containing peptide might be involved in 
regulation of SNAT activity [l30] through a process of protein 
thiol: di sulphide exchange [130,131]. The participation of acetyl 
coenzyme A in stabilizing SNAT may also represent an important 
regulatory mechanism [132]. It may be significant that cystamine, 
a compound capable of inactivating SNAT by thiol-dlsulphide 
exchange [l30], can also activate acetyl coenzyme A hydrolase by 
a similar mechanism [133]. The inactivation exerted by cystamine 
on SNAT activity directly would thus be enhanced by reduced 
acetyl coenzyme A concentration resulting from increased acetyl 
coenzyme A hydrolase activity. Prostaglandin stimulation of SNAT 
activi ty [134,135] may represent yet another mechanism for 
regulating melatonin production by the pineal gland. 
Centrally mediated mechanisms are also capable of modifying SNAT 
activity. The suprachiasmatic nuclei have been implicated as the 
control centre for maintenance of normal SNAT rhythm [136] and 
there is evi dence to suggest i nvo 1 vement of centrally medi ated "--
adrenergic mechanisms in control of the enzyme [137]. 
While melatonin is capable of inhibiting both rat liver and 
bovine pineal SNAT, no effect has been observed on the rat pineal 
enzyme [138]. SNAT has been thought to control melatonin 
production [139,140] and this may represent a negative feedback 
mechanism whereby increased me latonin levels would reduce output 
through inhibition of the enzyme. 
An O-acetyltransferase enzyme has been found in the pineal gland 
which catalyses formation of 0 -acetyl-5-methoxytryptophol [125]. 
The final enzyme involved in synthesis of melatonin, 
hydroxyi ndole-O-methyltransferase (HIOMT), was originally thought 
to be unique to the pineal [141] although it has now been found 
in tile retina and Ilarderian gland [142] and may be present in 
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enterochromaffin cells [85]. The enzymes from several mammals, 
including man, are immunochemically similar [143]. It has been 
localized in mitochondria [144] and is capable of methylating a 
variety of hydroxyindoles [76,141,145,146]. HIOMT activity is 
highest during the dark phase [147,148,149], a phenomenon 
presumed to be controlled by noradrenaline [149], although 
sympathomimetic action has also been shown to decrease HIOMT 
levels in the pineal [150]. No nocturnal increase in HIOt~T levels 
were found in this study (unpublished data) which suggests that 
increased melatonin production during the dark phase results frorn 
increased substrate availability. 
HIOMT may not be involved solely in production of methoxyindoles 
as it has been shown to methylate oestradiol [151] although no 
functional significance has been attached to this activity. 
Several reports have suggested that more than one HIOMT might 
exist [152,153,154] and differences in activity might result from 
association-dissociation of the various forms [152]. In this 
regard it is interesting to note that at night HIOMT appears to 
produce more melatonin than 5-methoxytryptophol, the reverse 
occurring during the day [155,156]. Such a difference might 
result from changes in association. Several enzymes with 
different isoelectric points have been found in the pineal [154] 
and this might also playa role in differential methylation. 
Several ci trate metabolites and some ani ons have been shown to 
activate HIOMT, presumably by an allosteric mechanism, while 
several compounds including cysteic and homocysteic acids, 
glutathione and S-adenosylhomocysteine inhibit the enzyme 
[153,157,158]. Thi s raises the possibil ity that changes in 
metabolic status of the pineal might serve to regulate 
methylation of hydroxyi ndoles. Inhibition of f1Iorn by S-
adenosylhornocysteine is competitive with respect to the substrate 
S-adenosylmethionine, implying that the catalytic mechanism is 
ordered Bi-Bi with S-adenosylmethionine the first substrate to 
bind to the enzyme [159]. 
S-adenosylmethionine is capable of protecting HIOMT from 
proteolysis [160] and the enzyme responsible for its formation, 
methionine S-adenosyltransferase, undergoes a circadian rhytlllTI in 
the pineal wi th peak activity during the dark phase [161]. 
Changes in HIQMT activity may therefore result from alteration in 
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synthesis of S-adenosylmethionine, a process which may be 
controlled by glucocorticoids [161J. 
Biogenic amines such as histamine and dopamine also inhibit HIOMT 
[162,163J, as can pyridoxal 5' -phosphate [164,165J maki ng the 
potential regulatory mechanisms extremely complex . 
A variety of drugs affect HIOMT, tranquilizers inhibiting [166J 
and psychotomimetics stimulating activity [163], which might 
affect normal levels of methoxyi ndoles. 
Moreover, the fact that seasonal variations exist in HIOMT 
activity [167,168J illustrates the complexity of indole 
metabolism in the pineal. 
It is apparent that melatonin synthesis can be controlled by 
hormones [169,170,171] presumably by an effect on HIOMT or 
possibly cyclic AMP phosphodiesterase [172J. Melatonin may well 
regulate its own production [173], and another pineal product, 
arginine vasotocin, has been shown to inhibit indole metabolism 
[174J. The rhythm in methylation of hydroxyindoles by HIOMT is 
also regulated by pteridines and pterins [175-178J. It may be 
significant that pineal tyrosine hydroxylase uses 
tetrahydrobiopterin as a cofactor [179J and synthesis of 
biopterin in the pineal is mediated by a noradrenergic cyclic AMP 
mechanism [180J. Vasoactive intestinal peptide can stimulate 
cyclic AMP production in the pineal [181] and may be involved in 
some control mechanisms. De-Tyr- -endorphin can cause elevated 
pineal melatonin [182,183J and may represent an endogenous 
control mechanism assisting in integration of information. 
Methoxyindoles might be involved with integration of va r ious 
information thus enabling maintenance of a normal environment 
[5,184J. The manner in whiCh the methoxyindoles mediate their 
action is not fully understood. Melatonin appears to stimulate 
cyclic GMP [185J and may affect secretory processes by impairing 
certain microtubule-dependent mechanisms . [186J. 
The im por tance of the pineal gland as a neuroendocrine modulator 
becomes apparent when one considers the extent of its 
physiological effects. 
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Isolated reports have indicated many potential functions for the 
pineal gland. Among these are the findings that melato nin 
enhances wound healing [187], is possibly involved in intestinal 
physiology [188], affects melanin synthesis [189J and may serve a 
neuromodulatory role in the salivary glands [190J. Pineal 
hypertrophy results f rom isolation [191J, activity decreases with 
age [192 J, so m e pin e alp r 0 du c t has the a b il i ty to i n hi bit 
placental chorionic gonadotrophin [193J and affects ornithine 
decarboxylase activity in a number of tissues [194J. The pineal 
gland is involved in tumcur growth [195J and abnormal melatonin 
rhythms have been found in 47 disease states [196J. 
Possibly the most extensively documented effects of the pineal 
are those on the reproductive system. Melatonin is capable of 
suppressing reproduction [197,198,199J an effect that apparently 
requires an intact pineal [199J. It has been postulated that 
changing photoperiod is translated into melatonin production by 
the pineal and that this conveys seasonal information to the 
gonads [200,201J. Apart from melatonin, 5-methoxytryptophol [202J 
and 5-methoxytryptamine [203J also exert antigonadotrophic 
effects. The effect of 5-methoxytrytpamine, unlike that of 
melatonin, does not require the presence of an intact pineal 
[203J. t·lo reover, the di scovery that levels vary with the 
menstrual cycle [204J also implies that 5-methoxytryptophol has 
an effect upon reproduction. 
Conflicting evidence exi sts as to the mode of action of these 
methoxyindoles on reproduction. It has been suggested that while 
melatonin inhibits luteinising hormone release, 5-methoxy-
trypt ophol inhibits follicle stimulating hormone and so 
suppresses reproductive axi s by alteration of gonadotrophi n 
release [205J. Contradictory findin gs indicate that melatonin 
inhibits follicle stimulating hormone release [206J. The pineal, 
through melatonin action, partiCipates in linking l uteinis ing 
hormone surge to photoperiod [207J . Despite the inconsistencies, 
it appears that the antigonadotrophic effects are mediated at a 
central level [206,208J. An antigonadotrophic effect has been 
shown with a melatonin free pineal extract [209J, Ivhich raises 
the possibility that products other than the methoxyindoles might 
control reproduction. For instan ce both pteridines and pte rins 
have been fo und to be anti gonadotrophic [210J. 
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It is i nteresti ng to note that the pi neal has been imp1 i cated as 
a target organ for androgens [211 ,2l2] and pi neal ectomy causes 
increased levels of testosterone and 17-ketosteroids [213], which 
tends to suggest that a pineal-gonadal feedback mechanism exists. 
The hypotha1amo-hypophysea1 system may serve as a target area for 
pineal melatonin [2l4,215,216] and a feedback mechanism between 
the pi neal and the hypotha1 amo-hy pophysea1 system has been 
suggested [2l7]. This control by the pineal may be mediated via 
the third ventricle [218], although melatonin affecting the 
hypotha1 amus may a1 so origi nate from the reti na [219] . Some 
effects exerted by the pineal on the hypothalamus are mediated by 
methoxyindo1es [10,220,221]' whilst other pineal products such as 
arginine vasotocin may also playa role [222]. 
The fact that the pineal has the capacity to activate the 
paraventricu1ar nuclei [223] and that a link between melatonin 
rhythm and drinking behaviour has been suggested [224] may 
i ndi cate yet another feedback mechani sm. 
Although it has been reported that there is no significant 
interaction between the pineal and hypotha1amo-hypophysea1-
thyroid axis [225], it appears that melatonin is capable of 
controlli ng thyrotropi n re1 easing hormone re1 ease [226J and is 
able to potentiate thyroid stimulating hormone action [227J. 
Apart from inhibition of thyrotropin releasing hormone 
production, a pineal compound has been found to inhibit prolactin 
releasing hormone [228]. This compound may be melatonin, which 
c au s e sin c rea sed do pam i n e 1 eve 1 sin the me d i alb a sal 
hypot halamus resulting in decreased prolactin secretion [229], or 
it may be arginine vasotocin, which can modulate prolactin 
secretion [230J. This implicates a number of pineal secretions in 
the control of pituitary hormone production. 
Melatonin does not appear to affect growth hormone in man [231], 
but with serotonin may modulate hypothalamic release of 
somatostatin [232J. Whereas pi nea1ectomy causes a reduction in 
grDllth hormone secretion [233 ] , so melatonin increases it [234]. 
This may be due to melatonin i nh ibition of dopamine release from 
the hypothal amus [235J, an effect which would reduce somatostatin 
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release [236] and hence increase growth hormone secretion. 
Pinealectomy also leads to increased follicle stimulating hormone 
and luteinising hormone levels [213,237]' seeming to 
desynchronise their release [237], while both melatonin and 5-
methoxytryptamine cause a decrease in luteinising hormone release 
[221]. The effect of melatonin on luteinising hormone may result 
from inhibition of prostaglandin E synthesis [238]. The presence 
of luteinising hormone releasing hormone in the pineal [239] may 
suggest the presence of a feedback mechanism controlling 
gonadotrophin release. 
Melatonin can also act on the pars intermedia to decrease 
melanocyte stimulating hormone release [240] and may indirectly 
affect EEG patterns by an effect on the hypothal amus [241]. 
Although reports have disputed any link between the pineal and 
pituitary-thyroid axis [242] there is considerable evidence 
suggesting a relationship [226,243-245]. 
Pinealectomy increases iodine accumulation by the thyroid, an 
effect reversed by melatonin [243,244], while thyroid hormones 
increase pineal melatonin [244,245,246]. It has been suggested 
that a receptor exists in the thyroid gland which is responsible 
for the effects elicited by melatonin [244]. The fact that 
melatonin can alter calcium and phosphate levels suggests an 
effect on the parathyroid gland [247] and it has been postulated 
that there is a feedback between the pineal and both the thyroid 
and parathyroid glands [248]. In this regard it is interesting to 
note that pineal cells shoVi a rhythm in sensitivity to thyroxine, 
being more responsive to excitation during the day [212]. 
Thyroid hormones may also alter pineal activity by influencing 
monoamine oxidase activity, either by affecting synthesis [249] 
or by suppression of an endogenous inhibitor and/or dissociation 
of less active aggregates [250]. 
There is evi dence that favours the presence of an adrenal-pi neal 
axis. Pinealectomy increases corticosterone levels [213,251] 
while melatonin administration reverses this effect [251,252]. 
The pineal induced decrease in corticosterone production appears 
to be an effect on protein synthesis rather than competition for 
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ACTH receptor sites [253]. 
Apart from melatonin, N-acetylserotonin [254], 5-methoxy-
tryptophol [255] and in certain instances serotonin, 5-hydroxy-
tryptophol and 5-hydroxyindole-3-acetic acid [256] have been 
shown to regulate adrenocortical function. 5-methoxytryptophol 
enhanced release of corticosterone [255], an effect opposite to 
that of melatonin, may indicate that changes in pineal output can 
alter adrenal honnonal status. 
Adrenolectomy activates the pineal, an effect which may be due to 
increased concentration of hypothalamic or pituitary hormones, 
decrease in adrenal hormones or ~-adrenergic receptor 
supersensitivity resulting from decreased adrenal catecholamines 
[257]. 
The adrenal-pineal axis may be involved primarily in modulation 
of stress. The adrenal gland has been reported to mediate stress 
by increasing pineal melatonin [258J while stress has been shown 
to increase uptake of tryptophan by the pineal [259] and to 
increase pineal adrenaline [72]. The adrenaline is presumed to 
originate from the adrenal gland [72]. 
Although melatonin receptors have been found in numerous 
peripheral tissues [260J and melatonin has been postulated to act 
i ntracellularly [260,261]' the brain has been suggested as the 
prima ry target for pineal hormones [262]. It is of interest that 
melatonin may be able to regulate its own receptors [263]. 
The presence of a habenulo-pineal axis has also been suggested 
[254]. Melatonin affects serotonin syn thesis in raph'e neur-ones, 
[257,265] but the highest concentration of melatonin receptors 
are in the medial basal hypothalamus [266]. Receptor agonist 
activity is abolished by 6-hydroxylation while metiloxyindoles 
have a greater activity than their hydroxy counterparts [266]. 
Melatonin enhances sleep, an effect apparently independent of 
changes in brain indoles, catecholamines or electrical activity 
[267]. ~1elatonin secretion associated with nocturnal arousals ha s 
been suggested to restore sleep [268] while other pineal products 
such as 5-hydroxytryptophol [9] and arginine vasotoc in [259] may 
17 
also be involved in the sleep mechanism. 
The pineal can regulate pain through a central effect [270] which 
may involve mediation by methionine-enkephalin [271]. Various 
indoles have been shown to inhibit benzodiazepine receptor 
binding [272,273], with the melatonin metabolite N-acetyl-5-
methoxy kynurenamine being the most potent, followed by mel a t on i n 
[273]. Both these indoles are more potent than the putative 
endogenous benzodiazepine receptor antagonists inosin e and 
hypoxanthine [273]. 
Although the choroid plexus cannot transport melatonin into the 
cerebro-spinal fluid it may possibly regulate central melatonin 
levels by affecting movement into the blood [274]. 
There are numerous reports which indicate that the pineal gland 
is involved in modulation of epileptic seizures. That audiogenic 
seizure suseptibility is regulated by light [275] might implicate 
pineal involvement. Some indoles have suggested anticonvulsant 
activi ty [276] as has tryptophol [277], serotonin and 5-
methoxytryptamine [278], while L-tryptophan [279] and indole 
aldehydes and alcohols may modulate seizure activity [280]. Most 
reports, however, implicate melatonin as the pineal anti-
convulsant principle [281-284]. 
Pinealectomy causes seizures which are not prevented by 
administration of melatonin or pineal extract [285,286]' thus 
implyi ng that an intact pi neal is essential for anticonvulsant 
activity. With an intact pineal, the removal of central melatonin 
causes transient seizure activity [287], hence further supporting 
a role for melatonin in sei zure modul ation. Some reports, 
however, find melatonin to be ameliorative in p ineal ectomy 
induced seizures [283]. These seizures may be faci 1 i tated by a 
decrease i n telencephalic catecholamines [288], an effect which 
might be reversed by melatonin [289]. r~e latonin has also been 
shown t o reduce the abil ity of epil eptic neurones to sustain 
activity [284,290] and may also alter EEG indirectly by an action 
on t he hypothalamus [241]. Thes e fi nd ings are consistent \>Iit~ t he 
proposal that pinealectomy induced seizures may result from the 
increas ed gonadotrophin and oestrogen levels [291]. A r eport 
i mp li cates decreased potassium levels in seizure generat i on [292] 
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whil st another suggests that the pineal suppresses seizures by 
affecting activation or by modifying the balance between 
inhibitory and excitatory post-synaptic potentials or, 
alternatively, that the effect is due to metabolic and hormonal 
changes [293]. The overall effect of the pineal in modifying 
seizure behaviour is probably a mixture of all these various 
effects, complicated by the observation that there is a diurnal 
rhythm in sensitivity to melatonin [294]. 
The pineal gland has been implicated as an endogenous time-
keeping device [295-298] but its role appears to be that of a 
'coupling device' rather than a controlling device [299]. The 
suprachiasmatic nuclei participate with the pineal in generation 
of rhythms and form an important part of the mechani sm [300]. 
Three types of electrically distinct cells have been isolated in 
the pineal [301]. One type, with a constant firing rate, is 
presumed to be under commisural fibre control, whilst the other 
two types exhibit increased firing, either during the day or 
during the night [301]. These two cell types might be responsible 
for time-keeping [301] and it has been suggested that melatonin 
may serve to indicate the middle of the dark phase [302]. While 
hydroxyi ndo 1 es were predomi nantly depressant the methoxyi ndol es 
were mostly excitatory in their effect on pineal cells [303]. The 
effects of melatonin and 5-methoxytryptophol, although similar, 
appear to be medi ated on different cell s [303]. 
Several reports indicate a role for the pineal gland in 
thermoregulation [304-307], and temperature has been found to be 
important for regulation of melatonin levels [308] thus favouring 
the presence of a temperature-pi neal feedback mechani sm. 
That hypoglycaemia decreases 5-methoxytryptophol levels [204], 
insulin inactivates SNAT [130] and pinealectomy causes an 
increased insulin secretion, apparently resulting from lack of 
pineal secretions [309], suggests feedback between these two 
sys terns. 
Reports on the effect of pineal products in self-regulation are 
contradictory. While some reports indicate that melatonin may 
influence its own synthesis [212] and affect serotonin rhythm 
[310], other fi ndi ngs fail to observe any effect [311]. There is 
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also evidence which indicates that 5-methoxytryptamine has no 
effect on pineal activity [312]. The fact that there may be 
mel atoni n receptors in the pi neal [313] and that melatonin can 
change firing rate of pineal cells [314] suggests some role in 
regulating pineal secretion, possibly of arginine vasotocin 
[315]. Pineal influence on physiological processes and influences 
exerted on the pineal can be summarized as follows (Figure 2). 
Although there appears to be only one report deal i ng wi th the 
effect of anticonvulsants on the pineal gland, many of the 
effects observed suggest that these drugs may exert an effect on 
the pi neal. 
Diazepam (DZP) is able to inhibit nocturnal increase in SNAT 
activity, possibly by an effect on the hypothal amus to decrease 
adrenergic stimulation of the pineal [316]. Phenobarbitone (PBT), 
however, has been found to have no effect [316]. 
Several reports show that various anticonvulsants have the 
ability to alter central cyclic nucleotide levels. Acetazolamide 
(ATZ), DZP, diphenylhydantoin (DPH) and PBT are all able to 
inhibit brain cyclic AMP phosphodiesterase [317 ,3 18] while DPH, 
PBT and carbamazepine (CSZ) decrease cerebrospinal fluid cyclic 
AMP levels [319] and DZP causes a decrease in cerebellar cyclic 
GMP [320]. Most anticonvulsant drugs appear to inhibit brain 
aldehyde reductase (EC 1.1.1.2). Inhibition by' CSZ, DPH, 
ethosuximide (ETH) and PST appears to be noncompetitive [321,322] 
although inhibition by DPH may be mixed [322]. Clonazepam (ClZ) 
and DZP [323], primidone (PRD) [324] and valproate (VPA) 
[323,324,326] also inhibit al dehyde reductase, VPA in an 
uncompetitive fashion [326]. 
Both DZP and DPH inhibit monoamine oxidase [327,328] and DPH 
inhibits noradrenaline uptake [327,329]; effects which would 
probably facilitate noradrenergic transmission. PST may also 
exert an effect by altering noradrenal ine rhythm [330]. 
Numerous effects on the serotoninergic system are mediated by the 
administration of anticonvulsants. An increase in brain serotonin 
1 evel s has been shown to result from ATZ [331], ClZ [332], DZP 
and DPH [333,334] and PBT [328] administration, an effect which 
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may be due either to decreased efflux or to metabolism [328J. The 
fi ndi ngs that ClZ reduces serotoninergic activity [335J and that 
DZP decreases serotonin synthesi s [336J add to the compl exi ty of 
the issue maki ng positive predictions difficult. PBT is capable 
of altering serotonin rhythm [330J whil e VPA has no effect on 
synthesis but increases 5-hydroxyindole-3-acetic acid levels, 
presumably resulting from inhibition of transport [337,338J. VPA 
may displace protein bound serum tryptophan, thus increasing 
brain levels [339], which may account for the increased 5-
hydroxyindole-3-acetic acid levels. Increased serotonin levels 
resulting from ClZ or DZP administration may be due to increased 
tryptophan uptake [340,341]. 
Inhibition of calcium uptake results from administration of CBZ, 
DZP, DPH and PBT while ETH and VPA are ineffective [342J. Another 
report, however, finds high ETH concentration to increase calcium 
influx [343J. DPH has also been shown to inhibit calcium 
stimulated protein phosphorylation [ 344J, to enhance potassium 
uptake [345J and to block potassium release [346J. CBZ can also 
decrease depo larization [347]. Although it is difficult to gauge 
what effect these changes might have, any change in membrane 
functi on has the potential for some response. 
While PBT can decrease excitatory transmission [348], both DZP 
[349J and CBZ [350J have been shown to decrease neurotransmitter 
release, which may influence pineal function. Changes in 
endocrine function occur with use of several anticonvulsant 
drugs. DZP increases release of growth hormone from the pituitary 
[351J and inhibits luteinising hormone release, possibly by an 
action on the hypothalamus [352J . Both luteinising and follicle 
stimulating hormone surges are blocked by PBT [353J' whilst CBZ, 
DPH, PBT and VPA increase plasma testosterone and sex hormone 
binding globulin levels [354J. 
Both DPH and VPA inhibit release of thyroid stimulating hormone 
from the pituitary [355,356J and CBZ increases extra -thyroid 
metaboli sm of thyroid hormones [357]. 
DPH but not PBT disrupts corticosterone output and inhibits 
pi tui tary-adrenal stress response [358J. 
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ATZ antagonizes dopaminergic pancreatic secretion [359] and 
alteres insuli n secretion, the effect being dependent on glucose 
concentration [360]. Inhibition of insulin secretion by DPH 
appears to result from blockade of calcium and/or sodium 
transport [361,362]. 
Inhibition of leucine enkephalin activity results from ETH and 
VPA but not from DPH and PBT administration [363] whilst DZP has 
been found to increase hypothalamic enkephalin levels [364]. VPA 
also inhibites oxidative phosphorylation [365], resulting in a 
low energy state with great potential for affecting overall 
metabo 1 ism. 
Central taurine levels are altered by DPH, ETH, PBT, sulthiame 
(5TH) and VPA [366]. DPH interfered with folate metabolism [367], 
and both DZP and PBT cause hypothermi a [368,369]; all effects 
which might involve the pineal gland. 
DZP can increase activity of prostaglandin synthetase [370] and 
it has been suggested to act through a non-serotoninergic 
indoleaminergic system [371]. This latter finding is interesting 
in that DZP action is presumed to be mediated through specific 
benzodiazepine receptors which may be regulated by endogenous 
ligands [372], and in that various endogenous indoles are capable 
of fulfilling such a role [272,273] . 
However attractive this evidence might appear in linking 
anticonvulsant drug effects with the pineal gland, it must be 
remembered that such a relationship may not in fact exist. The 
evidence does, however, give an indication of what effects might 
, 
be e xpected, and would certainly help to explain any observed 
effects. 
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Figure 2: Schematic representation of the various inputs presumed 
to influence pineal activity and the numerous physiological 
processes upon which the pineal is thought to exert an effect 
(modi fied from [lJ). 
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I NTRODUCTI ON 
With most pharmacological studies using laboratory animals there 
is often the problem of deciding what quantity of a drug to 
admi ni ster. 
The techniques frequently adopted rely on observation of gross 
changes in the behaviour of the animal after drug ad~inistration. 
In the case of anticonvulsants these methods include prevention 
of chemically induced convulsions [1], suppression of cobalt 
induced seizures [2] and prevention of components of amygdaloid 
kindled seizures [3]. 
All these methods have the same serious disadvantage in that they 
01>- M~60L..cn;;5 
gi ve an i ndi cati on of the abi 1 i ty of the drug" to prevent 
occurence of an event without giving an indication of the tissue 
concentration of drug. It is the tissue concentration that is 
important in order to give an indication of the amount of drug 
wh ic h is capable of el iciting a pharmacological response. 
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In view of this it was decided to determine the plasma 
concentrations of the various anticonvulsants used in this study. 
Several reports. have indicated the normal therapeutic plasma 
concentrations of anticonvulsants [4-7J and the dosages necessary 
to achieve these levels were sought. 
MATERIALS 
See Appendix A. 
METHODS 
Dosing and Sampling. Rats of both sexes (250-300g) were dosed on 
a mg/kg basis by intraperitoneal injection. Drugs insoluble in 
water were either di ssol ved or suspended in propylene glycol. 
Beclamide and pheneturide resisted both solution and suspension 
and were consequently given orally as powder in a syrup simplex 
matrix. At set interval s after dosing rats were anaesthetised 
using ether and blood samples were collected by cardiac puncture. 
After collection the samples were centrifuged and the resultant 
pl asma was stored at -200C for no longer than a week pri or to 
analysis of plasma levels . 
Carbonic Anhydrase Inhibition. Acetazolamide (ATZ) and sulthiame 
(STH) concentrations were determined using a carbonic anhydrase 
assay. Phenol red (12.5mg/l) was dissolved in O.OIM carbonate-
bicarbonate buffer pHIO and carbonic anhydrase (IOmg/l) in 
distilled water, both solutions being kept on ice before use. The 
reaction vessel was similar to that used previously [8J except 
that the C02 inlet was at the bottom of the vessel. It was 
immersed in an ice bath and was attached to a C02 supply which 
purged the vessel continuously at a constant rate. Prior to assqy 
700ul buffer/indicator solution was mixed with 100ul sample 
(standard or diluted plasma sample) and 100ul carbonic anhydrase. 
A 700ul aliquot was pipetted into the reaction vessel and time 
for indicator to change from red to yellow was noted. Plasma 
samples were diluted (15ul/ml) with distilled water immediately 
prior to assay, heated at 1000C for 5 minutes to denature native 
carbonic anhydrase and cooled before assay. A cal ibration curve 
was obtained as above using spiked serum samples. Reaction 
mixtures were agitated to prevent frothing and after reaction the 
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vessel was emptied by applying a suction to the second inlet. 
After removing the reaction mixture the vessel was rinsed twice 
with distilled water before reuse. 
Densitometry of Thin layers. Beclamide (BCL) and pheneturide 
(PTR) levels were evaluated using thin layer chromatography 
(TLC) . 
For determination of BCl 1ml of plasma containing 200ug/ml 
ethosuximide as internal standard was mixed with 50ul saturated 
sodium carbonate and 2ml chloroform, vortexed for a minute and 
centrifuged for 10 mi nutes to separate the two layers. The upper 
plasma layer was then aspirated off and a further 3ml chloroform 
and sodium sulphate were added, tubes being vortexed again for a 
minute. The sodium sulphate was quickly filtered off and the 
chloroform evaporated to dryness at 400 C under nitrogen. The 
sides of the tubes were washed down using chloroform, the final 
residue being taken up in 50ul chloroform. A 10ul quantity was 
spotted onto TLC plates, developed in chloroform:acetone (9 : 1) 
and examined at 217nm on a densitometer after dryi ng. The 
calibration curve was constructed by spiking plasma with BCL and 
treating as above. 
Evaluation of PTR used the same procedure except diazepam 
(10ug/ml) was the internal standard and the scanning wavelength 
on the densitometer was 220nm. 
Ultra-Violet Spectrophotometry. A UV assay was employed to 
analyse carbamazepine (CBI) plasma levels. Plasma samples (300ul) 
were dil uted with 500ul of 0.05r~ phosphate buffer pH6.8, 3ml 
dichl oromethane was added and after vortexi ng for a mi nute 
samples were centrifuged for 5 minutes. A 2ml aliquot of the 
organic phase was then evaporated to dryness at 40 0 C under 
nitrogen, 2ml of 4M hydrochloric acid was added and the tubes 
heated at 1500 C for -30 minutes. A further 2ml of 4M hydrochloric 
acid was added and the absorbance of this solution was read at 
258nm on a Beckman model 25 spectrophotometer. A calibration 
curve was constructed by spiking serum with CBI and treating 
these samples as above. 
Radioactive Drugs. Clonazepam-5-14C (l.lSMBq/mg) (ClI) and 
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diazepam-5-14C (6.88GBq/mg) (DIP) were diluted using non-
1 abell ed dru g and admi ni stered as outl i ned above. Radi oact i vi ty 
of plasma and, where possible, pineal glands were determined. 
Soluene 350 was used to solubilize pineal glands prior to 
introduction of scintillation cocktail. 
Both ClI and DIP were administered for three days and blood 
samples were collected as previously described. Samples (lml) of 
plasma were mixed with 1ml 2M borate buffer pH10 and 5ml toluene, 
vortexed for 2 minutes and centrifuged for 10 minutes. The 
organic phase was aspirated off and evaporated at 40 0 C under 
nitrogen. After washing down the sides with toluene the residue 
was dissolved in 50ul chloroform and this entire amount spotted 
onto thin-layer plates. These plates were developed in 
chloroform:n-heptane:ethanol (50:50:5) and autoradiographs taken 
using Kodak Plus-X pan film negative (125 ASA). After development 
of the autoradiographs the spots were scraped off the thin-layer 
plates and quantitated. 
Enzyme Multiplied Immunoassay Technigue (Emit). Diphenylhydantoin 
(DPH), ethosuximide (ETH), phenobarbitone (PBT) , primidone (PRO) 
and valproate (VPA) levels were determined by Emit using the 
Emit/lab 5000 system and standard reagent kits according to 
manufacturers specifications. 
Analysis of Data. For construction of calibration curves (ATZ, 
BCl, CBI, PTR and- STH) five concentrations of the drugs were 
assayed in triplicate on separate occasions and the means of 
these determinati ons were used. The best fit was obta ined using 
1 i near regression analysis using the method of least squares and 
the coefficient of determination (r2) was used as a' measure of 
correlation . Standard error of the mean (SEM) was calculated for 
each val ue and was omi tted from graphs where too small. 
RESULTS AND DISCUSSION 
The only problem encountered with the carbonic anhydrase 
i nnibi tion was determination of the end-point of the reaction as 
colour change was not abrupt. This problem was largely overcome 
with experience. As the reaction rate varied slighlty with each 
set of determinations, the calibration curves were plotted as 
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drug concentration versus percentage inhibition in order to 
standardise the procedure (Figure la and lb). To ensure the 
accuracy of the technique standard concentrations of either ATZ 
or 5TH were included with each batch of samples. These were all 
treated in the same way, the standard samples serving as controls 
to ensure that the technique was functioning in a satisfactory 
fashion. 
ATZ STH 
(lJglml) lug/mil 
15 
40 
30 10 • 
20 5 
10 
,2,0.99 ,2,0.99 
0 10 20 30 40 50 0 10 20 30 40 so 
'I. CA inhibition "I. CA inhibition 
Figure 1: Calibration curves used to determine plasma 
concentration of a) acetazolamide (ATZ) and b) sulthiame (5TH). 
Each point represents the mean of three determinations performed 
as outl i ned in the text. Coefficient of determination (r2) given 
as a measure of linearity. (CA = carbonic anhydrase). 
BCl 
ETH 
Rt 
I 
1 
I 
o 
DZP 
PTR 
i I 
0.5 1 
Rt 
Figure 2: TLC scans from plasma samples for a) beclamide (BCL) 
using ethosuximide (ETH) as internal standard and b) pheneturide 
(PTR) with diazepam (DZP) as internal standard. 
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The extraction and separation technique adopted for BCl and PTR 
gave good resolution with little background interference (Figure 
2a and 2b). Calibration curves were constructed as peak height 
ratios versus plasma concentration (Figure 3a and 3b). 
BCL PTR 
ETH DZP 
6 0,2 
4 
0,1 
2 
• 
,2 , 0,99 ,2.0,98 
° 
5 10 15 20 25 
° 
5 10 15 20 
(JJgIrrI) I)3CL] WmO[PTR] 
Figure 3: Calibration curves used to determine plasma 
concentration of a} beclamide (BCl) and b) pheneturide (PTR) 
using peak height ratio versus drug concentration. Each point 
represents the mean of three determinations performed as outlined 
in the text. Coefficient of determination (r2) given as a 
measure of linearity. 
Heating CBZ with hydrochloric acid resulted in the formation of 
9-methylacridine which gave the characteristic UV absorption at 
258nm. CBZ plasma levels were obtained using the calibration 
curve of absorption versus CBZ concentration (Figure 4). 
A 
0,3 
0,2 
0,1 
° 5 10 15 20 
WmO~8Z] 
Figure 4: Calibration curve of absorption (A) versus 
carbamazepine (CBZ) plasma concentration obtained as outlined in 
the text. Each point represents the m2an of three determinations. Coefficient of determination (r ) given as a me asure of 
1 inearity. 
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Usi ng radi oactive ClZ and DZP simplified evaluation and allowed 
determination of the metabolites with relative ease after thin 
layer separation using autoradiographic localisation (Figure 5a 
and 5b). The pineal DZP profile (Figure 6) closely parallels that 
of plasma DZP (Figure 11) suggesting that plasma levels give a 
good indication of the tissue concentrations at any time. 
i 
o 
2 
5 
0.5 
Rt 
ell 
i 
o 
2 6 
DIP 
0.5 
Figure 5: TlC scans constructed from autoradiographic 
determination of a) clonazepam (ClZ) and b) diazepam (DZP) 
metabolites after administration, extraction and separation of 
radioactive drugs as outlined in the text. 
a) ClZ metabolites as follows- 1 = 7-acetamidoclonazepam, 2 = 7-
aminoclonazepam, 3 and 4 = hydroxy metabolites and 5 = clonazepam 
b) DZP metaboli tes as follows- 1 = oxazepam, 2 = N-desmethyl-
di azepam, 3 = 5 (p-hydroxyphenyl )oxazepam, 4 = 3-hydroxydi azepam, 
5 = 5(p-hydroxyphenyl )desmethyl di azepam and 6 = di azepam. 
The pharmacoki netic profiles for the various drugs are shown in 
Figures 7-18. Each point represents the mean of three values with 
the standard error of the mean (omi tted where too small to 
display). 
In order to remain effective the plasma levels of a drug must be 
maintained above the minimum therapeutic level at all times. 
These concentrations were evaluated after twice daily 
administration of drugs for three days, samples being taken 
shortly before the second dose on the third day. These trough 
levels (Tl gave an indication of the amount of drug necessary to 
maintain a constantly effective plasma concentration and it was 
these dosages that were used in subsequent studies. These values 
were successfully determined for all drugs except VPA (Table 1, 
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Figures 7-18) in which twice daily administration was inadequate 
to maintain therapeutic levels due to rapid elimination. In order 
to maintain constant therapeutic VPA levels would require the use 
of a sustained release preparation or frequent dosing which is 
undesirable. 
The half-life (t1/2) and elimination rate constant (Ke) were 
also determined (Table 2) and it is apparent that drugs are 
removed from rats much faster than from human subjects [9,10,11J . 
This information allows accurate predictions to be made about 
plasma levels in rats whereas existing clinically evaluated data 
would give a false indication. In this regard it is interesting 
that the pharmacokinetic data evaluated here is similar to that 
obtained for the Mongolian Gerbil [12J although significant 
differences do occur. This serves to emphasise ' the observation 
that pharmacokinetic behaviour of drugs varies markedly with 
species and in order to make accurate predictions about plasma 
levels/elimination rate the data must be treated as species-
speci fic o 
Table 1: Plasma levels of anticonvulsant drugs after repeated 
administration compared to normal therapeutic levels. 
PLASMA TROUGH THERAPEUTIC$ 
DRUG DOSE (mg/kg)* (ug/ml ) LEVELS(ug/ml) 
Acetazolamide 100 13±1 10-14 
Beclami de 250+ 15±3 9-19 
Carbamazepi ne 25 7±1 6-12 
C 1 onazepam 0.1 0.005±0.002 0.005-0.05 
Diazepam 10 1±0.2 > 0.6 
Diphenylhydantoi n 100 11±2 10-20 
Ethosuximide 25 42±3 40-100 
Ph enetur i de 150+ 11±7 ±10 
Phenobarbi tone 12.5 19±1 10-30 
Primi done 142 9±1 5-15 
phenobarbitone-primidone metabolite 10±3 10-30 
Sulthiame 50 10±1 3-11 
Val proate 64 2±1 50:-100 
* administered twice daily intraperitoneally except + given 
orally. $ from [4-7]. 
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Table 2: Half-life (t 1 /2) and elimination rate constant (Ke) determined for the various anticonvulsant drugs . 
DRUG 
Acetazo 1 ami de 
Beclamide 
Carbamazepine 
C 1 onazepam 
Di azepam 
Diphenylhydantoi n 
Ethos uxi mi de 
Pheneturide 
Phenobarbi tone 
Primidone 
Sulthiame 
Valproate 
[DZP] 
Ipg/pineail 
0,01 
t1/2 (hr) 
1.5 
1.8 
1.0 
0.8 
1.4 
7.5 
3.6 
3.3 
2.5 
0.3 
0.46 
0 . 40 
0.69 
0.90 
0.50 
0.09 
0.19 
0.21 
0. 28 
2.31 
1mg/kg 
--+-r---.--':;~:::;:::=;=~=;=:;::~==r===;:=i-,o,1mg/kg 
o 2 3 4 5 6 7 8 9 10 11 12 T 
TIME IhrJ 
Figu re 6: Pineal diazepam (DZP) concentration after 
administration of radioactive drug at the dose indicated at 
various time intervals. (T = plasma trough after administration 
of dru g for three days). 
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Figures 7-18: Plasma profiles determined for the various drugs as 
outl i ned in the text. (T = plasma trough after administration of 
drug for three days). 
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[jig/mil 
100 
50 
l00mglkg 
--~~~-.-.~=;~=r=r=r~~.~~ 
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TlME (hr) 
Figure 7: Plasma acetazolamide (AIZ). 
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20 
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Figure 8: Plasma beclamide (BeL). 
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Figure 9: Plasma carbamazepine (CBZ). 
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Figure 10: Plasma clonazepam (CLZ). 
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Figure 11: Plasma diazepam (DZP). 
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Figure 12: Plasma diphenylhydantoin (DPH) . 
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Figure 13: Plasma ethosuximide (ETH) . 
20 
10 
o 2 3 4 S 6 7 
Figure 14: Plasma pheneturide (PTR). 
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INTRODUCTION 
The hormone melatonin, isolated by Lerner ~~ [1J is produced 
in the pineal gland by O-methylation of N-acetylserotonin [2]. 
The enzyme responsible for O-methylation in the pineal, 
hydroxyindole O-methyltransferase, can only utilise serotonin one 
tenth as efficiently as it can use N-acetyl serotoni n implyi ng 
that N-acetylation preceeds O-methylation [2]. Serotonin has been 
shown to be N-acetylated to N-acetylserotonin ~ vivo [3] and 
this reaction is catalysed by an Ij-acetyltransferase enzyme [4]. 
Thi s enzyme woul d be more accurately termed acetyl coenzyme A: 
arylamine N-acetyltransferase (EC 2.3 . .1.5) and is not unique to 
. the pineal gland being found in other tissues such as the liver 
56 
[5]. The pineal enzyme, however, is unique in that it is under B-
adrenergic cyclic AMP control [6], levels rising during the dark 
phase [7]. It is the formation of N-acetylseroton i n that is rate-
limiting in the formation of melatonin [8]. 
The labil ity of pi neal N-acetyltransferase has precluded any i n-
depth study and few ki netic determinations have been attempted 
[5] . The present study attempted to design an assay technique to 
permit sensitive evaluation of N-acetyltransferase activity in 
order to elucidate the catalytic behaviour of the enzyme. This 
information would allow a better understanding of pineal 
biochemistry and would enable more accurate interpretation of any 
pharmacological effects on the enzyme. 
MATERIALS 
See Appendi x A. 
METHODS 
Preparation of N-acetyltransferase. Prior to use groups of rats 
of both sexes (250-300g) were pretreated with isoprenaline HCl 
(25mg/kg ip) in order to induce N-acetyltransferase (SNAT) levels 
in the pineal. Maximum induction occured after three hours when 
the rats were sacrificed, pineal glands removed with minimum 
delay and homogenised on ice in 0. 05M phosphate buffer pH6 . 5 
(unless otherwise stated). Equal aliquots of this mixture were 
used for the determinations. Time between sacrifice and addition 
of enzyme homogenates to reaction vessels was kept to the 
absolute minimum to prevent excessive degradation of the enzyme. 
Assay for SNAT. A modification of the method of Deguchi and 
Axelrod [9] was used . This method relied on transfer of a 14C _ 
acetyl group from [l_14C]acetyl coenzyme A (AcCoA) to 
tryptami ne HCl (Tryp) to form N-acetyltryptamine (NAT) . Tryp' was 
used in place of the natural substrate serotonin (5-HT) as SNAT 
coul d util ize it far more readily than 5-HT . Incubation mixtures 
contained AcCoA and either Tryp or 5-HT, concentration depending 
on the parameter bei ng investigated. Variation in the incubate 
volume was found to affect enzyme activity and a volume of 300ul 
per pi neal gland was chosen for all determinations. Incubation 
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was performed at 20 0 C for an hour (unless otherwise stated), 
reaction being terminated by the addition of an equal volume of 
0.2M borate buffer pH10 . The radioactive product of the reaction 
was extracted into 3ml toluene:isoamyl alcohol (97:3) by 
vortexing for a minute. Recovery using this extraction procedure 
was about 97%. After centrifuging for 10 minutes, 2ml of the 
organic phase was aspirated off into 6ml scintillation cocktail 
and radioactivity quantitated by scintillation spectroscopy. 
Counting efficiency was determined using the external standards 
channel ratio and exceeded 90% in all cases. 
Blank incubations were performed in which only enzyme was omitted 
from the procedure, these values being subtracted from those of 
enzyme incubates to arrive at a true value for enzyme activity. 
That an enzyme was responsible for formation of extractable 
radioactivity was verified by the addition of 0.1% w/v trypsin to 
some reaction mixtures. Activity was abolished shortly after 
trypsin addition verifying protein involvement. 
Product Purity. Thin-layer chromatographic (TLC) separation was 
used to evaluate purity of the radioactive product. After 
incubation toluene:isoamyl alcohol extracts were evaporated to 
dryness at 40 0 C under nitrogen, the residue being dissolved in 
chloroform and spotted onto TLC plates. When 5-HT was used as a 
substrate plates were developed in chloroform:methanol:glacial 
acetic acid (97:3:1) and when Tryp was the indolic substrate the 
solvent system used was toluene:glacial acetic aCid:ethyl 
acetate:water (16:8:4:1). 
After development these plates were dried an? strips of 
photographic film negative (Kodak Plus-X pan, 125 ASA) were 
attached to the plates which were allowed to expose in light 
proof containers at DoC for several weeks prior to development. 
The NAT standard used to check purity of the radioactive product 
was synthesised by reacting equimolar quantities of Tryp and 
acetic anhydride in water at SOoC for an hour. The reaction 
mixture was acidified using hydrochloric acid (4M) and poured 
over ice before extraction into several aliquots of ethyl acetate 
which was evaporated to dryness under nitrogen at 400 C and the 
product purified by TLC using the solvent system above. 
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Effect of pH. Groups of pi neal glands from isoprenal i ne-
stimulated rats were pooled and homogenised in distilled water 
containing Tryp (6x10-3M) and AcCoA (l.2x10-4M) using 150ul 
per pineal gland. Equal aliquots of this mixture (150ul) were 
added to 150ul aliquots of O.lM phosphate buffer of varying pH. 
Reaction was monitored after incubation at 200C for three hours. 
Effect of Temperature. Groups of pi neal glands from i soprenal i ne-
stimulated rats were pooled and homogenised in O.05M phosphate 
buffer pH6.5 (300ul per pineal gland) containing both Tryp 
(1.5x10-3M) and AcCoA (6x10-5~1l. Equal aliquots (150ul) were 
incubated at various temperatures for varying lengths of time, 
activity being monitored as described above. 
Evaluation of Kinetic Constants. Equal aliquots · (150ul) obtained 
from homogenisation of pooled stimulated pineal glands were 
incubated at 200C for an hour. Reaction remained linear under 
these conditions. Homogenates contained one substrate in constant 
concentration (4.5x10- 3M for Tryp or 1.8x10-4M for AcCoA) 
while the concentrati~n of the second substrate was varied 
(1. 5x10-4-3x10-3M in the case of Tryp and 5-HT and 1. 5x10-6 
-3x10-5M in the case of AcCoA). 
Cosubstrate Effects. 80th Tryp and AcCoA were mixed in a ratio of 
their KSm values and concentration of this mixture was varied 
(5x10-5-1x10-3M) reaction being monitored as above. 
Alternate Substrate Effects. Equal aliquots of enzyme homogenates 
were incubated in which concentration of either 5-HT or Tryp were 
held constant and SUb-saturating (5x10-4M) while concentration 
of AcCoA -;'as varied (2x10-6M-3x10-5M). Velocity was monitored 
at each concentration. 
Product Effects. In all cases concentration of one substrate was 
kept constant (3x10-3M for Tryp and 1.8x10-4M for AcCoA) 
while concentration of the second substrate was varied (2x10-6-
3x10- 5M for AcCoA and 2x10- 4-3x10- 3M for Tryp and 5-HT). 
These incubations were performed in the presence and absence of 
the various products at several concentrations (lx10- 6 and 
1x10- 5M for coenzyme A, lx10- 4 and 1x10-3M for NAT and 
1x10- 5, 1xlO-4 and 1x10-3M for N -acetyl serotoni n (NAS)). 
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Effect of pH on Kinetic Behaviour. Buffer solutions of various pH 
were added to reaction tubes and evaporated to dryness prior to 
incubation. Enzyme and substrate solutions were made up in 
distilled water and added to these reaction vessels thus 
reconstituting the 0.05M phosphate buffer environment at various 
pH values. The tubes contained one substrate in constant 
concentration (3x10-3M for Tryp and 1.8x10-4M for AcCoA) 
while concentration of the second substrate varied (2x10-6-
3x10-5M for AcCoA and 2x10-4-3x10-3M for Tryp). 
Effect of temperature on Kinetic Behaviour. Incubates containing 
enzyme and substrates (concentrations as for effect of pH on 
kinetic behaviour) in 0.05M phosphate buffer pH6.5 were subjected 
to various incubation temperatures to monitor changes in kinetic 
behaviour. 
Evaluation of Data. Reactions were carried out in duplicate and 
the means were used for analysis. The effects of temperature on 
reaction rate with time were analysed using linear regression, 
the coefficient of determination (r2) being used as a measure of 
1 inearity. All kinetic determinations were evaluated using 
computer assisted non-linear iterative regression analysis. 
RESULTS AND DISCUSSION 
The exposed areas on the autoradiographs corresponded to pure NAT 
or NAS respectively verifying purity of the product. 
Activity of SNAT peaked at a pH of 6.4 (Figure 1). A tri-linear 
function was created by plotting log velocity versus . pH (Figure 
2), the points of inflection giving the pK values for ionizing 
groups which influence catalytic activity [10]. The points of 
inflection (6.4 and 6.8) imply participation of imidazolium 
groups and possibly ~-ammonium groups of cystine in maintaining 
the catalytic environment of the active sites. It is not known in 
what way these sites might affect activity but may influence 
active sites directly, alter substrate binding, enzyme 
conformation or some other mechanism. 
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Figure 1: Effect of change in pH on SNAT activity. Points are the 
means of duplicates. Incubation at 200C for three hours. 
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Figure 2: Plot of log V versus pH to determine pK values of 
groups important to SNAT activity. (pK = points of inflection). 
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Enzymes exi st in di ff.erent protonation states in apparent 
equilibrium [11] which can be represented as follows. 
The pH profile for SNAT (Figure 1) suggests that only the H1+E 
form of th e enzyme is active and either increase or decrease in 
protonation leads to loss of catalytic activity. If it is 
accepted that at optimal pH all the enzyme exists in the active 
form H1+E and as pH increases or decreases so H1+E levels 
decrease in direct proportion to decrease in activity, then the 
proportions of the three protonation states of the enzyme can be 
depicted as a function of pH (Figure 3) . 
SNAT 1'1.) 
'00 
90 H,'E 
ao 
70 H 'E 0 
60 
50 
40 HiE 
30 
20 
10 
5 6 7 a 
pH 
Figure 3: Hypothetical plot of change in proportion of the 
various protonation forms of SNAT with variation in pH. 
Determination as outlined in the text. 
Several inferences can be drawn from this information. Firstly, 
the rate constant k2 has a greater magnitude than k_1 as 
H1+E changes to HD+E with greater rapidity as pH decreases. 
Secondly, as rate of change of H1+E to HO+E is relatively 
uniform and goes essentially to completion with increase in pH 
impl i es that there are no ionizi ng groups wi th pK values in the 
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range 6.8-8.3 that directly affect the active site. On the other 
hand, as Hi+E changes to H2 +E with decrease in pH, the 
profile of the rate of change varies. Rate of change remains 
constant as pH falls to about 5 . 6 then decreases with further 
reduction in pH implying that below pH5.6 conversion to inactive 
form is being resisted, indicative of an involvement of ionizable 
groups with pK values below 5 . 6 in maintaining a measure of 
catalytic activity. The limitations of the phosphate buffer did 
not allow determinations below pHs.O. 
Rearrangement of the Arrhenius equation allows a plot of log 
initial velocity versus reciprocal of absolute temperature to 
yield activation energies for the reaction (Figure 4). 
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2,4 
2,2 
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3,2 3,3 3.4 
·3 (-10 ) 
3,5 
1 
T 
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Figure 4: Arrhenius plot of log initial velocity (V o ) versus 
reciprocal of absolute temperature illustrating change in 
activation energy with temperature. Pi!>' >lT", v:l-(L.G b u. I'I...{~ · 
Be tw e e n 17 and 42 0 C the fun c t ion was b i - 1 i n ear wit h a 
discontinuity at about 30.soC. Below this temperature activation 
energy was low (about 2.iKj mol-i) while above 3D.soC 
activation energy rose to about iD,5Kj mol-i. This change 
probably results from denaturation of the enzyme which becomes 
more pronounced above 30. SoC. 
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Between 5 and 15°C, although the plot was linear, it was 
independent of the other li near sections of the graph with an 
activation energy of about 1.7Kj mol-1 . The fact that this 
section of the plot is almost parallel to that between 17 and 
3D.5 0 C suggests that, although there is a break in continuity of 
the plot, this is not due to a change in the catalytic process as 
such. This difference could possibly be explained by an effect of 
a decrease in tempe.rature on the primary .hydration shell 
surroundi ng the enzyme. As incubation temperature falls from 17 
to 15 0 C the increase in density and decrease in degree of 
autoprotolysis causes the primary hydration shell to become more 
tightly bound thus impeding substrate entry into the active site. 
Enzyme, although still present in the active fonn, has a reduced 
turnover number hence the velocity versus time profile would be 
expected to differ from those at higher temperature which is 
indeed the case (Figure 5). 
• 0 
_.··10 
2 .--c:;;:::.~=-___ -17° 0 
.-5 
o 2 3 4 5 6 7 8 9 10 11 12 
Tme (hr) 
Figure 5: Product fonnation (NAT) with time at various incubation 
temperatures shown on the graph. Pon-ITS 'A-1!-e Du\' t.-l ~. 
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The anomalies observed in the Arrhenius plot could, however, be 
due to a phase transition in the enzyme [12,13]. The transition 
in this case would take place between 15 and l7oC, the result 
being a more accessible catalytic site, hence an increased 
turnover number. 
SNAT activi ty was found to obey the following first order 
function closely. 
10g([P]00_[p]) = -kt + 10g[P] 
where k is a constant,[p]OOis the maximum product concentration 
and [P] is product concentration at time t, with temperature 
remaining constant. 
The estimated regression coefficients k and 10g[P]00 were 
obtained for each incubation temperature employed in order to 
obtain the h4lf -life (tl/2) of the enzyme (Table 1, Figure 5). 
From these results it can be seen that decrease in incubation 
temperature led to a significant increase in enzyme activity 
allowing more sensitive determinations. This increase in activity 
can be presumed to be the result of decreased thermal degradation 
of SNAT encountered at higher temperatures. 
Table 1: Values derived for the function log ([P]OO_ [P]) = -kt 
+ log [P] where k is a constant, [P]OO is maximum product 
concentration and [P] is product concentration at time t, with 
temperature remaining constant. The coefficient of determination 
(r2) illustrates the linearity of the plots. 
INCUBATION HALF -LIFE 
TEMP (OC) K (sec1) LOG [P]OO (tl/2)( sec) . r2 
5 1.3xl0-5 3.401 2.3xl04 0.99 
10 2.5xlO-5 3.413 1.2xl04 . 0. 98 
17 8.0xl0-5 3.350 3.8xl03 0.92 
20 8.1xl0-5 3.242 3.7xl03 0. 99 
25 9.6xl0-5 3.136 3.1xl03 0.99 
30 3.2xl0-4 2.676 9.5xl02 0.98 
35 4.6xl0-4 2.088 6.5xl02 0.93 
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Kinetic evaluations were based on the theory of Michaelis and 
Menten [14] resulting in determination of the Michaelis-Menten 
constant (K S m) and saturation velocity (V s ) for the three 
substrates used (Table 2, Figure 6a, 6b and 6c). The KS m values 
were similar to those previously reported while the Vs values 
differed [5] . 
v 
2 
1-10 ) 
pmol 
10 
8 
6 
4 
2 
0 
2 
o 
1 
V 
1 
V 
1 
[AcCoA) 
2 
-S 3 
1-10 )M [AcCoA] 
1 
~ 
2 -3 3 
l- l0)M [S-HT] 
V 
1_103) 
pmol 
1 
V 
1 
[Try~ 
0 2 -3 3 
1-10 )M [rryp] 
.. 
Figure 6: Effect of substrate concentration on ve locity of 
redction (V) with a) acetyl coenzyme A (AcCoA), b) tryptamine 
(Tryp) and c) serotonin (5-HT) as the varied substrate . Doub l e 
reciprocal plots inset to illustrate linearity. 
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Table 2: 
saturation 
non-linear 
M i c h a eli s -M e n ten kin e tic con s tan t s (K s m) and 
velocities (V s ) determined for SNAT substrates using 
regression analysis. 
VARI ED SUBSTRATE KSm(uM) Vs(pmol/pineal/hr) 
Acetyl Co A 10.6±O.9 1607±55 
Tryptami ne 672.6±59.4 2157±71 
Serotonin 973.0±44.4 415±8 
When velocity wa s monitored as the concentration of both 
substrates varied in a constant ratio, the resulting double 
reciprocal plot was found to be parabolic-up, indicative of a 
sequential rather than ping-pong catalytic mechanism [15]. Using 
alternate substrates (Tryp and 5-HTl produced double reciprocal 
plots with dissimilar gradients ilso indicative· of a sequential 
mechanism [16]. 
V 1 ·NAT 2 V 
( .103) ·3 (.10 ) 
pmol 
2 
·NAT 1 
·NAT 1 
·NAT 2 
2 
o 2 .3 3 (. 10 )M [Tryp] 
o 2 3 4 3 5 1 (·10) -[rryp] 
Figure 7: Effect of N-acetyltryptamine (NATlon catalytic 
behaviour of SNAT with tryptamine (Tryp) as the varied substrate 
(NAT 1 = O.lmM, NAT 2 = ImM). Double reciprocal plot illustrates 
the competitive nature of the interaction. 
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Figure 8: Effect of N-acetylserotonin (NASJ on catalytic 
behaviour of SNAT with serotonin (5-HTJ as the varied substrate 
(NAS 1 = O.OlmM, NAS 2 = O.lmM, NAS 3 = 1mMJ. Double reciprocal 
plot illustrates the competitive nature of the interaction. 
All the product inhibition patterns were mixed non-competetive 
except the effect of NAT and NAS on the enzyme in which case 
competitive inhibition was observed (Figure 7 and 8J. This is 
indicative of an ordered Bi-Bi catalytic mechanism [17J which can 
be represented as follows. 
5-HT 
J 
E E. 5 -HT 
AcCoA 
1 
E. 5 -HT. AcCoA 
E.NAS.Co A 
Co A NAS 
1 i 
E.NAS E 
The binding of 5-HT to the enzyme causes some conformational 
change which allows binding of AcCoA, acetyl transfer then occurs 
and products leave, also in a sequential fashion. 
It is interesting that this catalytic mechanism appears to be 
similar to that of liver N-acetyltransferase [l8J and yet the 
liver enzyme is unaffected by sympathetic stimulation [5J. This 
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suggests that while B-adrenergic stimulation is capable of 
increasing pineal SNAT levels it does not influence catalysis ~ 
se. 
The effects of changing pH on kinetic behaviour of SNAT were 
varied (Table 3). An increase in pH led to increased affinity of 
the enzyme for Tryp while the saturation velocity rose to a 
maximum at pH6.5 before decreasing with further increase in pH. 
Affinity for AcCoA was greatest at pH6.5, saturation velocity 
decreasing with increase in pH. This suggests that change in 
activity does not result from change in affinity but from an 
effect on acetyl transfer thus hindering product formation . 
Table 3: Effect of varying pH on kinetic constants for SNAT 
substrates. 
VARIED SUBSTRATE pH KSm(uM) Vs(pmol/incubate/hr) 
Acetyl Co A 6.0 29.7±0.9 525±9 
" 6.5 13.1±0.5 226±4 
" 6.8 32.4±2.2 250 ±10 
Tryptami ne 6.0 1510.4±31.5 705±7 
" 6.5 987.3±15.1 967±6 
" 6.8 444.0±121.3 682±6 
" 7.0 43.8±6.0 201±2 
Increase in incubation temperature tended to increase affinity of 
enzyme for Tryp while the saturation velocities for both Tryp and 
AcCoA decreased (Tab 1 e 4). The apparent increase ina ff in i ty may 
be the result of increased thermal agitation a~ incubation 
temperature rises resulting in increased particle collisions. The 
decrease in velocity probably results from denaturation with 
increased temperature. 
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Table 4: Effect of va ry i ng incubation temperature on kinetic 
constants for SNAT substrates. 
VARIED SUBSTRATE TEMP (OC) KSm(uM) Vs(pmol/incubate/hr) 
Acety 1 Co A 35 21.5±1.2 43±1 
" 30 45. 6±3. 8 234±13 
" 25 39.7±1.3 557±1l 
" 20 11.9±C.4 798±1l 
" 15 70.1±2.2 1311±31 
" 5 12.1±0.6 249±5 
Tryptami ne 35 828.2±52.2 269±7 
" 30 1550.0±36.4 891± 10 
" 25 937.1±18.0 791 ±6 
" 20 1100. 3±14. 0 1285±7 
" 15 2680.5±32.7 2234±16 
" 5 10108.3±235.1 2115±40 
Although it was not possible to purify SNAT due to its 
thermolability, the purity of the product indicates that the 
observed effects were the exclusive result of SNAT activi ty and 
and hence gave a reasonable indication of the catalytic 
behaviour. 
REFERENCES 
lJ Lerner, A.B., Case, J.D., Takahashi, Y., Lee, T.H. and Mori, 
W.(1958)J Am Chem Soc 80:2587 
-----
2J Axelrod, J. and Weissbach, H.(1960)Science 131:1312 
3J McIsaac, W. and Page, I .H. (1959)~ Biol Chem 234:858-864 
4J Weissbach, H., Redfield, B.G. and Axelrod, J.(1960)Biochim 
Biophys Acta 43:352-353 
5J Deguchi, T.(1975)~ Neurochem 24:1083-1085 
6J Chan, A. and Ebadi, M.(1980)Neuroendocrinology 31:244-251 
7J Klein, D.C. and Weller, J.L.(1970)Science 169:1093-1095 
8J Axelrod, J.(1974)Science 184:1341-1348 
9J Deguchi, T. and Axelrod, J.(1972)Anal Biochem 50:174-179 
70 
10J Dixon, M. and \,ebb, E.C. (l958)Enzymes, Longmans, Green and 
Co. London. p149. 
IIJ Wong, J.T.-F.(1975)Kinetics of Enzyme Mechanisms, Academic 
Press. London. p210. 
12J Kumamcto, J., Raison, J.K. and Lyons, J.t1.(l971)~ Theor Biol 
31:47-51 
13J Adams, P.A. and Swart, E.R.(1977)Biochem ~ 161:83-92 
14J Michaelis, L. and Menten, M.L.(1913)Biochem ~ 49:333-369 
15J Fromm, H.J.(1975)Initial Rate Enzyme Kinetics, Springer. 
Berl i n. p71. 
16J Fromm, H.J .(l975)Initial Rate Enzyme Kinetics, Springer. 
Berlin. p73. 
17J Fromm, H.J.(1975)Initial Rate Enzyme Kinetics, Springer. 
Berli n. p127. 
18J Howd, R.A., Seo, K.S. and Wurtman, R.J.(1916)Biochem 
Pharmacol 25:977-978 
71 
CHAPTER 4 
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INTRODUCTION 
Hydroxyindole-O-methyltransferase was first detected in bovine 
pineal gland [1] and has since been found in the pineal glands of 
other mammals [2], birds, reptiles and amphibians [3]. Until 
recently it was thought to be unique to the pineal gland but has 
since been found in the retina and harderian gland [4] and may 
occur in enterochromaffin cells [5]. Retinal hydroxyindole-O-
methyltransferase exhibits similar properties to the pineal 
enzyme whil e that from the harderian gland is notably different, 
being stimulated by magnesium ions and showing a different 
spectrum of substrate specificities [4] . 
Hydroxyi ndole-O-methyltransferase catalyses the formation of a 
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variety of methoxyindoles including 5-methoxytryptophan and 5-
methoxytryptamine [6], melatonin [1], 5-methoxytryptophol [7] and 
5-methoxyindole-3-acetic acid [8]. It has been suggested that 
several such enzymes exist in the pineal [9], activity being 
regulated by pterins and pteridines [9,10] 
Although studies have evaluated some kinetic parameters [4] and 
several groups have obtained pure enzyme [11 ,12] only one report 
has suggested a catalytic mechanism [13]. This report proposed an 
ordered Bi-Bi mechanism for the enzyme [13]. 
The present study attempted to increase sensitivity of 
determination of the enzyme and to further characterise the 
catalytic mechanism. 
MATERIALS 
See Appendi x A. 
METHODS 
Preparation of Hydroxyindole-O-methyltransferase (HIOMT). Both 
rat and bovine enzymes were used. 
Rats of both sexes (2S0-300g) were sacrificed, pineal glands were 
removed and homogenised on ice in O.OSM phosphate buffer pH7.9 
(unless otherwise stated) using 160ul per pineal gland. These 
hom ogenates contained substrates in varying concentration 
depending on the parameter being investigated . . 
Bovine pineal glands were collected within an hour of death and 
homogenised in 0.15% w/v KCl (lml per 100mg tissue), centrifuged 
for 30 minutes at 40C to remove cell debris and the resu ltant 
supernatant was lyophilised. The lyophilisate (lmg per 12.37 1. 34 
mg wet tissue) was stored at -20oC and was used as a source of 
HIOMT. Prior to use this lyophilisate was dissolved in O.OSM 
phosphate buffer pH7.9 (unless otherwise stated) using 1mg per 
100ul final incubate volume. 
Assay for HIOMT. The assay technique adopted was modified from 
that of Axelrod ~ ~ [14] which relied on transfer of a 14C-
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methyl group from S-adenosylmethioni ne (AMe) to N -acetyl serotoni n 
(NAS) forming melatonin (MTN). Incubation was carried out at 
42 0 C for an hour (unless otherwise stated) and reaction was 
halted by the addi tion of an equal volume of 0.2M borate buffer 
pH10. Reaction remained linear under these conditions. 
Radioactive MTN was extracted into 3ml toluene:isoamyl alcohol 
(97:3) mixture by vortexing for a minute. After centrifugation, 
2ml of the organic phase was aspirated into 6ml scintillation 
cocktail and quantitated. Extraction led to about 98% recovery. 
Counting efficiency was determined using the external standards 
channel ratio and exceeded 90% in all cases. 
Blank incubations were performed in which only enzyme was omitted 
from the procedure, these values being subtracted from those of 
enzyme incubates to arrive at a true value for enzyme activity. 
Trypsin addition (0.1% w/v) to some incubates led to a rapid 
decrease in activity, verifying protein involvement in the 
formation of 14C-MTN. 
Product Purity. Toluene:isoamyl alcohol extracts were evaporated 
to dryness under nitrogen at 400C, the residue dissolved in 20ul 
chloroform and spotted onto thin-layer (TLC) plates. These TLC 
plates were developed in chloroform:methanol:glacial acetic acid 
(97:3:1). 
After development the plates were dried and strips of 
photographic film negative (Kodak Plus-X pan, 125 ASA) were 
attached and left to expose in light proof containers at OoC for 
several weeks prior to development. 
Effect of pH. Groups of rat pineal glands were pooled and 
homogenised in distilled water (80ul per pineal) and 80ul 
aliquots were added to an equal volume of O.lM buffer solutions. 
These mixtures contained AMe (4x10- 4M) and NAS (7.6x10-4M) 
and velocity was monitored for an hour at 380C. 
Effect of Temperature. Pooled rat pineal gland homogenates 
containing AMe (4x10- 4M) and NAS (7.6x10- 4M) in 0.05M 
phosphate buffer pH7.9 were divided into equal aliquots (160ul) 
and incubated at various temperatures for different times. 
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Evaluation of Kinetic Constants. The ~lichaelis-Menten kinetic 
constants [15J were determi ned for both rat and bovi ne pi neal 
HIOMT. While concentration of one substrate was kept constant 
(8xlO-4M) the concentration of the second substrate varied 
(l.5xlO- 5 -3.2xlO- 4M) velocity being monitored at each 
concentration . 
Cosubstrate Effects . Both AMe and NAS were mixed in a ratio of 
their KS m values and velocity was monitored as concentration of 
this mixture varied (5xlO-5-1xlO-3M). 
Product Effects. The effects of MTN and S-adenosylhomocysteine 
(SAH) on the kinetic behaviour of bovine pineal HIOMT were 
evaluated. In all cases concentration of one substrate was kept 
constant (8xlO- 4M) while the concentration of the second 
substrate was varied (2xlO- 5-3xlO-4M). Such determinations 
were carried out in the presence and absence of both products 
(saturating MTN and lxlO-5, 5xlO-5 and lxlO-4M SAH). 
Effect of pH on Kinetic Behaviour. Buffer solutions of various pH 
were added to reaction tubes and evporated to dryness prior to 
incubation . Enzyme and substrate solutions were made up in 
distilled water and added to these reaction vessels thus 
reconstituting the O.05M phosphate buffer environment at various 
pH values. The tubes contained one substrate in constant 
c oncentrat ion (8xlO-4M) wh i1 e the concentrati on of the second 
substrate varied (2xlO-5-3xlO-4M). 
Effect of Temperature on Kinetic Behaviour. Incubates in O.05M 
phosphate buffer pH7.9 containing one substrate in constant 
concentration (~xlO-4M) and the second substrat~ at various 
concentrations (2xlO- 5-3xlO-4M) were incubated at different 
temperatures. 
Evaluation of Data . Reactions were carried out in duplicate, the 
means being used for analysis. The effects of temperature on 
reaction rate with time were analysed using linear regression, 
the coefficient of determination (r2) being used as a measure of 
linearity. All kinetic determinations \~ere evaluated using 
computer assisted non-linear itera tive regression analysis. 
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RESULTS AND DISCUSSION 
On development of the autoradiographs only one exposed area was 
detected which corresponded to pure MTN verifying product purity. 
Although HIOMT activity increased by about 25% when determined in 
glycine buffer pH9 instead of phosphate buffer pH7.9 at 38 0 C 
(Figure 1) this increase was not maintained at higher 
temperatures . Consequently, it was concluded that the best buffer 
system was O.05m phosphate at pH7.9 and the optimum conditions 
for determi nation of HIOMT activity ~ vitro are incubation at 
420 C using a final incubate volume of 160ul/rat pineal gland or 
100ul/mg of bovine pineal lyophilisate. 
MIN 
(0102) 
pmol 
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~ 
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pH 
Figure 1: Effect of different buffer systems on rat HIOMT 
activity. Incubation at J80 C for one hour in O.05M buffer. C = 
carbonate, G = glycine, P = phosphate and T = tris buffer. 
A plot of log velocity versus pH gave a bi-linear function with 
the point of inflection at 7.8 (Figure 2). This value represents 
the pK value of ionizing groups which influence activity [16J and 
these groups may be "'-ammonium groups [17]. It is not known in 
what way these groups influence activity but may affect substrate 
binding, enzyme conformation or exert a direct effect on the 
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active site. The pH profile suggests that the higher protonation 
states of HIOMT are inactive and decrease in protonation leads to 
an increase in activity. 
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pH 
Figure 2: Plot of log V versus pH to determine pK values of 
groups important for HIOMT activity. The point of inflection 
indicates the pK value . Each point represents the mean of 
dupl i cates. 
The Arrhenius plot of reaction rate versus reciprocal of absolute 
temperature yi elded a bi-linear function with the point of 
inflection at 32 0 C (Figure 3). At lower temperatures the 
activation energy was about 10.5Kj mol-1 while above 32 0C the 
activation energy doubled. This discontituity may indicate that 
the enzyme is present in two active forms in equilibrium with one 
another, change in activity occuring with changes in incubation 
temperature. Evidence exists suggesting that HIOMT occurs in 
different molecular forms with differing activity [11] which 
would support this proposal. The discontinuity may also indicate 
a phase transition in the enzyme [18,19]. 
HIOMT activity with time was found to be first order for all 
temperatures tested and obeyed the following function closely 
where k is a constant, [P]OO is maximum product concentration 
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at anyone temperature and [P] is product concentration at time 
t, temperature remaining constant. 
10g([P]00_[p]) = -kt + 10g[P] 
This data was evaluated in order to obtain the estimated 
regression coefficients k and log[P]OO which enabled 
calculation of half-life (t1 / 2 ) and consequently rate 
constants for the reaction at all temperatures used. The 
coefficient of determi nation (r2) was used to illustrate 
linearity (Table 1, Figure 4). 
logY" 
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Figure 3: Arrhenius plot of log initial velocity (V o) versus 
reCiprocal of absolute temperature illustrating change in 
activation energy with temperature. 
The Michae1is-Menten constant (KS m) and saturation velocity 
(V s ) were calculated for both substrates using rat and bovine 
pineal HIOMT (Table 2, Figure 5a and 5b, 6a and 6b). These values 
di ffer sl i ght1y from those previously reported [4] probably as a 
result of differences in assay conditions employed. 
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Table 1: Values derived for the function log([PJoO_[PJ) = -kt + 
log[PJ where k is a constant, [PJoo is maximum product 
concentration and [PJ is product concentration at time t, 
temperature remaining constant. Values obtained from incubation 
of rat pineal incubates. The coefficient of determination (r2) 
illustrates the linearity of the plots. 
INCUBATION HALF -LIFE 
TEMP (OC) K (sec-1 ) lOG [PJoo (t1/2) (sec) r2 
34 2.7x10-5 2.931 1.5xl04 0.99 
38 3.7xlO-5 2.908 1.1xl04 0.99 
42 6.8xlO-5 2 . 858 6.0xl03 0.98 
44 1. 5xlO-4 2.736 2.7xl03 0 . 94 
46 2.3xlO-4 2.599 1. 7xl03 0.90 
o 2 3 4 5 6 7 8 9 10 11 12 
Time (hr) 
Figure 4: Effect of different incubation temperatures and times 
on melatonin formation . Incubation was in 0.05t~ phosphate buffer 
(pH7.9) for varying · lengths of time at the temperatures shown on 
the graph. 
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Table 2: Michaelis-Menten kinetic constants (K Sm) and 
saturation velocities (V s ) determined for rat and bovine pineal 
HIOMT using non-linear regression analysis. 
VARIED 
TYPE OF HIOMT SUBSTRATE KSm(uM) Vs(pmol/incubate/hr) 
Rat AMe 75.8±3.2 708±11 
" NAS 129 . 2±21.5 nO±56 
Bovine AMe 55.3±2.3 4722±70 
" NAS 35. 6±3. 2 6138±176 
v V 
(0102) (0102) 
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I 
V 
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2 2 
I I tame] VIm:r 
0 2 '4 3 0 2 ·4 3 (010)M /AMi! (010 )M [NASJ 
Figure 5: Effect of substrate concentration on velocity of 
reaction (V) for rat pineal HIOMT with a) S-adenosylmethionine 
(AMe) and b) N-acetylserotonin (NAS) as the varied substrate. 
Double reciprocal plots inset to illustrate linearity. 
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Figure 6: Effect of substrate concentration on velocity of 
reaction (V) for bovine HIOMT with a) S-adenosylmethionine (AMe) 
and b) N-acetylserotonin (NAS) as the varied substrate. Double 
reciprocal plots inset to illustrate linearity. 
When concentration of both substrates was varied in a constant 
ratio the double reciprocal plo't was parabolic-up, indicative of 
a sequential rather than ping-pong catalytic mechanism [20]. 
Melatonin was an uncompetitive inhibitor of HIOMT with respect to 
NAS and a mixed non-competitive inhibitor with respect to AMe_ On 
the other hand, SAH was a mixed non-competitive inhibitor with 
NAS as the varied substrate and exerted a competitive inhibition 
when AMe was the varied substrate (Figure 7). This product 
inhibition pattern is indicative of an ordered Bi-Bi mechanism 
[21] which is in agreement with a previous report [13] and may be 
represented as follows. 
AMe 
~ 
E E.AMe 
NAS 
~ 
E.AMe.NAS 
E.SAH.MTN 
MTN SAH 
i i 
E_SAH E 
81 
Catalysis begins with binding of AMe to HIOMT, such binding 
causing a change in conformation which allows NAS to bi nd to the 
enzyme, methyl transfer then occurs and products leave in a 
sequenti al fashi on. 
V I 
(_IOJ) '!, ·SAHJ (-IO ) 
pmol ·SAHI 
·SAH2 • 
20 7 
'SAH2 
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Figure 7: Effect of S-adenosylhomocysteine (SAH) on catalytic 
behaviour of HIOMT with S-adenosylmethionine (AMe) as the varied 
substrate. (SAH 1 = lOuM, SAH 2 = SOuM, SAH 3 = lOOuM). Double 
reciprocal plot illustrates the competitive nature of the 
interaction. 
Change in pH appeared to have little effect on NAS utilization by 
HIOMT while affecting both intrinsic activity and affinity for 
At1e (Table 3). At the lower pH affinity for AMe was about double 
that at higher pH while the intrinsic activity was less than half 
that at higher pH. The ratios between KAMe
m 
and VAMe 
varied little, suggesting an effect on the rate constant for 
dissociation of enzyme-substrate complex to yield products. This 
effect probably results from a change in protonation in the 
vicinity of the active site allowing product to leave more 
readily at a higher pH. The fact that affinity of HIOMT for Af1e 
increased with decrease in pH implied that an electron rich area 
of the AMe molecule was attracted to the active site. That 
velocity was reduced under these conditions implied that positive 
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charge in the vicinity of the active site inhibited transfer of 
the methyl group to NAS. As enzyme activity remained constant 
with increase in pH once a certain level of deprotonation had 
been reached supports the proposal that positive charge in the 
vi ci nity of the active site enhanced bi ndi ng of AMe but 
interfered with the catalytic process as such. Removal of 
positive charge from the active site allowed transfer of the 
methyl group. 
Table 3: Effect of varyi ng pH on ki netic constants for bovi ne 
pineal HIOMT substrates S-adenosylmethionine (AMe) and N-
acetyl serotonin (NAS). 
VARI ED 
SUBSTRATE pH K Sm( uM) Vs(pmol/incubate/hr) 
AMe 7.5 269.6 ±1. 0 16868±36 
u 7.9 570.1±2.8 36078±128 
u 8.8 517.0±1.0 36264±51 
NAS 7.5 109.9±O . 2 21503±13 
" 7.9 109.8±0 . 3 21239±25 
" 8.8 130.0±0.2 23281 ±13 
It is probable, therefore, that the electron rich flat adenosyl 
ring structure of AMe is attracted to the active site on HIOMT 
and this binding then enables the enzyme to accept NAS. Methyl 
transfer could be a nucleophilic substitution in which case 
presence of a group such as the imidazole side chain of histidine 
would enhance the nucleophilicity of the hydroxyl group on NAS . 
The presence of such a group would also account for the observed 
pH effects. That histidine is present in HIOMT [11,12] may 
indicate such a role although it is largely conjectural at this 
stage . 
The lower the incubation temperature the greater the affinity of 
HIOMT for its substrates while the saturation velocity decreased 
(Table 4) implying that activity of the enzyme was largely 
dependent on particle colli sions. With decrease in temperature 
particle-particle interactions decrease and activi ty followed a 
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similar pattern despite the increased affinity for substrates. 
Table 4: Effect of varying incubation temperature on kinetic 
constants for bovine pineal HIOMT substrates S-adenosy l methionine 
(AMe) and N-acetylserotonin (NAS). 
VARI ED 
SUBSTRATE 
AMe 
" 
" 
" 
NAS 
" 
" 
" 
TEMP (DC) 
42 
35 
30 
25 
42 
35 
30 
25 
KSm(uM) Vs(pmol/incubate/hr) 
470.6±3.0 29907±129 
109 . 1±1.2 7018±32 
40.3±6.1 1883±357 
9.8±O.1 1341±1 
381. 7±1. 7 25043±73 
643.6±0.1 2559±1 
70.1±0.8 905±4 
68.9±0.9 509±2 
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CHAPTER 5 
EFFECT OF ANTICONVULSANT DRUGS in vi tro ON THE ENZYMES INVOLVED 
IN PINEAL GLAND INDOLE METABOLISM 
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I NTRODUCTI ON 
The metabol ic fate of serotonin is complex and may be summarized 
as foll ows. HIOMT 
Serotonin ) Methoxytryptami ne 
~O SNAT 
N -.COW 1 ;eeot" '" A::: d""l "do 1 '-\t:: :':' d, 
5-hydroxytryptopho 1 5 -hydroxyi ndo 1 e-3 -acet i c aci d 
HIOMT lHIOMT 1 HIOMT 
Melatonin 5-methoxytryptophol 5-methoxyindole-3-acetic acid 
SNAT = N-acetyltransferase, MAO = Monoamine oxidase, Ald D and 
A 1 d R = Aldehyde dehydrogenase and reductase respectively and 
HIO~lT = Hydroxyi ndole-O-methyltransferase. 
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Although it has been suggested that a deacetylase [1] and 0-
acetyltransferase [2] also participate in indole metabolism, the 
vast majority of metabolised serotonin proceeds along the paths 
outlined above, 
There is evidence implicating the involvement of the pineal gland 
in seizure states [3,4]. A number of reports attribute the anti-
seizure activity of the pineal gland to the hormone melatonin [4-
7]. In the light of these findings it is interesting that no 
reports have studied the effect of anticonvulsant drugs on the 
pineal gland and more specifically on the enzymes responsible for 
the synthesis of melatonin. It is not possible, however, to 
consider any part of this scheme in isolation as any change in 
one pathway is bound to affect the others to a certain extent. 
An attempt was made to ascertain to what extent anticonvulsant 
drugs affected these enzymes ~ vitro. This information would 
give a valuable insight into what changes to expect in thei.!!. 
vivo situation, although not all ~ vitro effects woul d 
necessarily become manifest in vivo, ">11-\1: ... 6 ~ \J~ 1>oS"-
M\4y ~T ~e;rc.-e:cr lti \J,\J"------C::O .... w:; 104T1l-''""'O .... S . 
MATERIALS 
See Appendix A. 
METHODS 
Assay for Acetyl Co A:Arylamine N-acetyltransferase. Rats of both 
sexes (200-300g) were treated with isoprenaline HCl (25mg/kg ip) 
three hours before sacrifice in order to induce levels of N-
acetyltransferase (SNAT). Pineals were removed with mini mum delay 
and homogenised in O.05M phosphate buffer pH6.5 containing one 
substrate in constant concentration (3x10-3M in the case of 
tryptamine HCl and lxlO-4M in the case of acetyl coenzyme A) 
while the concentration of the second substrate varied (2xlO- 6 -
3x10-5M in the case of acetyl coenzyme A and 2x10-4-3xlO-3M 
in the case of tryptamine HC1). These homogenates were incubated 
at 20 0C for an hour in the presence and absence of the drugs 
used (lxlO-6 -1xlO-3M). Reaction remained linear under these 
conditions. After incubation reaction was terminated by addition 
of an equal volume of O.2M borate buffer and 14C- N-ac e tyl-
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tryptamine was extracted into 3ml toluene:isoamyl alcohol (97:3) 
mixture by vortexi ng for a minute. After centrifugation 2ml of 
the organic phase was aspirated off into 6ml scintillation 
cocktail and radioactivity quantitated. External standards 
channel ratio was used to calculate counting efficiency which 
exceeded 90% in all cases. 
Assay for Hydroxyindole-D-methyltransferase. Bovine pineal glands 
were collected shortly after sacrifice, homogenised in 0.15% KCl 
(lml per 100mg tissue), centrifuged at 40 C for 30 minutes in 
order to remove cell debris and the resultant supernatant was 
lyophilised and stored frozen. This lyophilisate served as a 
source of hydroxyindole-D-methyltransferase (HIOt1T) and prior to 
assay was dissolved in O.05M phosphate buffer pH7.9 (lmg in 
100ul). The assay relied on transfer of a 14C-methyl group from 
S-adenosylmethionine to N-acetylserotonin, the 14C-melatonin 
formed being extracted by vortexing for a minute with 3ml 
toluene:isoamyl alcohol (97:3) mixture. After centrifugation, 2ml 
of the organic phase was transfered to 6ml scintillation cocktail 
and quantitated. Incubation was performed at 420C for an hour, 
during which time reaction remained linear. Enzyme incubates 
contained one substrate in constant concentration (4x10-4M) 
while the concentration of the second substrate varied (2x10- 5-
3x10-4t~) reaction being monitored in the presence and absence 
of the various drugs (lx10-6-1x10-3M). Counting efficiency 
was determined using the external standards channel ratio and 
exceeded 90% in all cases. 
Assay for Monoamine Oxidase. Commercial monoamine oxidase (MAO) 
was obtained as a suspension in 2M ammonium sulphate 
(lunit/1.5ml). A spectrophotometric assay was employed which 
monitored formation of benzal dehyde from benzylamine at 250nm. 
Incubation was performed at 25 0 C for 30 minutes in O.lM 
phosphate buffer pH7.4, the reaction remaining linear under these 
conditions. A benzylamine concentration of 5x10-4M was used and 
activity monitored in the presence and absence of the 
anticonvulsant drugs (lx10- 7-1x10- 4M). Where the drug 
absorbed significantly at the wavelength used the maximum 
concentration tested was dictated by the interfering absorption. 
Reaction was initiated by addition of 40ul t1AO suspension to 3ml 
buffer / benzylamine mixture preheated to 25 0c. Absorption was 
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detennin"d after 30 minutes without terminating the reaction 
Assay for Al dehyde Dehydrogenase. This assay was conducted 
spectrophotometrically by monitoring formation of NADH at 340nm. 
Commerci al al dehyde dehydrogenase (Ald D) lyophilisate was 
dissolved in distilled water (lmg/lOml) and 100ul was added to 
2.8ml buffer/NAD mixture which was preincubated for 2 minutes 
prior to start of the assay. A O.lM tris buffer pH9 containing 
0.05t~ potassium dihydrogen phosphate, dithiothreitol (0.15mg/ml) 
and EDT A (0.4mg/ml ) was employed and reaction was initiated by 
addition of 50ul acetaldehyde solution to give a final 
concentration of 2x10-4M. The final incubate concentration of 
NAD was 2x10- 3M. I 'ncubation was performed at 25 0 C for 30 
minutes, reaction remaining linear and absorption was determined 
without terminating the reaction. Reaction was . monitored in the 
presence and absence of the various drugs (lx10-6-1x10-4M) . 
Assay for Aldehyde Reductase. Commercial lyophilised al dehyde 
reductase (Ald R) was dissolved in distilled water (0.02mg/ml) 
while the substrates were dissolved in O.lM phosphate buffer 
pH7.2. Reaction was monitored spectrophotometrically by observing 
decrease in absorption at 340nm as NADH was converted to NAD. 
Incubates contained NADH (lx10-5M) and acetaldehyde (5x10-2 ) 
and reaction was monitored in the presence and absence of the 
various drugs (lx10-6-1x10-3M). Reaction was initiated by the 
addi tion of 50ul Ald R solution to 2.95ml buffer/substrate 
mixture and was incubated at 25 0 C for 5 minutes, reaction 
remaining linear under these conditions. 
Evaluation of Data. Kinetic constants were determined using 
computer assisted non-linear regression analysis. As 'the MAO, Ald 
o and Ald R assays were not sensitive enough and the enzymes were 
not of pineal origin, data was used to calculate gross changes in 
activity rather than kinetic effects. In all cases points 
represent the mean of duplicates. 
RESULTS AND DISCUSSION 
None of the drugs tested affected HIOMT and only sulthiame (STH) 
had an effect on St~AT (figure 1 and 2). 
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Figure 1: Effect of 5ulthiame (STH) on SNAT activity as 
concentration of tryptamine (Tryp) varied. Double reciprocal 
plot shown to indicate the nature of the interaction (STH 1 = 
2ug/ml, STH 2 = 5ug/ml, STH 3 = 10ug/ml and STH 4 = 20ug/ml). 
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Figure 2: Effect of sulthiame (STH) on SNAT activity as acetyl 
coenzyme A (AcCoA) concentratio n varied. Double reciprocal plots 
shown to indicate the nature of the interaction. (STH 1 = 2ug/ml, 
STH 2 = 5ug/ml, STH 3 = 10ug/ml and STH 4 = 20 ug/ml). 
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This effect was mixed non-competitive inhibition with respect to 
tryptami ne and the rate expression can be represented as follows 
[8]. 
1 = 1 1 + STH + Kia 1+ STH 
_----'1=---__ .... (1 ) 
V Vs Ki i Kis [tryptamine] 
where V is velocity at a certain tryptamine concentration 
([tryptamine]), Vs is saturation velocity, Kii is dissociation 
constant for STH from E.tryptamine.STH complex, Kia is 
dissociation constant for E. tryptamine complex and Kis is the 
dissociation constant for E.STH complex. 
These dissociation constants are related to Kiii (dissociation 
constant for tryptamine from E.tryptamine.STHcomplex) in the 
following way [8]. 
Kiii = Kia.Kii .... (2) 
Kis 
As the double reciprocal plots are linear it may be assumed that 
the rapid equilibrium rather than the steady-state condi tion is 
met for the reaction. 
Using the Dixon plot [9] in which reciprocal of velocity is 
plotted against inhibitor concentration at different fixed levels 
of tryptamine it is possible to obtain values for Kii and Kis in 
that the coordinates of the points of intersection of the lines 
are (-Kis, 1/Vs[l-Kis/Kii]). From these values it is possible to 
calculate Kia using equation 1 and hence Kiii using equation 2 
(Tab 1 e 1). 
Table 1: Dissociation constants for the various complexes found 
between SNAT, tryptamine (Tryp) and sulthiame (STH) calculated as 
described in the text. 
DISSOCIATION CONSTANTS (uM) 
Kia = 547.4±17.6 
Kis = 4.4±0.1 
Kii = 1. 6±0. 4 
Kiii = 200. 9±6. 5 
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When the UV spectra of 5TH, tryptamine and acetyl coenzyme A were 
obtained in O.05M phosphate buffer pH6.5 it was interesting to 
note that there appeared to be an interaction between 5TH and 
tryptamine (Figure 3) . 
A 
200 300 },(nm) 
Figure 3: UV spectra obtained from sulthiame (5TH) and 
tryptamine in O.05M phosphate buffer pH6.5.(* = hypothetical 
addi tion of individual traces and '* = actual spectrum from the 
two together}. 
This interaction may also occur when tryptamine has bound to the 
enzyme and, although it is likely to interfere with catalysis, 
the major inhibitory effect of 5TH on 5NAT can be assumed to be 
as a result of binding to the enzyme, such binding inhibiting the 
catalytic process in some way. 
As the effect on catalysis is dependent on 5TH concentration but 
independent of tryptamine concentration it is likely that 
inhibition occurs at some stage after tryptamine has bound to the 
enzyme. 
From the dissociation constants (Table 2) it is apparent that 
5NAT has a far greater affinity for 5TH than for tryptami ne and 
also 5TH tends to bind better to the enzyme.tryptamine complex 
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rather than to the enzyme alone. This favours the proposal that 
inhibition occurs at some stage after tryptami ne bi ndi ng to the 
enzyme. 
Considering that the inhibition is largely dependent on 
concentration of acetyl coenzyme A it is likely that STH exerts a 
competitive-type interaction with acetyl coenzyme A for catalytic 
sites. These inhibition patterns are compatible with the 
mechanism being random Bi-Bi although studies indicate that the 
catalytic mechanism is ordered Bi-Bi with tryptamine the first 
subs trate to bi nd to the enzyme (see Chapter 3). 
This contradiction may be resolved as fo.llows- the increasing 
non-linearity of the double reciprocal plot with higher STH 
concentration (with acetyl coenzyme A as the varied substrate) 
suggests that presence of the inhibitor in the catalytic process 
is introducing complex second degree terms to the rate equation. 
As a result the plots may appear competitive whereas the 
interact i on may not be. The interference exerted by STH probably 
results from the drug bi ndi ng to the enzyme, such bi ndi ng 
i nterferi ng wi th normal acceptance of acetyl coenzyme A at the 
catalytic site, affecting either acetyl transfer or product 
removal after catalysis. 
To a certain extent the dissociation constants favour a 
competitive-type interaction with acetyl coenzyme A in the 
framework of an ordered Bi-Bi catalytic mechanism. In the 
envisaged ordered Bi-Bi mechanism tryptamine binding would cause 
a change in the catalytic site which could th en accept acetyl 
coenzyme A, affinity of SNAT for STH follows a similar pattern in 
that affinity for the enzyme.tryptamine complex is greater than 
that for the enzyme alone. Whether this action exerted by STH 
occurs at the catalytic site itself or some other part of the 
enzyme molecule is unknown . 
Inhibition of SNAT by STH occurs in the normal therapeutic range 
of the drug (3-11ug/ml) [10J and considering that SNAT is the 
rate-limiting step in production of melatonin [11-15J it might be 
expected that a significant reduction in mE:latonin production be 
observed in subjects taking STH. Considering the many effects 
postulated for melatonin (see Chapter 1) such an effect would be 
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bound to cause some physiological changes. Whether this occurs ~ 
vivo and what significance such an effect would have on anti-
seizure therapy is unknown at this stage . 
Of the drugs tested only clonazepam, di azepam, diphenylhydantoin, 
phenobarbitone and sulthiame exerted an inhibitory effect on 
monoamine oxidase (Table 2). 
Table 2: Effect of anticonvulsant drugs on monoamine oxidase 
(~IAO) activity. (100% activity = no inhibition). 
DRUG AND CONCENTRATION (uM) 11110 ACTIVITY (% ) 
No dru g 100 
Clonazepam 50 82 
Di azepam 50 89 
D ipheny 1 hy da ntoi n 50 81 
Phenobarbi tone 50 77 
5ulthiame 0.1 93 
Due to interference at the wavelength employed it was not 
possible to get accurate results for higher 5TH concentrations or 
to determine whether the other drugs might inhibit MAO at higher 
concentrations. On the basis of these results, however, it 
appears that 5TH is the most powerful and diazepam the weakest 
inhibitor. This verifies previous reports which showed di azepam 
and diphenylhydantoin to be MAO inhibitors [16,17] . 
Al d D was weakly inhibited by diazepam, diphenylhydantoin, 
pheneturide and phenobarbitone while primidone, sulthiame and 
valproate all exerted a noticeable inhibition on the enzyme 
(Tab le 3). 
Only acetazolamide exerted a powerful i nhibi tory effect on the 
Ald R used (Table 4) while carbamazepine, diazepam, diphenyl-
hydantoin and phenobarbitone were weak inhibitors and the other 
drugs used showed no inhibitory action. 
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Table 3: Effect of anticonvulsant drugs on aldehyde 
dehydrogenase (Ald D) activity. (10 0% activity = no inhibition). 
DRUG AND CONCENTRATION (mM) A 1 d 0 ACTI V ITY (% ) 
No dru g 100 
Di azepam 0.1 93 
Diphenylhydantoi n 0.1 93 
Phenetur i de 0.1 94 
Phenobarbi tone 0.1 95 
Primidone 0.1 87 
Sulthiame 0.1 79 
Valproate 0.1 87 
Table 4: Effect of anticonvulsant drugs on aldehyde reductase 
(Ald R) activity. (l00% activity = no inhibition). 
DRUG AND CONCENTRATION (mM) Al d R ACTIVITY (%) 
No drug 100 
Acetazolamide 1.0 35 
Carbamazepi ne 1.0 92 
Di azepam 0.1 95 
Diphenylhydantoi n 0.1 97 
Phenobarbi tone 1.0 97 
These results must be treated with caution, however, as the Ald R 
used was NADH-dependent whil e that in the pineal may be NADPH-
dependent. Existing reports have shown carbamazepine, clonazepam, 
diazepam, diphenylhydantoin, ethosuximide, phen~barbitone, 
primidone and valproate to be inhibitors of NADPH-dependent Ald R 
[18-23] and this suggests that the two types of enzyme are 
dissimilar. The fact that different Ald R isozymes showed 
di fferences insensitivity to valproate [23] supports this 
proposal. 
Whether the corresponding pineal enzymes would be inhibited to 
the same extent or not bears further investigation and these 
results should be treated merely as a guide which may assist in 
explaination of observed effects in vivo. 
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EFFECT OF ANTICONVULSANT DRUGS in vivo ON RAT PINEAL ACETYL CO A: 
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INTRODUCTION 
Considering the evidence which implicates involvement of the 
pineal gland in seizure states [1,2] and especi ally those which 
attribute the anti -seizure activity to melatonin [2-5J there is 
little evidence of any significant investigation into the effect 
of anticonvulsant drugs on the pineal gland. 
The present study was aimed at investigating the effect of 
anticonvulsant drug administration on levels of the two enyymes 
involved in melatonin synthesis, acetyl Co A:arylamine N-acetyl-
transferase and hydroxyindole-O-methyltransferase. Theoretically 
any drug which coul d cause an increase in the activity of these 
enzymes, and therefore increase pineal melatonin output, would 
have a potentially ameliorative effect on seizures. 
In the light of this hypothesis it is interesting that a report 
found phenobarbi tone to have no effect on acetyl Co A: aryl ami ne 
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N-acetyltransferase 11hile diazepam reduced the nocturnal activity 
[6]. As melatonin production appears to be dependent on N-acetyl-
transferase activity [7-11] this diazepam mediated effect would 
reduce melatonin levels and presumably enhance seizure activity 
if mel a toni n is assumed to act as an endogenous anticonvul sant 
agent. 
MATERIALS 
See Appendtx A. 
METHODS 
Dosing. Male rats (200-250g) were housed under constant lighting 
conditions (05hOO-17hOO light) with access to unlimited food and 
water. Rats were not used until they had been exposed to the 
1 ight cycle for at least two weeks. In all cases rats were dosed 
at 07hOO and 16h45 for"three days, either with drugs or normal 
saline (in the case of controls) prior to sacrifice. 
Drugs were injected intraperitoneally on a mg/kg basis at the 
doses previously determined (see Chapter 2) and where they were 
insoluble in water were dissolved or suspended in propylene 
glycol. Both beclamide and pheneturide resisted solution and 
suspension and were consequently administered orally as powder in 
a syrup simplex matrix. 
Preparation of Enzyme Homogenates. Rats were sacrificed at IlhOO, 
22h30, 23hOO and 23h30 and pineal glands were removed with a 
mi nimum of delay and homogenised on ice in di still ed water 
(120ul/pineal gland). When rats were sacrificed 'at night the 
entire procedure was conducted in red light (15W photographic 
safe light). These homogenates were divided into two equal 50ul 
aliquots for assay of acetyl Co A:arylamine N-acetyltransferase 
(SNAT) and hydroxyi ndole-O-methyltransferase (HIOr~T) activity 
respectively. 
Assay for SNAT. The technique adopted relied on acetylation of 
tryptamine HCl using 14C-acetyl coenzyme A as an acetyl donor 
[12]. As the quantity of enzyme present in the pineal gland 
increased dramatically at night different incubate volumes were 
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required in order to ensure optimum conditions. 
Wi th homogenates resulting from sacrifice at 1100 the final 
incubate volume was 75ul (50ul pineal homogenate and 25ul 
buffer/substrate mixture) while those from rats sacrificed during 
the dark phase employed a final incubate volume of 135ul (50ul 
pineal homogenate and 85ul buffer/substrate mixture). The final 
reaction mixtures were such that enzyme was dissolved in 0.05M 
phosphate buffer pH6.5 containing tryptamine HCl (3x10- 3M) and 
acetyl coenzyme A (l.8x10-4M). These were incubated at 20 0 C 
for an hour and reaction was terminated by addi tion of an equal 
volume of 0.2M borate buffer pH10. 
Assay for HIOMT. Assay relied on the formation of 14C-melatonin 
fran N-acetylseroto nin using S-adenosyl [14C-methyl] methionine 
as a methyl donor [13J. In all cases the final incubate volume 
was 90ul (50ul pineal homogenate and 40ul buffer/substrate 
mixture). Reaction mixtures contained enzyme, N-acetylserotonin 
(7x10- 4M) and S-adenosylmethionine (4x10- 4 M) in 0.05M 
p hos pha te bu ffer pH 7.9 and were i ncuba ted at 420 C for an hour . 
. Reaction was terminated by the addition of an equal volume of 
O.2M borate buffer pH10. 
Extraction and Quantitation. The radioactive N-acetyltryptamine 
(resulting from SNAT activity) or melatonin (resulting from HIOMT 
activity) formed was extracted into 3ml toluene: isoamyl al cohol 
(97:3) mixture by vortexing for a minute. After centrifugation a 
2ml aliquot of the organic phase was aspirated into 6ml 
scintillation cocktail and quantitated . Counting efficiency was 
determined using the external standards channel ratio and 
exceeded 90% in all cases. 
Analysis of Data . All results were obtained in triplicate and 
analysed statistically in order to obtain mean values with the 
standard error of the mean (SEM). Probabilities were calculated 
using the Student-t di stribution. 
RESULTS AND DISCUSSION 
Although few of the results are statistically significant in 
almost all cases HIOMT levels were lower than controls (Table 1). 
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Table 1: Effect of in vivo administration of anticonvulsant 
drugs on pineal HIOMilevels at the times indicated. Results 
given as mean with standard error of the mean (SEM). 
HIOMT ACTIVITY (pmol/pineal/hour) 
DRUG AND DOSE (mg/kg) llhOO 22h30 23hOO 23h30 
No dru g 
Acetazo 1 ami de 
Beclamide 
100 
250 
Carbamazepine 25 
Clonazepam 0.1 
Diazepam 5 
Diphenylhydantoi n 100 
Ethosuximide 25 
Pheneturide 150 
Phenobarbitone 12.5 
Primidone 142 
Sulthi arne 50 
Valproate 64 
* P=0 . 05 and ** P=0.025 
501±22 
346±63 
372±67 
382±44 
245±47 
359±76 
432±40 253±03* 
334±31** 309±26 
313±53* 
293±55* 
299±71 
354±31 
344±38 
298±63 
94±1l** 352±51 
285±84 311±43 
327±33** 331±38 
308±85 
345±99 
335±12 
344±33 
436±96 
404±32 
388±77 
362±13 
270±65 
222±25 
319±50 
313±47 
327±59 
290±40 
373±54 
475±47 
303±76 
460±57 
401±67 
475±44 
323±49 
291±77 
599±168 
379±72 
445±134 
495±23 
412±75 
334±53 
491±44 
531±40 
Table 2: Effect of in vivo administration of anticonvulsant 
drugs on pineal SNAT levels at the times indicated.Results given 
as mean with standard error of the mean (SEM). 
SNAT ACTIVITY (pmol/pineal/hour) 
DRUG AND DOSE (mg/kg) llhOO 22h30 23hOO 23h30 
No drug 178±O8 1854±211 2795±426 2325±127 
Acetazolamide 100 108±01*** 1945±278 2667±237 2739±402 
Beclamide 250 169±09 1244±054 1949±171 2195±019 
Carbamazepi ne 25 36±08**** 1640±256 2213±157 2612±023 
C 1 onazepam 0.1 47±01***** 1440±293 2003±701 2044±207 
Diazepam 5 79±OI **** 1078±l60* 1647±482 2260±397 
o i pheny 1 hy da ntoi nl00 89±O2**** 1737±261 1976±402 1736±559 
Ethosuximide 25 84±07*** 2119±333 2106±129 2709±386 
Pheneturide 150 196±13 2145±470 2121±306 3354±165 
Phenobarbi tone 12.5 75±01**** 460±117** 671±228**2299±204 
Primidone 142 129±04** 1465±296 1949±228 2023±399 
Sulthiame 50 213±07* 1609±328 2501±372 2698±400 
Valproate 64 85±09*** 2439±223 1970±422 2488±345 
* P=0.05. ** P=0.025, *** P=O.OI, **** P=0.005 and ***** P=0.0025 
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Figure 1: Graphical representation of the nocturnal increase in 
SNAT levels after administration of the various anticonvulsant 
drugs (thin lines) compared to control levels (thick lines). 
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The effects on SNAT were more variable than those on HIOMT and 
the overall trend, if a trend can be said to exi st, was towards 
lovler enzyme levels (Table 2). Both these observations imply that 
anticonvulsant drug treatment would lead to a reduced pineal 
melatonin output although this may not necessarily become 
manifest in vivo. 
Regardless of the actual SNAT levels it is interesting to note 
that in all but two cases (diphenylhydantoin and valproate) the 
nocturnal peak in activi ty appears to be shifted towards the 
following light phase (Figure 1). The most significant shift was 
caused by phenobarbitone, an effect which is apparently abolished 
by high doses [6]. That increased diazepam dose caused greater 
reduction in SNAT activity [6] suggests that these drugs are 
acting, at least in part, on different mechanisms to modulate 
enzyme level s. 
Reduction in SNAT activity and shift in rhythm caused by 
primidone may be the result of its metabolite phenobarbitone 
rather than primidone as such. That the observed effects were 
less pronounced than those exerted by phenobarbitone can be 
rationalised when one considers that the plasma concentration of 
phenobarbitone resulting from metabolism of primidone at the dose 
given woul d be about half that resulting from the administration 
of phenobarbitone at the dose used (see Chapter 2). Although 
primidone may be able to affect SNAT levels per ~ at least some 
of the effect must be considered to result from phenobarbitone 
action. 
The shift in rhythm may be modulated to a certain extent by an 
effect on benzodiazepine receptors which may be present in the 
pineal, although they are most likely to be centrally situated. 
That seizures increase benzodi azepine receptor bi ndi ng [14] may 
indicate an involvement in modulation of seizure states. It is 
also tempting to suggest an involvement of benzodiazepine 
receptors in modulation of pineal function and vice versa on the 
basis of evidence which claims that pineal indolic products can 
inhibit benzodiazepine receptor binding [15,16] and that pineal 
indoles may regulate pineal function [17,18,19]. If this were in 
fact the case then it could explain, to a ,large extent, the 
effects on SNAT rhythm exerted by clonazepam, diazepam, 
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phenobarbitone and primidone. The effect of phenobarbitone and 
thus of primidone may result from interaction with the 
barbiturate-picrotoxin component of the benzodiazepine-GABA 
receptor complex [20]. The effects may also involve interaction 
wi th phenobarbi tone bi ndi ng sites [21] and possibly with both 
classes of receptor. 
This evidence would suggest that the pineal gland, by al teration 
of benzodi azepi ne bi nding, may modulate seizure states although 
further extensive studies would be required to verify this 
suggestion. 
Anticonvulsant drugs may exert some of their therapeutic action 
by an effect on this system although a decrease in melaton in 
output woul d tend to be epileptogenic [2-5]. This is complicated 
by the fact that decreased melatonin levels would reduce 
inhibition of benzodiazepine receptor binding [15,16] which could 
enhance anticonvulsant effects [22]. 
Evidence that diphenylhydantoin may bind to benzodiazepine 
receptors [23] and the observation that it had no effect on StJAT 
rhythm while decreasing SNAT levels suggests that these receptors 
are not exclusively responsible for changes in SNAT rhythm and 
some other mechanism must be considered to exist. 
Overall this evidence strongly supports some interaction between 
the pi neal gland and benzodi azepine receptors in modulation of 
anticonvulsant drug effects although the entire mechanism is 
undoubtably multi-factorial and highly complex. 
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INTRODUCTION 
It is apparent that anticonvulsant drugs are capable of affecting 
the enzymes responsible for pineal gland indole metabolism both 
in vivo and in vitro. On the basis of this evidence it is not 
possible to state that the effects would becane manifest in the 
intact animal although the potential for such effects exi sts . 
Ideally a technique is required which will enable sensitive 
determination of normal function while allowi' ng for drug 
manipulations. The fact that the rat pi neal gland is small and 
readily accessible makes intact organ culture suitable for such 
purposes. Numerous organ culture techniques have been developed 
for the pi neal gland and used wi th canparative success [1-5J. 
As none of these methods totally satisfied the requirements of 
this study an attempt was made to develop a new method for pineal 
organ culture which would allow simple sensitive determinations 
of all serotonin metabolites formed. 
See Appendi x A. 
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MATERIALS 
r~ETf10DS 
Treatment of Rats. Both male and female rats (150-200g) kept 
under constant light conditions (05hOO-17hOO light) were allowed 
at least two weeks in which to become acclimatized to the light 
cycle before being used. Rats were sacrificed at 15hOO and pineal 
glands removed with minimum delay using sterile forceps and 
placed into culture medium. 
Organ Culture using 14C-Seroton-in. Pineal glands were incubated 
in pairs in 95ul culture medium (B.G.J.b. medium, Fitton-Jackson 
modification) containing 5-hydroxy [2_14CJ tryptamine 
creatinine sulphate (lxlO- 4 M) and in certain cases 
noradrenaline (NA) or gamma-aminobutyric acid (GABA) (lxlO-L 
lxlO-4M). Pineal glands were placed into culture medium shortly 
after removal, the tubes were gassed with 95% 02/5% C02 prior 
to sealing and were incubated at 37 0 C for 24 hours. After 
i ncubati on pi neal glands were removed and the medium evaporated 
to dryness under nitrogen at 400 C. Tubes were washed down with 
95 % ethanol and the residue taken up in 100ul 95% ethanol 
containing 5ug of each of the serotonin metabolites. These 
ethanolic solutions were then applied to thin layer 
chromatographic (TLC) plates, dried and metabolites separated by 
two dimensional development. 
Control cultures were treated in the same way except pineal 
glands were omitted from the culture medium. 
Organ Culture using 3H-Serotonin. Pineal glands were incubated 
individually in 50ul culture medium (B.G.J.b. medium, Fitton-
Jackson modification) containing 5-hydroxy [G_3HJ tryptamine 
creatinine sulphate (1.6xlO-5M). Pineal glands were placed into 
culture shortly after sacrifice, tubes were gassed with 95% 02/ 
5% CO 2 , sealed and incubated at 37 0 C for 24 hours. After 
incubation pineal glands were removed and 5ul aliquots of the 
culture medium spotted onto pretreated TLC plates. The 
pretrea ting involved applying 5ul 95% ethanol containing 2.5ug of 
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each of the serotoni n metaboli tes. These spots were dried prior 
to application of the 5ul culture medium and served to local ise 
the various spots after two dimensional development. 
Control tubes were treated in the same way except that no pineal 
glands were present and served to calculate background 
radioactivity for the different metabolites. 
TLC Separation and Quantitation. Spotted plates were dried and 
first developed in chloroform:methanol (9:1) followed by 
development in ethyl acetate at right angles to the first run. 
Before development and after each run the pl a tes were dri ed by 
brief exposure to heat (65 0 C) unless otherwise stated. After 
development in ethyl acetate the plates were dried and sprayed 
with Van Urk's reagent (1g 4-dimethylaminobenzaldehyde in 50ml of 
25% hydrochloric acid and 50ml ethanol) followed by heating at 
950 C for a short whil e. The coloured spots which resulted were 
scraped into scintillation cocktail and radioactivity present was 
quantitated. Counting efficiency was determined using the 
external standards channel ratio and exceeded 90% in all cases 
where 14C-metabolites were evaluated and 20% in all cases where 
3H-metabolites were evaluated. 
Plates resulting from control incubations were treated in a 
similar fashion, the radioactivity present at the various spots 
being subtracted from pineal values to obtain a true quantity for 
the metabolites produced. 
Autoradiography. Sheets of Kodak professional fil m negative (25 
ASA) were attached to HC plates developed after organ culture 
using 14C-serotonin. After varyi ng lengths of expo~ure at OoC 
these nega t i ve s were deve loped accordi ng to the manu facturers 
speci fications. 
Purity of Serotonin Metabolites. Some 5ul aliquots of medium from 
cultures using 3H-serotonin were treated in the same way as 
other samples except that after development these plates were not 
sprayed wi th Van Urk' s reagent. The areas of the plates 
corresponding to N-acetylserotonin, 5-hydroxyindole-3-acetic acid 
and 5-hydroxytryptophol were scraped off and eluted into 95% 
ethanol and evaporated to dryness under nitrogen at 40oC. The 
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sides of the tubes were washed down with successive quantities of 
95% ethanol and the residue was taken up in 95% ethanol (20ul). 
These residues were divided in half and spotted onto TLC plates, 
one plate being treated according to the scheme outlined above. 
The other spot was scraped into scintillation cocktail and served 
as a control . 
The various methoxyindoles were synthesised using hydroxyindole-
O-methyltransferase (HIOMT). Bovine pineal lyophilisate prepared 
as previously outlined (see Chapter 4) was dissolved in 0.05M 
phosphate buffer pH7 . 9 (lmg lyophilisate/100ul) containing N-
acetylserotonin, 5-hydr oxyindole-3-acetic acid or 5-hydroxy-
tryptophol (3x10-4M) and S-adenosyl [14C-methyl] methioni ne 
(3x10 - 4M) . These mixtures were incubated for an hour at 42 0 C 
and extracted into toluene:isoamyl alcohol (97:3) mixture (3ml) 
by vortexing for a minute. After centrifugation. the organic phase 
was evaporated to dryness under nitrogen at 40 0 C, tubes were 
washed down with 95% ethanol and the residue taken up in 95% 
ethanol (20ul). This residue was divided into two equal aliquots, 
both being spotted onto TLC plates and treated as above. 
Enzyme incubates were performed in the absence of a hydroxy 
substrate and were treated as above. These values were used to 
ascertain the level of non-indolic radioactivity extracted. 
RESULTS AND DISCUSSION 
A total of 26 solvent systems were tried before choosing the 
systems used (see Appendix B) . The resulting separation using 
chloroform:methanol (9:1) and ethyl acetate at right angles was 
excellent and reproducible (Figure 1). Change-s in ambient 
temperature and humidity led to a change in position of the spots 
although separation always remained good and the position of each 
spot in relation to the others remained the same. The colours 
produced after spraying could be used for partial identification 
(Figure 2). Although this technique also allows separation of 6-
hydroxymelatonin (Figure 1 and 2) it does not appear to be a 
normal pineal metabolite. Possibly the only major pineal 
metabolites of melatonin are 5-methoxytryptamine and possibly 6-
methoxyh armal an (results not shown). 
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A previously reported technique used ascorbic acid to protect the 
indoles sensitive to oxidation [5]. The protective capacity of 
ascorbic acid can be disputed considering evidence which suggests 
that it can catalyse aromatic hydroxylation [6] and consequently 
was not used in this study. Solutions of the various hydroxy- and 
methoxy-indoles in 95% ethanol were stored at -20 oC and no 
decomposition was detectable after 9 months indicating that 
inclusion of an antioxidant was unnecessary. 
Figure 1: Typical arrangement of spots of the various serotonin 
metabolites after two dimensional development as outlined in the 
text. Development in chloroform:methanol (9:1) in direction 1 
followed by development at right angles (direction 2) in ethyl 
acetate. (HT = serotonin, MT = 5-methoxytryptamine, NAS = N-
acetylserotonin, 6-0H-MTN = 6-hydroxymelatonin, MTN = mel atoni n, 
HIAA = 5-hydroxyindole-3-acetic acid, t~IAA = 5-methoxyindole-3-
acetic acid, HTOL = 5-hydroxytryptophol and MTOL = 5-methoxy-
tryptopho 1). 
1 2 3 4 
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Figure 2: Colours produced after spraying spots of the various 
i ndoles with Van Urk' s reagent, dryi ng at 95 0 C and 1 eavi ng for 
24 hours . Colours vary with age and caution must be exercised 
when used for identification purposes. Spots from left to right-1 
= serotonin, 2 = 5-methoxytryptamine, 3 = N-ace~lserotoni n, 4 = 
melatonin, 5 = 6-hydroxymelatonin, 6 = 5-hydroxyindole-3-acetic 
acid, 7 = 5-methoxyindole-3-acetic acid, 8 = 5-hydroxytryptophol 
and 9 = 5-methoxytryptophol . 
The possibi lity of decanposition resulting from exposure to heat 
and light was also investigated. Several identical extracts from 
cultures were spotted onto TLC plates and developed either in the 
1 ight or dark and were dried either by heating (650 C) or under a 
stream of nitrogen. None of these treatments had any noticeable 
effect on the quantities of the various metabolites extracted. As 
a result drying using brief heating and development in the dark 
were used for convenience although other methods could be used 
without affecting results. 
Exposed areas on the developed autoradiographs corresponded 
exactly with the coloured spots resulting from the spray reagent, 
verifying that the visualised spots actually contained the 
radi oactive metaboli tes produced. The absence of unaccountable 
exposed areas suggested that recovery was high. Using the 
synthesised radioactive metabolites this was verified and 
recovery was found to be 93 ±l%. 
Pineal glands removed from culture media after incubation were 
di srupted by ultrasonication and aliquots spotted onto TLC 
plates, metabolites being separated and quantitated as above. The 
proportions of the various indoles contained by the glands were 
similar to those in the media (Table 1). This indicated that 
determination of quantities of metabolites in the medium gave an 
accurate indication of both pineal production and content . 
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Table 1: Comparison of the amounts of various serotonin 
metabolites present in the pineal gland and culture medium after 
24 hours incubation with 3H-serotonin. Results given as the 
percentage of the total radioactivity present. 
~1ETABOLITE MEDIUM (%) PI NEAL (%) 
Serotonin 30 29 
N -acety 1 serotoni n 3 4 
Melatonin 4 5 
5 -hy droxyi ndo 1 e-3 -aceti c acid 49 45 
5 -methoxyi ndo 1 e-3-aceti c acid 2 3 
5 -hy droxytryptopho 1 10 11 
5 -methoxytryptopho 1 1 4 
Although the technique was not used for pharmacological studies 
preliminary investigation with 14C-serotonin enabled 
autoradiographic characterisation of the procedure which was not 
possible using 3H-serotonin. A total of B3 cultures were 
performed using 14C-serotonin with pineal glands from both mal e 
and female rats. Some of the culture media contained neuro-
transmitters to vary quantities of metabolites. Analysis of data 
from these cultures revealed an interesting relationship between 
hydroxy- and corresponding methoxy-indoles (Figure 3). It is 
striking that melatonin production was found to be directly 
proportional to N-acetylserotonin production, while production of 
the other methoxyindoles was not directly related to levels of 
their hydroxy counterparts. This implied that melatonin 
production is dependent on N-acetylserotonin production and hence 
on N-acetyltransferase activity verifying previous reports [7-
10J . 
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Figure 3: Relationship between hydroxy- and corresponding 
methoxy-indoles for rat pineal glands in organ culture. The 
coefficient of determination (r2) is given as a measure of 
linearity.(See Table 2 for abbreviations). 
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Table 2: Amounts of methoxyindoles formed by rat pineal glands 
in organ culture. Values are means wi th standard error of the 
mean (SEM) for 83 cultures. (NAS =. N-acetylserotonin, MTN = 
melatonin, HlAA = 5-hydroxyi ndole-3-acetic acid, MlAA = 5-methoxy 
-indole-3-acetic acid, HTOL = 5-hydroxytryptophol and MTOL = 5-
methoxytryptopho 1). 
[14C]-serotonin present as methoxyindoles 
NAS converted to MTN 
HlAA converted to MlAA 
HTOL converted to MTOL 
% 
8. 95±O. 32 
77 . 82 ±l. 36 
10.90±0.75 
3 . 92±0.23 
The fact that the total amount of methylation occuring in a 
pineal gland varied little (Table 2), despite relatively large 
changes in the proportions of the various methoxy products, 
implies that a nearly constant amount of HlOMT (or several HlOMT 
enzymes) is present in the pineal gland. The results may suggest 
the presence of one HlOMT enzyme with a greater affinity for N-
acetyl serotoni n, methyl a ti on of the other hydroxyi ndoles 
depending on their concentration, affinity and the number of free 
catalytic sites on the enzyme . It is also possible that several 
H 10MT enzymes exi st in the pineal gland al though those not 
directly responsible for methylation of N-acetylserotonin must 
either be present in low concentration or have a low affini~ for 
other hydroxyi ndoles since relatively small proportions are 
methylated when compared to N-acetylserotonin (Table 2). Thi .s is 
in agreement wi th another report which suggests the presence of 
multiple fonns of the enzyme [11],Lrl.]. 
While GABA exerted inconsistent and variable effects on pineal 
indole metabolism noradrenaline appeared to have a characteristic 
action (Figure 4). The most striking observation was the 
considerable increase in production of both N-acetylserotonin and 
melatonin by the pineal after noradrenaline treatment. The 
increase in melatonin closely paralleled N-acetylserotonin 
production which suggests that melatonin formation is dependent 
on N-acetyltransferase activity, again verifying previous reports 
[7-10]. 
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Fig u r e 4: E f f e c t of nor a d r e n erg i c (N A) s tim u 1 at ion 0 n 
production of pineal indoles in organ culture. (NAS = N-acetyl-
serotonin, MTN = melatonin, CH30 = total methoxy products, MIAA 
= 5-methoxyi ndole-3-acetic acid and MTOL = 5-methoxy-
tryptophol). 
It is interesting to note that the overall production of 
methoxyindoles followed a very similar trend to that of N-
acetylserotonin and melatonin which may suggest some degree of 
noradrenergic control over HIOMT 1 evels. The increase in 
methoxyi ndol e levels may, however, be due to the increased 
availability of substrate rather than a direct effect on HIOMT. 
Although 5-methoxytryptophol levels were erratic, increase in 
noradrenergic stimulation led, by and large, to a decrease in 
both 5-methoxyi ndole-3-acetic acid and 5-meth0xYtryptophol as 
opposed to the increase in melatonin production. This 
observation, coupled with the fact that HIOMT has a relatively 
low affinity for 5-hydroxyindole-3-acetic acid and 5-
hydroxytryptophol (Table 2) supports the proposal that HIOMT is 
primarily involved in methylation of N-acetylserotonin, any free 
catalytic sites being occupied by the other hydroxyindoles 
dependent on their concentration and affinity, 
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That the overall level of methylation remains more or less 
constant (Table 2) and that amounts of methoxy products formed 
vary, to a certain extent, with variation in N-acetylserotonin 
levels may suggest that it is not only the absolute quantity but 
also the ratios between the different methoxy products that is 
important for mediation of pineal action. 
The fact that the counts per minute (cpm) determined for the 
various metabolites using both isotopes of serotonin were not 
vastly different (Table 3) indicates that sensitivity is similar 
using either method. The reduction in manipulations necessary 
using 3H-serotonin made this method much faster and possibly 
more accurate and it was consequently adopted for the various 
pharmacological studies. 
!able 3: Comparison of the values obtained using 14C_ and 
H- serotonin in organ culture. (NAS : N-acetylserotonin, MTN : 
melatonin, HIAA : 5-hydroxyindole-3-acetic acid, MIAA : 5-methoxy 
-indole-3-acetic acid, HTOL : 5-hydroxytryptophol and MTOL : 5 -
methoxytryptophol) . 
CPM 14C CPM 3H 
METABOLI TE (total incubate) ( 5ul i ncuba te) 
NAS 2448 1860 
MTN 10262 7512 
HlAA 189139 109985 
MIAA 6415 3302 
HTOL 44854 15429 
MTOL 8552 2065 
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CHAPTER 8 
EFFECT OF ANTICONVULSANT DRUGS ON PI NEAl GLAND INDOLE METABOLISM 
IN ORGAN CULTURE 
INTRODUCTION 
MATERIALS 
METHODS 
Dosing and Removal of Pineal Glands 
Organ Culture 
HC Separation and Quantitation 
Analysis of Data 
RESULTS AND DISCUSSION 
REFERENCES 
I NTRODUCT ION 
Considering the foregoing chapters it is apparent that all the 
anticonvulsant drugs used in this study exert effects on the 
pineal gland, predominantly on the melatonin synthetic pathway, 
although other effects also occur. 
The question remained as to whether these effects were mediated 
locally or centrally and so the effect of the various agents .2..!2. 
vitro and in vivo on indole metabolism was studied. This it was 
---
hoped would allow effects to be separated into iocal and/or 
central effects or indicate where interactions were possibly 
mediated by an action on multiple sites. 
MATERIALS 
See Appendi x A. 
METHODS 
Dosing and Removal of Pineal Glands. For the.2..!2. vivo studies male 
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rats (200-250g) kept under constant light conditions (04hOO-16hOO 
1 ight) were used. The rats were dosed with the various drugs at 
the dose levels previously determined (see Chapter 2) while 
controls were treated with normal saline. The rats were allowed 
at least two weeks in which to become acclimatized to the light 
cycle before being used. Drugs were dissolved or suspended in 
propylene glycol where insoluble in water and administered intra-
peritoneally. Both beclamide and pheneturide resisted solution 
and suspension and were consequently giyen orally as powder in a 
syrup simplex matrix. Rats were dosed twice daily at 06hOO and 
15hOO, were sacrificed at 15hOO on the third day and pineal 
glands removed with minimum delay using sterile forceps and 
placed into culture medi a. 
Female rats (180-220g) were kept under similar conditions to male 
rats and were also only used after at least two weeks 
acclimatization. Before use it was ascertained that the rats 
were not pregnant and oestrous smears were taken to determine the 
phase of the sexual cycle. The oestrous smears were taken at the 
s.ame time every day (l1h30) and only those showing positive 
cornification were used that afternoon. After sacrifice at 15hOO 
the pineal glands were removed and treated as outlined above. 
Organ Culture. Pineal glands were incubated individually in 50ul 
culture medium (B.G.J . b. medium, Fitton-Jackson modification) 
containing 5-hydroxy [G_3H] tryptamine creatinine sulphate 
(1.6xl0- 5M). Culture media for the.:L.r!. vivo determinations 
contained the various drugs at a concentration in the normal 
the rap e uti era n g e ( Tab 1 e 1) w h i 1 e me d i a for .:L.r!. vi t r 0 
determinations contained the drugs in varying concentration 
(lxl0- 6 -1xl0- 3M). Pi neal glands were placed into culture 
shortly after sacrifice, tubes were gassed wi th 95% 02/5% C02, 
sealed and incubated at 37 0 C for 24 hours. After incubation 
pineal glands were removed and 5ul aliquots of the culture medium 
spotted onto pretreated thin layer chromatography (nC) plates. 
The pretreating involved applying 5ul of 95% ethanol containi ng 
2.5ug of each of the serotonin metabolites . These spots were 
dried prior to application of the culture media and served to 
local i se the various metabolites after two dimensional 
development . 
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Control tubes were treated in the same way except pineal glands 
were omitted and served to calculate background values. 
TLC Separation and Quantitation. The spotted plates were dried 
and first developed in chloroform:methanol (9: 1) followed by 
development in ethyl acetate at right angles to the first run. 
Before development and after each run the plates were dried by 
brief exposure to heat (65 0 C). After development in ethyl 
acetate the plates were dried and sprayed with Van Urk's reagent 
(1g 4-dimethylaminobenzaldehyde in 50ml 25% hydrochloric acid and 
50ml ethanol) followed by heating at 95 0 C for a short whil e . The 
coloured spots which resulted were scraped into scintillation 
cocktail and radi oactivi ty present quanti tated. Counti ng 
efficiency was determined using the external standards channel 
ratio and exceeded 20% in all cases. 
Control incubations were treated in the same way, radioactivity 
resulting being subtracted from pineal values to obtain a true 
quantity for the metabolites produced. 
Analysis of Data. Counts per minute (cpm) were converted into the 
required values with standard error of the mean (SEM) using 
computer assisted analysis. The specific activity of the 
metabolites varied due to removal of some of the original 
tritiated hydrogen atoms on serotonin. As a result a correction 
factor was built into the programs to enable accurate calculation 
of the quantities 'of metabolites produced. The Student-t 
distribution was used to calculate probabilities. 
The quantities of various metabolites produced were calculated as 
nanograms (ng) produced/pineal gland/24 hours. In the case of 
monoamine oxidase (MAO) activity (5-hydroxyindole-3-acetal dehyde 
production), hydroxyindole-O-methyltransferase (HIO~1T) activity 
(total methYlation) and total metabolic activity, the results 
were calculated as the amount of serotonin oxidised, serotonin 
methylated and serotonin metabolised respectively. All 
determinations were conducted in triplicate, the three sets of 
results being obtained at different times . 
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Table 1: Concentration of anticonvulsant drugs used in culture 
media for in vivo determinations. 
---
DRUG CONCENTRATION (ug/ml) 
Acetazo 1 ami de (All ) 10 
Beclamide (BCL) 5 
Carbamazep i ne (CBZ) 6 
C 1 onazepam (C LZ) 0.005 
Diazepam (DZP) 0.2 
Di pheny 1 hy da ntoi n (DPH) 10 
Ethos uxi mi de (ETH) 40 
Ph enetur i de (PTR) 5 
Phenobarbi tone (PBT) 10 
Primidone (PRD) 5 
Sulthiame (STH) 5 
Val proate (VPA) 50 
RESULTS AND DISCUSSION 
The results from both in vivo and in vitro determinations are 
summarised in tabular form (Tables 2-5). For convenience each set 
of results has been divided into two sections- the first dealing 
with total metabolic activity and production of hydroxyindoles 
(Tables 2a, 2b and 4) and the second with total methylation and 
prod.uction of methoxy i ndoles (Tables 3a, 3b and 5). 
In all 2..!!. vitro determinations except high diazepam and 
diphenylhydantoin concentration (10- 3M) the overall indole 
metabolic activity of the pineal increased (Table '2a and 2b). 
This effect is probably due primarily to enhanced r~AO activity, 
wi th increases in al dehydye dehydrogenase and al dehyde reductase 
output being secondary to this change as a result of increased 
substrate availability. Increase may be due either to increased 
availability of serotonin for oxidation, possibly by some effect 
on uptake, or may be the result of an increased quantity of t~AO. 
In this regard it is interesting to note that acetazolamide [lJ, 
c l onazepam [2J, diazepam and diphenylhydantoin [3,4 J and 
phenobarbitone [5J all increased brain serotonin levels, an 
effect attributable to either decreased efflux or metabolism [5J 
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and it is possible that in the pineal these drugs are capable of 
inhibiting efflux which would have the same effect as increased 
uptake. Thi s statement would be correct if the drugs do not also 
inhibit serotonin uptake in which case an opposite effect would 
be expected. 
The decrease in activity caused by high diazepam and 
diphenylhydantoin concentration is most likely due to a MAO 
inhibitory effect which is unable to reduce the enhanced activity 
below contral levels at lower drug concentrations. Although both 
diazepam and diphenylhydantoin have been shown to inhibit MAO 
[5,6J the fact that diphenylhydantoin could inhibit noradrenaline 
uptake [6,7] may indicate an ability to block uptake systems 
which could contribute to the decreased activity observed. The 
possibility exists that both decrease in uptake and inhibition of 
MAO participate in the reduced activity . 
Clonazepam, phenobarbitone and sulthiame are capable of 
inhibiting MAO ill vitro (see Chapter 5) and therefore an increase 
in activity was most likely to be due either to increased 
availability of substrate for catalysis or to increased enzyme 
levels. Although the MAO inhibitory effect was apparent, 
increasing with clonazepam, phenobarbitone and sulthiame 
concentrations, the overall increase in metabolic activity was 
such that serotonin oxidation remained above control levels. Very 
high clonazepam levels (10- 3M) appear to have the opposite 
effect and MAO activity increased, possibly the result of an 
enhancement of oxidation such as to totally negate inhibitory 
effects on the enzyme itself . Such du a l effects on a metabol i c 
pathway complicate predictions regarding ove rall e,ffects after 
drug ad ministration especially as plasma levels are bound to vary 
duri ng th erapy . 
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Table 2a: Effect of various anticonvulsant drugs in vitro on 
total activity (as ng serotonin used/pineal/24 hours) and amounts 
of hydroxyindoles formed. (NAS = N-acetylserotonin, HIAlD = 5-
hy dr oxyi ndo 1 e -3 -ac eta 1 dehy de, H IAA = 5 -hy droxyi ndo 1 e-3 -aceti c 
acid and HTOl = 5-hxdroxytryptophol). 
TOTAL 
DRUG (M) ACT IV ITY 
HYDROXY INDOLE FORMED (ng/pineal/24hr) 
NAS HIAlD HIAA HTOl 
No drug 84±04 4.9±0.4 78±04 
ATZ 10-3 116±01*** 3.4±1.5 112±03* · 
10-4 111±04** 2.3±0.2** 108±04* 
10-5 118±21 
10-6 125±31 
BCl 10-3 116±32 
10-4 99±23 
10-5 106±20 
10-6 151±38 
CBl 10-3 102±06 
10-4 105±08 
10-5 115±12 
10-6 125±33 
ell 10-3 126±23 
10-4 103±O6 
10-5 162±42 
10-6 178±50 
DlP 10-3 66±23 
10-4 86±17 
10-5 127±28 
10-6 106±23 
_ DPH 10-3 66±21 
10-4 92±19 
10-5 122±40 
10-6 169±63 
3.0±0 . 6 114±22 
3 . 6±O.7 121±32 
3.7±2.2 112±35 
6.0±2.3 91±22 
5.4±1.2 100±21 
2.1±0.3** 149±38 
2. 8±0. 3* 98±O6 
2.1±0.6* 102±07 
1. 5±0. 3** 113 ±12 
1.8±0.3** 122±33 
1.7±0.1*** 124±23 
3.1±0.6 99±05 
3.2±1.0 158±43 
3.1±0.8 175±50 
1.5±0.4** 
3.8±1.1 
4.1±0.6 
4.9±0.2 
3.3±0.9 
3.5±1.1 
3.2±1.1 
2.9±0.8 
64±22 
8l±18 
122±28 
100±21 
62±20 
88±17 
118±39 
165±62 
71±05 
97±06* 
97±05* 
100 ±17 
109±32 
97±30 
82±15 
89±14 
137±40 
72±O7 
86±l0 
100±13 
111±33 
106 ±18 
82±02 
139±36 
158±43 
56±19 
72±13 
117±28 
93±21 
56±19 
80±16 
106±36 
142±52 
* P = 0.05, ** P = 0 . 025, *** P = 0. 01, **** P = 0.005 
13±2 
22±4 
19±2 
22±7 
20±2 
22±8 
16±8 
18±8 
23±2* 
32 ±l **** 
23±2* 
21±1* 
21±3 
26±8 
24±7 
30±9 
29±9 
12±5 
14±7 
15±3 
14±2 
10±4 
14±3 
20±7 
34±15 
123 
Table 2b: Effect of various anticonvulsant drugs in vitro on 
total activi~ (as ng serotonin used/pineal/24 hours) ~d amounts 
of hydroxyi ndoles formed. (NAS = N -acetyl serotoni n, HIALD = 5-
hy dro xyi ndo 1 e -3 -ac eta 1 de hy de, HIAA = 5-hydroxyi ndole-3-acetic 
acid and HTOL = 5-hydroxytryptophol). 
TOTAL HYDROXY INDOLE FORMED (ng/pineal/24hr) 
DRUG (M) ACTIVITY NAS HIALD HIAA HTOL 
No dru 9 84±04 4 . 9±D.4 78±O4 7l ±05 13±2 
ETH 10-3 130±13* 6.5±2 . 8 122 ±12 114±15 17±2 
10-4 138±1l** 5.2±2.4 132±12* 121±14* 20±1* 
10-5 173±23* 5.5±l.1 166±22* 154±21 * 24±4 
10-6 166±07*** 2.7±l.0 162±06**** 143±04**** 31±3** 
PTR 10-3 154±07*** 5.1±l.7 148±07** 135±O8** 23±3* 
10-4 153±21* 3.5±l.4 148±22 133±21 26±2** 
10-5 159±17** 3.0±0.5* 155±17* 142±16* 24±2* 
10-6 145±22 5.7±2.2 138±21 123±23 24±1 ** 
PBT 10-3 168±22* 6.3±l.8 160±24 147±27 25±7 
10-4 189±26* 2.5±0.3** 186±26 166±33 34±6* 
10-5 200±32* 7.0±3.2 191±29* 173~27* 32±4* 
10-6 186±15** 5.4±0.2 180±15*** 167±09*** 26±7 
PRD 10-3 209±17*** 3.7±1.0 205±16*** 185±15*** 34±6* 
10-4 234±29** 3.0±0.4* 230±28** 213±32** 34±3** 
10-5 210±58 2.8±l.5 206±56 185±54 36±8 
10-6 256±36** 7.7±4.8 246±36* 228±40* 37±9 
STH 10-3 132±08** l.5±0 . 3** 130±08* 103±07* 35±3*** 
10-4 166±33 2.9±0.7 163±32 145±36 29±2** 
10-5 174±22* 4.0±1.1 169±21* 160±23* 22±2* 
10-6 142±19* 7.9±l.7 132±21 121±22 20±1* 
VPA 10-3 170±37 2.3±0 . 1** 168±37 160±40 20±2 
10-4 1ll±05** 5.9±l.8 104±06 87±09 24±5 
10-5 178±23** 2.3±0.3** 175±13** 154±13** 33±4** 
10-6 180±17** 2 .1±0.1 ** 178±17* 155±23* 35±5** 
* P = 0.05, ** P = 0.025, *** P = 0 . 01, **** P = 0.005 
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Table 3a: Effect of various anticonvulsant drugs in vitro on 
indole methylation in organ culture (total methylaTIon as ng 
serotonin methylated/pineal/24hours). See Table 1 for drug 
abbreviations. (MTN = melatonin, MIAA = S-methoxyindole-3-acetic 
acid and MTOl = S-methoxytryptophol). 
DRUG (M) 
No dru g 
ATZ 10-3 
10-4 
10-S 
10-6 
BCl 10-3 
10-4 
10-5 
10-6 
. CBZ 10-3 
10-4 
lO-S 
10-6 
elZ 10-3 
10-4 
10-5 
10-6 
DZP 10-3 
10-4 
10-5 
10-6 
DPH 10-3 
10-4 
lO-S 
10-6 
TOTAL 
METHYLATION 
METHOXYINDOlE FORMED (ng/pineal/24hr) 
MTN MlAA MTOl 
10.1±0.3 4.S±0.4 
9.3±l. 8 3 .O±l. 7 
9.2±2.1 1.8±0.1** 
7.9±1.5 2.2±0.3** 
ll.S±2.3 3.0±0.5 
10.3±0.9 3.4±2.3 
9.0±1.7 S.4±2.2 
ll.0±l. 7 4.9±1.3 
7.7±1.2 1.5±0.3** 
9.7±1.8 2.3±0.S* 
9.0±1.2 1.6±0.4** 
12.1±l.l 1.0±0. 2*** 
13.3±3.S 1.3±0.1*** 
9.0±l.O 1. 1±0. 2*** 
10.0±0.7 2.S±0.7 
12.9±1.5 2.5±l.O 
14.2±3.2 2.4±0.7 
4.6±0.6*** 0.9±Q.3*** 
5.9±1.4* 2.9±1.0 
6.S±1.1* 3.3±0.7 
9.1±0.4 3.9±1.S 
6.5±1.6 3.0±0.9 
9. S±l. 6 3. O±l. 2 
9.6±1.9 2.8±1.0 
13.4±2.9 2.4±0.9 
S.8±0.7 
4.7±0.3 
5.5±l.4 
4.8±l.l 
6.8±0.9 
4.9±1.0 
4.2±0.7 
5.0±0.6 
4.9±1.3 
4. 8±1. S 
4.S±1.1 
6.8±0.4 
7 .3±l. 7 
6.4±0.9 
6.1±1.3 
7 .1±0. 7 
7. 5±l. 2 
3.9±0.7 
3.0±0.8 
3.2±0.3 
4.3±0.S 
3.4±0.6 
5.2±D.2 
S.1±0.4 
7.5±1.2 
1. 9±0. 9 
3.3±0.9 
3.5±1.1 
2.3±0.8 
3.6±l.S 
3.9±1.5 
l.4±0.4 
3.3±2.2 
2.S±0.1 
4.2±1.0 
4.3±1.4 
6.0±0.9* 
6.6±2.2 
2.9±0.9 
3.1±0.S 
S. 4±2. 3 
6.4±3.2 
0.S±0.2 
1.3±0.9 
1.4±0.S 
2.6±0.9 
1.4±0.4 
3.0±1.2 
3.4±1.4 
5.S±l.6 
* P = O.OS, ** P = 0.025, *** P = 0.01 
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Table 3b: Effect of various anticonvulsant drugs in vitro on 
indole methylation in organ culture (total methylaTIon as ng 
serotonin methylated/pineal/24hours). See Table 1 for drug 
abbreviations. (MTN = melatonin, MlAA = 5-methoxyindole-3-acetic 
acid and MTOl = 5-methoxytryptophol). 
DRUG(M) 
No drug 
ETH 10-3 
10-4 
10-5 
10-6 
PTR 10-3 
10-4 
10-5 
10-6 
PBT 10-3 
10-4 
10-5 
10-6 
PRD 10-3 
10-4 
10-5 
10-6 
STH 10-3 
10-4 
10-5 
10-6 
VPA 10-3 
10-4 
10-5 
10-6 
TOTAL 
ME THYLA TI ON 
10.1±0. 3 
10.6±2.0 
9.7±1.0 
9.7±0.6 
12.4±1.2 
11.3±1.4 
12.8±2.6 
10.4±2.6 
13. 3±1. 8 
12.3±0.6* 
14.8±0.4**** 
15. 8±1. 6* 
12.7±2.7 
17.5±2.1* 
15.4±2.0 
17.4±2.9 
16.0±5.9 
11. 6±1. 4 
11.1±1.0 
10.6±0.7 
11.4±0 .6 
12.1±2.3 
11.0±0.6 
14.4±1.0* 
13.0±2.3 
METHOXYINDOlE FORMED (ng/pineal/24hr) 
MTN MlAA MTOl 
4.5±0.4 
5.9±3.0 
4.6±2.2 
4.7±0.8 
2.3±0.9 
4.6±1.7 
2.9±1.4 
2.1±0.6* 
5.l±2.2 
5.4±2.2 
1. 7±0. 2** 
6.3±3.3 
4.6±0.2 
2.7±1.1 
2.2±0.5* 
2.3±1.4 
7.2±4.6 
O. 8±0.1 *** 
2.2±0.6* 
3.5±1.3 
7 .3±1. 7 
1. 6±0. 2** 
5.3±1.7 
1. 8±0. 3** 
1.4±0.1 *** 
5.8±0.7 
4.3±0.9 
5.2±0.7 
5.3±0.8 
6.7±0.4 
6.l±0.7 
7.4±1.7 
6.0±1.4 
6.3±1.3 
6.2±0.8 
6. 8±0. 6 
6. 8±1. 2 
6.4±1.2 
9.4±1.2 
9.l±1.l 
8.7±1.5 
7.4±0.6 
6.0±1.1 
5. 7±0.7 
6.2±1.2 
4.4±1.0 
5.9±1.8 
3.8±0.6 
7.6±0.2 
6.3±0 .4 
1. 9±0. 9 
2.6±0.9 
2.0±0.1 
1. 8±0. 3 
5.3±O. 8* 
2.7±0.7 
4.6±1.3 
3.9±1.7 
4.3±2.0 
3.0±0.9 
8.4±0.1*** 
5.5±1.2 
4.l±1.9 
8.0±2.4 
6.5±1.6 
8. 9±1. 6 
4.5±2.1 
6.4±0.6** 
4.9±0.2* 
2.9±0.9 
2.3±0.9 
6.3±1.3 
4.1±1.0 
6.9±1.4* 
7.0±2.4 
* P = 0.05, ** P = 0.025, *** P = 0.01, **** P = 0.05 
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Table 4: Effect of in vivo anticonvulsant drugs on total 
activity (as ng serotonllrl U5e0!pineal/24hours) and hydroxyi ndo 1 e 
production. See Table 1 and 2 for abbreviations. 
TOTAL HYDROXY INDOLE FORMED (ng/pineal/24hr) 
DRUG ACTIVITY NAS HIAlD HIAA HTOl 
No drug 88±1l 12.3±1.8 73±10 68±09 10±2 
ATZ 70±06 2.9±1.2** 66±07 58±04 13±5 
SCl 71±1l 2.3±1.2** 68±12 64±1l 9±1 
CSI 7l±06 3.4±1.3* 67±07 54±07 17±1* 
ClI 84±10 3.5±0.5** 80±10 70±09 15±3 
DIP 75±05 7.6±5 . 4 66±09 59±07 12±3 
DPH 74±09 8.4±4.2 64±04 61±04 8±1 
ETH 98±1l 9.2±5.0 87±17 78±14 15±4 
PTR 82±06 9.9±5.5 70±08 64±05 1l±4 
PST 149±06** 3.9±0.7** 144±06** 137±05** 18±2* 
PRO llO±17 4 .1±0. 7** 105±18 98±18 14±2 
STH 97±01 4.1±0.6** 92±Ol 82±04 17±4 
VPA 101±04 8.1±3.5 9l±05 84±04 13±1 
* P = 0.05, ** P = 0.025 
Table 5: Effect of in vivo anticonvulsant drugs on indole 
methylation (total methylation as ng serotonin methylated/pineal/ 
24hours). See Table 1 and 3 for abbreviations. 
TOTAL METHOXYINDOlE FORMED (ng/pineal/24hr) 
DRUG (M) METHYLATION MTN MIAA MTOl 
No drug 11. 2±1. 8 11. 5±1. 9 2.2±0 . 2 0.6±0.2 
ATZ 6.4±1.3 2.1±1.1 * 3. 8±1. 5 1.6±O.7 
BCl 5.6±0.7 1. 8±1. 2** 2.5±0.9 2.2±0 . 9 
CBI 6.5±1.1 2.8±1.1* 3.0±1.0 1. 9±1. 2 
ClI 6.5±0.9 3.1±0.6* 3.5±1.1 1. 2±0.3 
DIP 9.7±3.7 7.2±5.4 3.1±0 . 4 1.8±O.6 
DPH 9.4±2.8 8.0±4.0 2.6±0 .3 1. 2±0. 3 
ETH 10.3±1.8 6.8±0.4 3.6±0.7 2.3±1.0 
PTR 7.8±3.7 7.8±4.9 1. 5±0. 5 0.7±0.3 
PST 8. 3±1. 3 3.0±0.4** 3.5±0.7 3.3±1.2 
PRD 7.4±1.4 3.3±0.5* 3.4±0. 8 2.1±0.9 
STH 7.8±0.7 3.6±0.4* 3.6±0.3* 2.1±0.9 
VPA 11. 2 ±1. 0 7. 1±3.2 4.3±0.8 2.3±1.3 
* P = 0.05, ** P = 0.025 
127 
In most instances, although not always significant, there was a 
noticeable decrease in N-acetylserotonin production from ~ vitro 
anticonvulsant drugs (Table 2a and 2b). Acetazolamide, 
carbamazepi ne, clonazepam, di azepam and diphenylhydantoin caused 
a reduction in N-acetylserotonin possibly due to decreased SNAT 
1 evel s, decreased subs trate ava il abil ity resulting from increased 
I~AO activi ty or a combi nation of these effects. The observation 
that carbamazepine and diphenylhydantoin coul d decrease cerebro-
spinal fluid cyclic At~P levels [8] may indicate an ability for 
these drugs to reduce pineal cyclic AMP and hence cause decrease 
in SNAT activity. Diphenylhydantoin may possibly decrease SNAT 
activity by an effect on protein synthesis [9]. Inhibition of 
calcium uptake by carbamazepine, diazepam and diphenylhydantoin 
[10] if it al so occured in the pi neal woul d 1 ead to decreased 
cyclic AMP levels and may participate in .the reduced NAS 
production. The fact that diphenylhydantoin increased potassium 
uptake [11] and decreased potassium release [12] would tend to 
inhibit hyperpolarization and as this has been thought to be 
necessary for SNAT increase [13] such an effect would account for 
reduced SNAT levels. Diazepam induced decrease in SNAT activity 
may al so be the result of decreased serotonin uptake. 
At concentrations above 10-5M ethosuximide caused an increase 
in N-acetylserotonin production which may be due primarily to 
increased subs trate ava il abil ity result i ng from increased 
serotonin upta~e. This effect is apparently enhanced by reduction 
in MAO activi ty as ethosuximide concentration increased and may 
also involve increase in SNAT levels which can be rationalised 
when considering evidence which suggests that ethosuximide can 
increase calcium influx at high concentration [14]. 
Beclamide at low concentration (10- 6M) caused significant 
reduction in N-acetylserotonin production which is less marked at 
high concentration (l0-3M). Intermediate concentrations led to 
an increase in N-acetylserotonin production, these variable 
effects being closely related to changes in MAO output. The dose 
dependent variable effects of beclamide on N-acetylserotonin 
production can, therefore, be best explained as an effect on MAO 
rather than on SNAT. 
Valproate caused a significant reduction in N-acetylserotonin 
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production at all concentrations except 10-4M, effects on MAO 
leading to changes in substrate availability rather than changes 
in SNAT activity as such . 
High and low pheneturide concentrations (10- 3 and 10-6M) had 
little effect on SNAT while intermediate concentrations, 
especi ally 10-5M caused a significant reduct i on in production, 
an effect not entirely consistent wi th a primary change in MAO 
activity and may indicate a dose-specific alteration of SNAT 
levels. The var i able effects may indicate effects on both 
membrane hyperpolarization and 6-receptor stimulated adenyl 
cyclase activi ty wi th one effect predomi nati ng dependent on dru g 
concentration. This, however, is merely conjecture and further 
investigation would be necessary to elucidate the mechanicm. 
Phenobarbitone caused significant reduction in N-acetylserotonin 
only at concentrations of 10-4M, all higher and lower 
concentrations increasing activity. Changes in SNAT activity or 
levels are most likely responsible for these changes as 
differences in MAO activity do not account for the variations. 
Evidence that phenobarbitone could inhibit cyclic AMP 
phosphodiesterase [15,16J could account for increased SNAT 
activity by virtue of the decreased cyclic AMP degradation. A 
similar effect occured with primidone except low concentrations 
(10- 6M) enhanced whil e all higher concentrations decreased NAS 
production. The chemical similarity between the two drugs may 
indicate a common mode of action. The variable effects may be due 
to action at more than one site as discussed for beclamide. 
Inhibition of cyclic AMP phosphodiesterase activity is also 
caused by acetazolamide, diazepam and diphenylhydantoin [15,16J 
although an increase in SNAT levels wa s not obs erved, indicating 
that the actions are due to multiple effects some of which are 
antagoni stic. 
Sulthiame at low concentration (l0-6M) increased N-acetyl-
serotonin production while higher concentrations caused a dose 
dependent decrea se , apparently independent of MAO activity and 
serotonin upt ak e . This effect is most likely due to direct 
inhibition of SNAT (see Chapter 5) although other effects cannot 
be r ul ed out. 
129 
Increase in SNAT activity may be the result of Il-receptor 
stimulation or membrane hyperpolarization leading to increase in 
cyclic AI~P thus inducing SNAT levels. The observation that 
diphenylhydantoin, ethosuximide, phenobarbitone, sulthiame and 
valproate can alter brain taurine levels [17] may suggest an 
effect on pineal taurine which could account for effect on SNAT 
as taurine has been suggested to exert modulatory effects on the 
pineal gland [18,19]. 
In JrOst cases melatonin production mirrored N-acetylserotonin 
production (Table 3a and 3b) and can be assumed to be due to the 
changes in SNAT rather than an effect on HIOMT. This would be 
consistent with the reports that suggest melatonin production is 
regulated by change in SNAT activity [20-24]. 
In all instances where overall methylation increased (Table 3a 
and 3b) the effects coul d be attributed to an increase in MAO 
activity resulting in increased substrate availability rather 
than an effect on HIOMT. 
Increase in carbamazepine and sulthiame concentration caused an 
increase in 5-hydroxytryptophol production, an effect which 
appears to be independent of an effect on MAO and is therefore 
probably due to inhibition of al dehyde dehydrogenase al though it 
may also involve increase in aldehyde reductase. This effect is 
interesting by virtue of the evidence that suggests carbamazepine 
to be a non-competitive inhibitor of brain aldehyde reductase 
[25]. This apparent discrepancy may be due to insensitivity of 
pineal al dehyde reductase to carbamazepi ne i nhibiti on, or to 
inhibition of al dehyde dehydrogenase which may be far greater, 
therefore seeming to increase 5-hydroxytryptophol production 
merely by vi rtue of increased substrate available although 
inhibition in fact occurs. 
Although clonazepam, diazepam [26], diphenylhydantoin, 
ethosuximide, phenobarbitone [25,27], primidone [28] and 
valproate [26,29,30] have all been shown to i nhibi t brai n 
aldehyde reductase only diphenylhydantoin, ethosuximide and 
valproate exert a noticeable dose dependent inhibition on the 
pineal enzyme. Overall 5-hydroxytryptophol production remained 
above control levels (Table 2a and 2b) primarily due to increased 
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MAO activity. The possibility therefore exists that pineal 
aldehyde reductase is noticeably different from the brain enzyme 
although the lack of inhibitory effects may be due to other 
factors. 
In the instances where a variable effect on N-acetylserotonin and 
melatonin production is exerted it is possible that the drugs are 
acting on at least two sites which are antagonistic, the overall 
effect being dependent on the drug concentration. 
The foregoing di scussion gives some indication of the effects 
exerted on indole metabolism by a direct action of the various 
drugs on the pi neal gland. In the intact animal numerous other 
factors could affect activity, especially centrally mediated 
i nfl uences. These may enhance, aboli sh or otherwi se modify the 
effects resulting from a direct local action of the drugs on the 
pineal. It is therefore interesting to compare these ~ vitro 
effects with the ~ vivo effects on indole metabolism using the 
same system. By and large if similar effects occur in both 
systems then effects can be presumed to be predominantly locally 
mediated while a difference would suggest central participation. 
Possibly the most striking observation ~ vivo is that in all 
cases both N-acetylserotonin and melatonin production were 
decreased by anticonvulsant drug administration (Table 4 and 5). 
This decrease in activity was probably due primarily to lower 
SNAT levels although it may also have been the result of lower 
HICl>lT levels as overall methYlation was reduced (Table 5). That 
SNAT 1 evel s appear to be reduced by all drugs except 
acetazolamide and pheneturide and HIOMT levels are reduced by all 
drugs used (see Chapter 6) tends to favour this hypothesis. 
Thi s decrease probably results from reduced s-adrenergi c cycl i c 
AMP mediated induction of SNAT. The fact that most of the drugs 
coul d reduce N-acetylserotonin production ~ vitro indicates that 
this effect is probably largely medi ated by local effects 
although central effects may also playa role. In certain 
instances beclamide, ethosuximide, pheneturide, phenobarbi tone, 
primidone,sulthiame and valproate were able to increase N-acetyl-
serotonin production ~ vitro whereas they all caused a reduction 
in vivo which suggests the involvement of central mechanisms in 
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causing an ultimate decrease in SNAT activity in the intact 
animal. The central depressant effect woul d be capable of 
overridi ng the locally medi ated stimulant action on SNAT levels 
resulting in decreased N-acetylserotonin production. 
In the case of sulthiame induced reduction of N-acetylserotonin 
and melatonin levels the best interpretation would probably be 
based on direct inhibition of SNAT by sulthiame (see Chapter 5), 
an observation borne out by the dose dependent reduction in SNAT 
activity observed.i.!2. vitro. Participation of other local and even 
central effects, however, cannot be compl etely ru 1 ed out . 
That methYlation increased in vitro (Table 3a and 3b) coul d be 
explained by an effect on ~lAO activity leading to increased 
substrate ava il abil i ty rather than to an effect on H rOMT and 
suggested that these drugs did not influence HIOMT through a 
direct effect on the pineal. The reduction in methylation 
observed .i.!!. vivo in organ culture (Table 5) and the reduction in 
total HIOMT levels (see Chapter 6) suggests that anticonvul sant 
drug-induced decrease in HIOMT levels is mediated from the 
central nervous system with no local component. To a certain 
extent decreased methylation may be the result of reduced 
substrate in the case where MAO activity was decreased .i.!!. vivo. 
The decrease in melatonin output was accompanied by an increase 
in both 5-methoxyindole-3-acetic acid and 5-methoxytryptophol 
which suggests that the catalytic sites on HIOMT can utilise a 
number of substrates, probably dependent on their concentration 
and affinity verifying a previous report [23]. 
Carbamazepine admi nistration, apart from causing a decrease in N-
acetyl-serotonin and melatonin, led to a significant increase in 
5-hydroxytryptophol production (Table 4) which may result from 
decreased activity or inhibition of al dehyde dehydrogenase or 
increase in al dehyde reductase levels. This effect probably 
originates primarily at the local level. 
Ethosuximide, phenobarbitone, primidone, sulthiame and valproate 
caused an increase in overall metabolic activity (Table 4), an 
effect wh i ch probably results primarily from i ncreased ~lAO 
activity, although levels of aldehyde dehydrogenase and al dehyde 
reductase may also be increased. Evidence that phenobarbitone is 
132 
capable of inhibiting 1·1AO (see Chapter 5) suggests that either 
MAO levels increase to an extent that overrides inhibition or 
that pineal MAO is unaffected by phenobarbitone. This increased 
activity, although it may involve a central component, is 
predominantly locally mediated. The fact that phenobarbitone has 
been shown to increase activity of aldehyde dehydrogenase in 
1 iver [31,32J may indicate that a similar effect occurs in the 
pineal. 
All the other drugs caused a reduction in overall activity which 
suggests that they exert a central effect cancelling the locally 
mediated increase in metabolic activity. This again indicates 
that dual effects may occur which are antagonistic to each other 
and have the potential to modulate overall activi ty in a compl ex 
f ash i on. 
Sulthiame, apart from reducing melatonin production, also caused 
significant increase in 5-methoxyindole-3-acetic acid output, an 
effect probably resulting from the reduction in N-acetylserotonin 
output, leaving more catalytic sites available for the other 
hydroxyi ndoles. 
From these results it is apparent that the most consistent effect 
of anticonvulsant drugs on the pineal gland is the reduction in 
melatonin synthesis. Whether this would influence therapeutic 
activity or affect nonnal physiological processes would require 
further intensive investigation. Such studies would be 
complicated as it would be necessary to divide observed effects 
into those resulting from direct action of the drug and those due 
to change in melatonin levels. 
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CHAPTER 9 
CONCLUSION 
Of all the varied effects exerted by the anticonvulsant agents on 
pineal gland indole metab olism, the most striking is the 
reduction in melatonin production. It is significant that all the 
drugs used had this effect l.!l vivo and all, except diphenyl-
hydantoin and valproate, appear ed to cause a shift in the 
nocturnal rhythm of SNAT activity. The new peak activi ty in the 
drug treated animals occured later in the dark phase. It is 
difficult to assign an importance to these observations and 
although they have potential therapeutic significance they may 
not contribute to the anti-seizure activity of the drugs. 
The reduction in melatonin production can be largely attributed 
to reduction in SNAT activity which in turn appears to be 
mediated primarily by local effects, although in certain cases 
there is a definite involvement of central mechanisms. That HIOtn 
1 evels were al so largely decreased l.!l vivo by all the drugs might 
indicate that decreased melatonin could also result from 
decreased methylating capacity of the pineal. The reports which 
indicate that SNAT is rate limiting in the production of 
melatonin [1-5] tend to favour reduction in N-acetylserotonin 
production as being primarily responsible for depressed melatonin 
synthes is. 
Any reduction in SNAT levels and hence of N-acetylserotonin 
production would almost certainly involve decreased cyclic AMP 
. 
stimulated induction of enzyme levels . This may occur at a local 
level or may be initiated by depression of a central neural 
pathway. The ultimat e effect would be reduced cyclic AMP level s 
which may result from decreased adenyl cyclase activity, 
increased cycli c At~P phosphodi esterase activity or a combi na tion 
of both these effects . In this respect it is interesting to note 
that carbamazepine, clonazepam, diazepam, diphenylhydantoin and 
phenobarbitone have been shown to prevent rise in cyclic At1P [6] 
while acetazolamide, diazepam, diphenylhydantoin and 
phenobarbitone can inhibit cyclic At~P phosphodiesterase [7,8] 
~Ihich would tend to increase cyclic AMP levels. If these drugs 
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are capable of inhibiting pineal cyclic At~P phosphodiesterase 
then reduction in SNAT activity must result primarily from 
reduced adenyl cyclase activity which implies 8-adrenergic 
receptor blockade or reduced tl-stimulation. 
It has been suggested that both increased cyclic A~lP levels and 
membrane hyperpolarization are necessary for complete expression 
of 8-adrenergic stimulation [9] and the findi ng that di phenyl-
hydantoin [10,11] and carbamazepine [12] can prevent 
hyperpolarization may partially account for the reduced SNAT 
activi ty . Cal cium ions are essential for mediation of pineal 8-
receptor activation and the fact that carbamazepine, diazepam, 
diphenylhydantoin and phenobarbitone can inhibit calcium uptake 
[13] may indicate that reduced 8-stimulant action is involved in 
the decreased melatonin production resulting from anticonvulsant 
drug administration. SNAT induction is also dependent on 
phosphorylation of nuclear proteins [14,15] and diphenylhydantoin 
can inhibit calcium stimulated protein phosphorylation [16], 
again an effect which would reduce SNAT levels. Decrease in 
protein synthesis associated with diphenylhydantoin 
administration [17] would also account for the reduction in SNAT 
levels, again if such an effect occured in the pineal. 
From thi s ci rcumstanti al evi dence it is apparent that many of the 
anticonvulsant drugs have the potential for inhibiting induction 
of SNAT in the pineal, which would account for the reduction in 
melatonin production. The fact that some drugs stimulated 
melatonin production l..!!. vitro while inhibiting melatonin 
production ~ vivo is suggestive of a central inhibitory action 
on SNAT induction, presumably by decreasing pineal sympathetic 
stimulation, although it is conceivable that inhibitory pathways 
innervate the pineal directly and that these might be stimulated 
by tile anticonvulsant drugs. AL-"""f'E'IL\4,q-,-tV8-'"I', ili ,,~ ~D 
J.!:i \l~O 1>CI.4.I:. u>~"llU!'n~" M'I>">' ~E. \)\ FFen-ec ( . 
Havi ng ascertained that the reduction in melatonin production is 
largely due to locally mediated effects with the participation of 
some central actions it is necessary to examine the possible 
significance of reduced melatonin levels on seizure activity. The 
most obvious effect would be the reduced ameliorative action on 
seizures exerted by melatonin directly . This, however, may not 
have a significant influence on seizure therapy in the short term 
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as the decreased effectiveness of melatonin would probably be 
more than compensated for by a direct anticonvulsant action of 
the drug concerned. With the development of tolerance to the 
drugs and the consequent reduction in effectiveness it is 
possible that the reduced ameliorative effect of melatonin may 
become apparent . 
As melatonin levels and/or rhythm have been shown to be abnormal 
in 47 disease states [21] it is likely that some abnormality also 
exists in epileptic conditions . If this were indeed the case then 
the shift in melatonin rhythm caused by the various drugs might 
have some therapeutic importance in that the drugs could 
rei ns ta te normal rhythms. Thi sis important as ci rcadi an rhythms 
have been shown to have profound effects on seizure activity [22] 
and seizure susceptibility varies with changes in the light phase 
[23]. That melatonin administration can decrease sensitivity of 
the photosensitive baboon [24] may also suggest a link between 
melatonin, circadian rhythm and seizure activity. 
It is possible that reduced melatonin levels can exert an 
i ndi rect anticonvulsant effect which is capable of compensating 
for the decrease in directly ameliorative action attributable to 
me"latonin. One of the possible indirect mechanisms involves the 
benzo~azepine (BZD) receptors. Both melatonin and its brain 
me tab 01 ite N -acetyl-5-methoxy kynurenami ne have been found to be 
capable of inhibiting BZD receptor binding [25,26] and are more 
potent than the putative endogenous BZD receptors inosine and 
hypoxanthine [26]. A correlation has been found between BZD 
receptor occupancy and anticonvulsant effectiveness [27] and 
therefore reduced melatonin levels would increase anti seizure 
activity by decreasing inhibition and allowing for increased 
agonist binding. 
If this were indeed the case then it could partially explain the 
effectiveness of the following four groups of drugs . Firstly the 
benzodiazepines clonazepam and diazepam, secondly, diphenyl-
hydantoin which has been shown to compete for diazepam binding 
[28], thirdly, phenobarbitone \vhich can bind to the barbi turat2-
picrotoxi n component of the BZD-GABA receptor complex [29] and 
lastly primidone through the action of its metabolite 
phenobarbitone . Marked similarities in molecular conformation of 
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di azepam and di phenylhydantoi n [30J al so favour a simil ar mode of 
acti on wh il e drugs such as sulthiame have a conformation totally 
different from that of other anticonvulsants [31J and would thus 
have a di fferent mode of action. It is most likely that the BZD 
receptors involved in such a mechanism would be situated 
centrally, although th"e presence of BZD receptors in peripheral 
tissues [32J might suggest some effect via these areas, perhaps 
even the pineal although there is no evidence as such to support 
this proposal. 
The scant evidence available supports an involvement of melatonin 
in modulation of BZD receptors and hence in prevention of seizure 
activity. Whether this is the normal role of melatonin as an 
endogenous modulator of seizure activity or merely "a positive 
consequence of drug administration remains to be established. 
Reduction in melatonin output also has the potential for 
affecting a variety of endocrine and homeostatic mechanisms (see 
Chapter 1) which woul d influence seizure states to some extent. 
The overall effects resulting from anticonvulsant drug action are 
undoubtably complex and multifactorial and further extensive 
investigation would be necessary to fully characterise the 
mech ani sms i nvo 1 ved. 
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ABBREVIA nONS 
ACTH: adrenocorticotrophic hormone 
AId D: al dehyde dehydrogenase 
AId R: al dehyde reductase 
AMe: S-adenosylmethionine 
M1P: adenosine monophosphate 
APUD: amine precursor uptake and decarboxylation 
ATZ: acetazolamide 
BCl: becl ami de 
BZD: benzodiazepine 
CA: carbonic anhydrase 
CBZ: ca rbamazep i ne 
ClZ: c I onazepam 
CoA: coenzyme A 
cpm: counts per mi nute 
DPH: di phenylhydantoi n 
dpm: disintegrations per 
DZP: di azepam 
E: enzyme 
mi nu te 
EDTA : ethylenediaminetetraacetic acid 
EEG: electroencephalogram 
Emit: enzyme multiplied immunoassay technique 
ETH: ethosuximide 
FSH: follicle sti~ulating hormone 
GABA : gamma-amino butyric acid 
GBq: gi gabecquerel 
GMP: guanosine monophosphate 
HIAA: 5-hydroxyindole-3-acetic acid 
H IAlD: 5 -hy droxyi ndo I e-3 -acetal dehy de 
H IOMT: hy droxyi ndo I e -0 -me thy ltrans ferase 
hr: hour 
5 -HT: serotoni n 
HTOl: 5-hydroxytryptophol 
i p: i ntraperi toneal 
Ke: elimination rate constant 
Kg: kilogram 
Kia: dissociation constant for E.Tryp complex 
Kii: dissociation constant for STH from E.Tryp.STH complex 
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Kiii : dissociation constant for Tryp from E.Tryp.STH complex 
Kis: dissociation constant for E.STH complex 
Kj: kil ojoule 
KS m: Michaelis-Mentenconstant 
1: litre 
LH: luteinising hormone 
LHRH: luteinising hormone releasing hormone 
M: J1)'Jlar 
MAO: J1)'J noami ne oxi da se 
MBq: megabecquerel 
mg: mill i gram 
MIAA: 5-methoxyindole-3-acetic acid 
mol: J1)'Jle 
MIF: melanocyte inhibitory factor 
ml: milli1itre 
mM: millimolar 
MSH: melanocyte stimulating hormone 
MT: 5-methoxytryptami ne 
MTN: mel a toni n 
MTOL: 5-methoxytryptophol 
NA: noradrenaline 
NAO: n i c ot i nami de ade nine di nu c 1 eot ide 
NAOH: dihydronicotinamide adenine dinucleotide 
NAOPH: dihydronicotinamide adenine dinucleotide phosphate 
NAS: N-acetylserotonin 
NAT: N -acety ltryptami ne 
ng: nanogram 
nm: nanometre 
6-0 H-I~TN: 6-hydroxymelatonin 
PRL: prolactin 
PT R: pheneturide 
PBT: phenobarbitone 
pmo l: picomole 
PRO: pr imi done 
r2 : coefficient of determination 
SAH: S-adenosylhomocysteine 
SEM: standard error of the mean 
SNAT: (serotonin) N-acetyltransferase 
STH: sulthiame 
tl/Z: half-life 
TBq : terabecquerel 
TLC: thi n layer chromatography 
Tryp: tryptami ne 
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TSHRH: thyroid stimulating hormone releasing hormone 
ug: microgram 
ul: microlitre 
uM: micromolar 
UV: ultra violet 
VPA: val proate 
V: vel oci ty 
Yo: initial velocity 
Vs: saturation velocity 
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APPENDIX A 
MATERIALS 
The following list summarises the various materials used in this 
study giving specifications \~here necessary and indicating 
supplier. 
Animals . Rats of the Wistar strain kept under constant lighting 
conditions (12 hours light/12 hours dark) with access to 
unlimited supplies of food and water were used. Both male and 
female rats (150-300g) were used and differences are outlined in 
the text. As far as possible temperature of the living quarters 
was kept constant (15-2 50 C) and an extractor fan ensured 
constant removal of stale air . 
Anticonvulsant Drugs. These were mostly donated by the 
pharmaceutical manufacturers to whom I am indebted. 
Acetaz 01 ami de: Sigma, USA 
Beclamide: Rona Labs Ltd., UK 
Carbamazepine: Ciba-Geigy (Pty) Ltd., RSA 
Clonazepam: Roche Products (Pty) Ltd., RSA 
Diazepam: Roche Products (Pty) Ltd., RSA 
D i pheny lhy da ntoi n: Parke -Davi s (Pty) Ltd., RSA 
Ethosuximide: Parke-Davis (Pty) Ltd . , RSA 
Pheneturide: Sapos SA, Switzerland 
Phenobarbi tone: Maybaker (SA) (Pty) Ltd., RSA 
Primidone: ICI (Pharmaceuticals) (Pty) Ltd., RSA 
Sulthiame: Bayer (SA) (Pty) Ltd., RSA 
Valproate : R+C Pharmaceuticals (Pty) Ltd., RSA 
Biochemicals. The follo~ling were purchased from Sigma Chemical 
Corporation, USA. 
Acetic anhydride 
N -acety 1 serotoni n 
Gamma-amino butyric acid 
5-hydroxyi ndole-3-acetic acid 
6 -hy droxymel a toni n 
5 -hy dr oxytryptami ne crea ti ni ne sul phate 
5 -hy droxytryp top ho 1 
Isoprenaline HCl 
Melatonin 
5-methoxyi ndole-3-acetic acid 
5 -methoxytryptami ne 
5 -methoxytryptopho 1 
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a-nicotinamide adenine dinucleotide 
B-nicotinamide adenine dinucleotide (reduced) 
Noradrenaline HCl 
Tryptami ne HCl 
The followimg were obtained from P-L Biochemicals, USA. 
S -adenosyl homocys tei ne 
Coenzyme A 
Culture Medium. This was obtained from Gibco Europe, UK. 
B.G.J.b. medium (Fitton-Jackson ITOdification) 
Enzymes. These were mostly obtained from Boehringer-Mannheim, 
West Germany . 
Alcohol dehydrogenase 
Aldehyde dehydrogenase 
Carbonic anhydrase 
Monoamine oxidase (Sigma, USA) 
Enzyme Immunoassay Kits. These were supplied by Syva Diagnostics, 
USA for the fo 11 owi ng dru 9s. 
Diphenylhydantoi n 
Ethosuximide 
Phenobarbi tone 
Primidone 
Valproate 
Radiochemicals. The following were supplied by the Radiochemical 
Centre, Amers ilam , UK. 
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Cl-14C] acetyl coenzyme A (specific activity 205HBq/mmol and 
2.09GBq/mlrol) 
S-adenosyl-L-[methyl-14C] methionine (specific activity 
18.5MBq/mlrol and 2.18GBq/mlrol) 
S-adenosyl-L-[methyl-3H] methionine (specific activity 
2 .22TBq/mlrol) 
5-hydroxy [side chain-2- 14C] tryptamine creatinine sulphate 
(specific activity 2.22GBq/mlrol) 
5-hydroxy [G-3 H] tryptamine creatinine sulphate (specific 
activity 37OGBq/mIro1) 
Radioactive benzodiazepines were supplied by Hoffman La Roche, 
Switzerland as a gift for ~Ihich I am grateful. 
Clonazepam-5-14C (specific activity 1.15t~Bq/mg) 
Diazepam-5-14C (specific activity 6.88GBq/mg) 
Scintillation Cocktails. Insta-Gel, Insta-Gel II and Soluene 350 
were supplied by Packard, USA. 
Sundries. All solvents, chemicals and thin layer chromatographic 
plates (silica-gel 60) were obtained from t~erck, West Germany. 
Photographic film used for autoradiography was Kodak Plus-X pan 
(125 ASA) or Kodak professional copy film (25 ASA). Double 
distilled deionized water was used throughout. 
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APPENDIX B 
THIN LAYER CHROMATOGRAPHY SOLVENT SYSTEMS 
Various solvent systems were tested for thin layer 
chromatographic separation of pineal serotonin metabolites and 
are outlined below. Rf values given for development on microscope 
slide sized TLC plates. It must be noted that these Rf values 
should be used comparatively rather than absolutely as migration 
distance varies with change in climatic conditions. The relative 
position of each spot with respect to the others, however, 
rema i ns the same. (HT = serotoni n, MT = 5-methoxy-tryptami ne, NAS 
= N - ace ty 1 s e rot 0 n in, MT N = me 1 at 0 n in, 60 H M T N = 6-
hydroxymelatonin, HIAA = 5-hydroxyindole-3-acetk acid, MlAA = 5-
methoxyi ndole-3-acetic acid, HTOL = 5-hydroxytryptophol and MTOL 
= 5-methoxytryptophol). 
SOLVENT SYSTEMS 
1] Chlorofonn 
2] Ethanol 
3] Ethyl acetate 
4] 20% KCl 
5] Isoamyl al coho 1 
6] Chloroform acetone (9:1) 
7] Chloroform ether (8:2) 
8] Chlorofonn ethanol (8:2) 
9] Chloroform methanol (9:1) 
10] Dioxane: water (9:1) 
11] Methanol: 25% ammonia (25: 1) 
12] 20% KCL 25% ammo nia 
13] 20% KCl : glacial acetic acid (25:1) 
14] n-[lu tanol : 5t~ acetic acid (100:35) 
15] Chlorofonn methanol glacial acetic acid (92:7:1) 
16] Chloroform methanol: glacial acetic acid (75:20:5) 
17] Chlorofonn methanol: glacial acetic acid (80 :15 :5) 
18] Methyl acetate: isopropanol 25% ammonia (45 :35 :20) 
19] Methyl acetate: isopropanol 25% ammonia (35:45:2) 
20] Butano l etha nol: 25% ammonia (8:1:1) 
21] Butanol glacial acetic acid: water (4:1:5)-upper phase 
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22] Isopropanol ethyl acetate 25% ammoni a (7: 9:4) 
23] Isopropanol ethyl acetate : glaci al aceti c aci d water 
(75:25:2:3) 
24] Isopropanol water : 25% ammonia (75:20:5) 
25] Methy 1 ethy 1 ketone: n-hexan e (35:65) 
26] Methyl ethyl ketone: acetone: 2.5M acetic acid (2:1:1) 
Rf VALUES FOR SOLVENT SYSTEMS ABOVE 
HT r'<1T NAS MHJ 60HMTN HIAA t1IAA HTOL MTOL 
1] 0 0.07 0 0 0 0 0.03 0 0.11 
2] 0 0 0. 86 0. 86 0. 84 0.77 0.75 0.88 0.88 
3] 0 0 0.38 0.41 0.36 0.81 0.83 0.76 0.83 
4] 0.83 0.70 0.65 0.38 0.54 0.78 0.53 0.83 0.67 
5] 0 0.04 0.47 0.37 0. 27 0.33 0.20 0.88 0.81 
6] 0 0 0.05 0. 15 0 0 0.08 0.09 0.35 
7] 0 0 0.05 0.12 0 0 0.08 0.08 0.30 
8] 0 0 0.67 0. 75 0.73 0.35 0.67 0.71 0.91 
9] 0 0 0.30 0.51 0.38 0. 12 0.40 0.35 0.57 
10] 0.98 0.99 0.98 0.98 0.70 0.98 0. 99 0.98 0.99 
11] 0.35 0.38 0.89 0.89 0.87 0.90 0.91 0.89 0.89 
12] 0.92 0.75 0.83 0.67 0. 74 0. 93 0.80 0. 98 0.82 
13] 0.92 0.75 0.79 0.61 0.67 0.83 0. 74 0.89 0.74 
14] 0.42 0.43 0.82 0.82 0.78 0.90 0.90 0.92 0.92 
15] 0 0 0.34 0.76 0.38 0.24 0.76 0.36 0.80 
16] 0. 13 0.31 0.81 0.96 0.86 0.81 0.96 0.82 0.97 
17] 0.13 0.26 0.72 0.97 0.80 0.65 0.96 0.72 0.97 
18] 0.63 0.65 0.91 0.93 0. 55 0.37 0.56 0.91 0.93 
19] 0.13 0.15 0.90 0.90 0.85 0.10 0.11 0.95 0.95 
20] 0.40 0.58 0.82 0.87 0.69 0;15 0.23 0.84 0.89 
21] 0.67 0.67 0.80 0.80 0.75 0.86 0.86 0.87 0.87 
22] 0.48 0.51 0.85 0.88 0.78 0.27 0.35 0.85 0.88 
23] 0.78 0.79 0.95 0. 95 0.94 0.98 0.98 0.98 0.98 
24] 0.47 0.57 0.89 0.89 0.85 0. 63 0.67 0.90 0.90 
25] 0 0 0 0.08 0 0 0.10 0.12 0.28 
26] 0.74 0. 75 0.92 0.92 0.90 0.96 0.96 0.96 0.96 
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INDEX 
Acetazolamide (ATZ) 19,20,40,42,43,48,93,94,100-103 120,122,124, 
126-128 135 
Acetylcholine (see parasympathetic nervous connections) 
Acetyl coenzyme A 10,56,58,59,66-69,86,89 98,99 
Acetyl coenzyme A:arylamine N-acetyltransferase (see N-acetyl-
transferase) 
Acetyl coenzyme A hydrolase 10 
N-acetyl-N-formyl methoxy kynurenamine 7,16,137 
0-acetyl-5-hydroxytryptophol 7 
0-acetyl-5-methoxytryptophol 7,10 
N-acetylserotonin (NAS) 7-9,16,55 56,58,67,72,79,80,82,83,87,99, 
107-115,122,123,125-132 
N-acetyltransferase (SNAT) 3,7 , 9,10,18,55-69,86,89-92,97-102,111, 
128-131,135,136 
O-acetyltransferase 7,10,86 
. N-acetyltryptamine 56,57,66,99 
ACTH (see adrenocorticotrophic hormone) 
Activity 22 
3' ,5'-adenosine monophosphate (see cyclic AMP) 
S-adenosylhomocysteine (SAH) 11,74,80,81 
S-sdenosylmethionine 11,72,79,80-83,87,99,108 
Adenyl cyclase 3,4,128,135,136 
Adrenal gland 22 
Adrenalectomy 16 
Adrenal-pineal axis 16 
Adrenaline 6,16 
a-adr energ ic receptor 4-6,10 
B-adrenergic receptor 3,4,6,8,9,15,56 ,68,128,136 
Adrenocorticotrophic hormone (ACTH) 15 
Alcohol dehydrogenase (see aldehyde reductase) 
Aldehyde dehydrogenase 7-9,85,88,93,94,120,129,131,132 
Aldehyde reductase 7,9,19,85,88,93,94,120,130,131 
Amine precursor uptake and decarboxylation (APUD) system 2 
-amino butyric acid (GABA) 5,6,106,113 
Androgens 13,22 
Anticonvulsants (see also individual agents) 40,46,47,86-88, 
97-102,105,117-120,130,132,135 
Antigonadotrophic activity 13 
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APUD (see amine precursor uptake and decarboxylation system) 
Arginine vasotocin 5,14,16.19 
Arrhenius plot 62,63,76 , 77 
Aromatic L-amino acid decarboxylase 7 
Ascorbic acid 109 
Autoradiography 42,57,59,73,75,107,110,111 
Beclamide (BCL) 4B , 100-103,120,122,124,126,127,130 
Benzodiazepine (BZD) receptors 17,21,102,103,138 
Biogenic amines 12,22 
Brain 16 
Breasts 22 
Calcium ions 3,4,15 20,21,127,136 
Cancer (see tumours) 
Carbamazepine (CBZ) 19,20,41,42,44,49,93,94,100-103,120,122,124, 
126,127,129,131,135,136 
Catalytic mechanisms (see individual enzymes) 
Catecholamines 16,17,22 
Cerebrospinal fluid 17,19 
Cholinergic fibres (see parasympathetic innervation) 
Chorionic gonadotrophin 13 
Choroid plexus 17 
Circadian rhythm 8,9,11,18,137 
Clonazepam (CLZ) 20,41,42,44,45,49,93,100-103,120-122,124,126, 
129,135,137 
Coenzyme A 58,67 
Commisural fibres 17 
Corticosterone 16 
Cyclic AMP 3,4,10,12,19,56,127-130,136 
Cyclic AMP phosphodiesterase 3,4,12,19,128,135,136 
Cyclic GMP 4,5,12,19 
Cytochrome oxidase 6 
Deacety 1 a se 86 
Decarboxylase 7 
Densitometry of thin-layers 41 
Diazepam (DZP) 19-21,41,42,44,45,47,50,93,94,98,100-103 
120-122,124,126 -129,135-137 
Diencephalon 3 
Di ffu'se neuroendocri ne system 2 
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Diphenylhydantoin (DPH) 19-21.42,50,93,94 100 -103,120-122,124, 
126-129 135-138 
Disulphide exchange 10 
Dopamine 6,12,14,20 
Drinking behaviour 14 
Electroencephalogram (EEG) 15,17 
Electrolyte balance (see fluid and .. ) 
Elimination rate constant 46,47 
Enterochromaffin cells 8,11 
Enzyme multiplied immunoassay technique 42 
Epilepsy 17,18,22,39,86,92,97,136-138 
Ethosuximide (ETH) 20,21,42,51,100-103,120,123,125-127,129-131 
Eye (see retina) 
Fluid and electrolyte balance 3 
Follicle stimulating hormone (FSH) 13,14,20,22 
Formyl kynurenamine 7 
GABA (see -amino butyric acid) 
Glucocorticoids 12 
Glucose-6-phosphate dehydrogenase 6,9 
Gonads 13 
Gonadotrophins 15,17 
Growth 22 
Growth hormone 14,20 
Guanyl nucleotides (see cyclic GMP) 
Habenular posterior commisure complex 2 
Habenulo-pineal axis 16,22 
Half-life 46,47,64,78 
Harderian gland 10 
HIOMT (see hydroxyindole-O-methyltransferase) 
Histamine 5,12 
Homeostasis 3,12,138 
5-hydroxyindoles (see individual compounds) 
5 -hy droxyi ndo 1 e -3 -acetal dehyde 7,9,85,122,123,125,126 
5-hydroxyi ndole-3-acetic acid 7,9,16,20,85,107-115,122,123,125, 
126 
Hydroxyi ndo 1 e -0 -me thy 1 trans ferase (H IOMT) 7,10,12,71-88,97 -1 00, 
102,108,113,129-131,135 
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6-hydroxymelatonin 6,7,109,110 
5 -hydroxytryptami ne (see serotoni n) 
5 -hydroxy tryptophan 6,7 
Hydroxy tryptophan decarboxylase 7,8 
5-hydroxytryptophol 7,9,16,85 107-115,122,123 125 , 126,129,131 
Hyperpolarization 3,4,127,128,136 
Hypoglycaemia 18 
Hypothal amo-hypophys eal system 14 
Hypothal amo-hypophyseal-thyroid axi s 14 
Hypothalamus 14,16,17,19,21,22 
Hypothermia 21 
Indoleamines 21 
Indoleami ne-2 ,3-dioxygenase 7 
Insulin 18,20 
Intes tine 13 
Interstitial cells (see macroglia) 
Isolation 13 
17-Ketosteroids 14 
Lacta te dehy drogenase 6 
Leucine enkephalin 21 
Light (see photic input) 
Luteinising hormone (LH) 13,15,20,22 
Luteinising hormone releasing hormone (LHRH) 15,22 
Macroglia 2 
Medi al basal hypothal amus 14,16 
Medial forebrai n bundle 2 
t~e lan ocyte stimulating hormone (,1SH) 15,22 
MSH-inhibiti ng factor (MIF) 22 
Melanin 13 
Melatonin 7,8,10-18,55,56,72-74,80,85,86,92,97-99,109-111,113-115 
117,123,125,126,129-132,135-138 
Mel atonin receptors 16 
Menstrual cycle 13 
Methionine S-adenosyltransferase 11 
Methionine enkephalin 17 
6-methoxyhamalan 108 
5-m",tll0xyindoles (see individual compoun ds) 
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5-methoxyi ndole-3-acetal ctehycte 7,85 
5-methoxyinctole-3 -acetic acid 7,72,109-115,123,125,125,131,132 
5-methoxytryptamine 7,8,13,15,17,18 , 72,85,108-110 
5 -metho xytryptophan 7,72 
5 -methoxytryptopho 1 7,11,13,16,18,72,85,109-115,123,125,126, 
131 
Michaelis-Menten constants 64-66,68,69,73,74,77.79,80,82,83 
MicrotubuTes 12 
Midbrain raphe neurons (see raphe neurons) 
Mitochondria 8,11 
Monoamine oxidase (MAO) 7,8,15,19,85,87,93,120,121,127-130,132 
Muscarinic receptors (see parasympathetic innervation) 
Noradrenaline 3,4,11,12,19,106,113,114,121 
Oestrogen 22 
Organ culture 105-115,117-133 
Ornithine decarboxylase 13 
Oxytoci n 2 
Pain 17,22 
Pancreas 20,22 
Parasympathetic innervation 2,5,6,22 
Parathyroid 15,22 
Paraventricular nuclei 14 
Pars intermedia 15 
Pentose nucleotides 6 
Peptictes 2 
pH effects 58-61,68,73-76,81,82 
Pheneturide (PTR) 41-44,51,93,94,100-103,120,123,125,126,128-131 
135-137 
Phenobarbitone (PBT) 19-21,42,52,93,94,97,100-103,120, 121 ,123, 
125,126,128-132,135-137 
Phosphate levels 15 
Phospholipids 4,5,8 
Phosphorylation 4,20,136 
Photic input 2,5,10,22 
Photosensitive 137 
Pigmentation 22 
Pi neal actomj 8,13,15,17 
Pinealocytes 2,5,6,8 
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Pineal-gonadal feed back 14 
Pinealo-habenular axis (see habenulo ... ) 
Pituitary 14,16 ,20 ,22 
Pituitary-thyroid axis 15 
Posterior cerebral artery 2 
Potassium 17,20,127 
Primidone 19,42,52,93,94,100-103,120,123,125,126,128-131,137 
Progesterone 22 
Prolactin (PRL) 14,22 
Prolactin releasing hormone 14 
Prostaglandin 10,15 
Prostaglandin synthetase 21 
Psychotomimetics 12 
Pteridines 12,13,72 
Pterins 12,13,72 
Pyridoxal compounds 9,12 
Rap he neurons 16 
Receptors (see various ligands) 
Reproduct ion 13 
Retina 6,10,14 
Retino-hypothalamic tract 2 
Rhythms (see circadian) 
Ribonucleic acid (RNA) 3 
Salivary glands 13 
Seizures (see epilepsy) 
Serotonin 3,5-8,14-18,20,56,58,66,67,85,106,107,109-113,115, 
118,119,121,128 
Sex hormones 4,17,22 
Sex organs 22 
Sleep 16,22 
Smell 22 
SNAT (see N -acety 1 trans ferase) 
Somatostatin 14 
Sound 22 
Stress 5,16 
Subsensitivity (see -adrenergic receptor) 
Sulthiame (STH) 21,40,42,43,53,88-94,100-103,120,121,123,125,126 
128-1 32,138 
Superior cervical ganglion 2,3,5 
155 
Supersens i ti vity (s ee -adrenergi c receptor) 
Suprachiasmatic nucleus 3,10,17 
Sympathetic innervation 3,5,8,1 1,22,67 
Taurine 4,21,129 
Temper ature effects 18,22,58,59,62-64,68,73-78,82,83 
Testosterone 14,20 
Therapeutic drug levels 46 
Thermoregulation 18,22 
Thin layer chromatography 41,42,57,73,106-108,110,111,118,119 
Thiol-disulphide exchange (see disulphide exchange) 
Thyroid 15,22 
Thyroid stimulating hormone (TSH) 14 
Thyrotrophin releasing hormone (TSHRH) 14,22 
Thyroxi ne 15 
Time-keeping device 18 
Tranquilizers 12 
Tryptamine 56-59,66,68,69,86,89-92,98,99 
Tryptophan 6,7,16,17,20 
Tryptophan hydroxylase 7,8 
Tumour 13,22 
Tyros i ne hy droxyl a se 12 
Ultra violet spectrophotometry 41 
Underfeedi ng 22 
Valproate (VPA) 20,21,42,45,46,53,93,94,100-103,120,123,125,126 
129-131,135 
Vasoactive intestinal polypeptide 12 
Vascular supply (see posterior cerebral artery) 
Vasopressin 2 
Ventricle 14 
Visual pa thways (see photic input) 
Water balance (see fluid and ... ) 
Wound healing 12,22 
